

BIOPHAN TECHNOLOGIES INC
Form S-1
October 25, 2007

As filed with the Securities and Exchange Commission on October 25, 2007
Registration No. 333-_____

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
WASHINGTON D.C. 20549

FORM S-1
REGISTRATION STATEMENT
UNDER
THE SECURITIES ACT OF 1933

BIOPHAN TECHNOLOGIES, INC.
(Name of small business issuer in its charter)

Nevada
(State or other Jurisdiction of
Incorporation or Organization)

3841
(Primary Standard Industrial
Classification Code Number)

82-0507874
(I.R.S. Employer
Identification No.)

15 Schoen Place
Pittsford, New York 14534
(585) 267-4800
(Address and telephone number of principal executive offices and principal place of business)

John F. Lanzafame
Biophan Technologies, Inc.
15 Schoen Place
Pittsford, New York 14534
(585) 267-4800
(Name, address and telephone number of agent for service)

Copies to:
Gregory Sichenzia, Esq.
Yoel Goldfeder, Esq.
Sichenzia Ross Friedman Ference LLP
61 Broadway, 32nd Flr.
New York, New York 10006
(212) 930-9700
(212) 930-9725 (fax)

APPROXIMATE DATE OF PROPOSED SALE TO THE PUBLIC:
From time to time after this Registration Statement becomes effective.

If any securities being registered on this Form are to be offered on a delayed or continuous basis pursuant to Rule 415 under the Securities Act of 1933, other than securities offered only in connection with dividend or interest reinvestment plans, check the following box: x

If this Form is filed to register additional securities for an offering pursuant to Rule 462(b) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. o

If this Form is a post-effective amendment filed pursuant to Rule 462(c) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. o

If this Form is a post-effective amendment filed pursuant to Rule 462(d) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. o

CALCULATION OF REGISTRATION FEE

Title of each class of securities to be registered	Number of Shares to be registered	Proposed maximum offering price per share	Proposed maximum aggregate offering price	Amount of registration fee
Common Stock, \$0.005 par value	38,102,868	\$ 0.145(1)	\$ 5,524,916(1)	\$ 169.61(2)

(1) Computed in accordance with Rule 457(c) under the Securities Act of 1933 (the "Securities Act"), solely for the purpose of calculating the registration fee, and based on the average of the high and low prices of the Common Stock of the Registrant as reported on October 22, 2007 on the NASDAQ OTC Bulletin Board.

(2) Computed in accordance with Section 6(b) under the Securities Act, solely for the purpose of calculating the registration fee.

The Registrant hereby amends this registration statement on such date or dates as may be necessary to delay its effective date until the registrant shall file a further amendment which specifically states that this registration statement shall thereafter become effective in accordance with Section 8(a) of the Securities Act or until the registration statement shall become effective on such date as the Commission, acting pursuant to said Section 8(a), shall determine.

The information in this Prospectus is not complete and may be changed. The selling stockholders may not sell these securities until the registration statement is filed with the Securities and Exchange Commission and becomes effective. This Prospectus is not an offer to sell these securities and is not soliciting an offer to buy these securities in any state where the sale is not permitted.

PRELIMINARY PROSPECTUS SUBJECT TO COMPLETION, DATED OCTOBER 25, 2007

**BIOPHAN TECHNOLOGIES, INC.
38,102,868 Shares of
Common Stock**

This prospectus relates to the sale of 38,102,868 shares of our common stock that may be sold from time to time by the selling stockholders named herein.

This offering is not being underwritten. The selling stockholders may offer the shares through public or private transactions at the market price for our common stock at the time of the sale, a price related to the market price, a negotiated price or such other prices as the selling stockholders determine from time to time. See "Plan of Distribution" beginning on page 56.

All of the net proceeds from the sale of these shares of common stock will go to the selling stockholders. We will not receive any proceeds from sales of these shares. We will bear the costs relating to the registration of these shares.

Our common stock is quoted on the OTC Bulletin Board under the symbol "BIPH". On October 22, 2007, the last reported sale price on the OTC Bulletin Board for our common stock was \$0.15 per share.

You should read this prospectus carefully before you invest.

Investing in these securities involves substantial risks. See "Risk Factors" beginning on page 8.

Neither the Securities and Exchange Commission nor any state securities commission has approved or disapproved of these securities or determined if this Prospectus is truthful or complete. Any representation to the contrary is a criminal offense.

The date of this prospectus is _____, 2007.

Table of Contents

	Page
Prospectus Summary	6
Risk Factors	8
Forward-Looking Statements	12
Use of Proceeds	12
Dividend Policy	12
Selected Consolidated Financial Data	12
Management's Discussion and Analysis of Financial Condition and Results of Operations	13
Business	26
Management	34
Beneficial Ownership of Common Stock by Directors, Officers and Principal Stockholders	48
Certain Relationships and Related Party Transactions	50
Transactions with Selling Stockholders	51
Selling Stockholders	53
Plan of Distribution	56
Description of Capital Stock	57
Legal Matters	59
Experts	59
Where You Can Find More Information	59
Index to Consolidated Financial Statements	61

You should rely only on the information contained in this prospectus. We have not authorized anyone to provide you with information different from that contained in this prospectus. We and the selling stockholders are offering to sell, and seeking offers to buy, shares of our common stock only in jurisdictions where offers and sales are permitted. The information in this prospectus is accurate only as of the date of this prospectus, regardless of the time of delivery of this prospectus or any sale of shares of our common stock.

PROSPECTUS SUMMARY

This summary highlights information contained elsewhere in this prospectus. This summary does not contain all of the information you should consider before investing in our common stock. You should read this entire prospectus carefully, especially the risks of investing in our common stock discussed under "Risk Factors" beginning on page 8, and the consolidated financial statements and notes to those consolidated financial statements, before making an investment decision.

BIOPHAN TECHNOLOGIES, INC.

Our Corporate Information

We were incorporated in the State of Idaho on August 1, 1968, under the name Idaho Copper and Gold, Inc. On February 9, 1999, we changed our name to Idaho Technical, Inc. On January 24, 2000, we changed our domicile to Nevada by merging into our wholly-owned Nevada subsidiary. We began our current line of business on December 1, 2000. On December 1, 2000, we changed our name to GreatBio Technologies, Inc. and on July 19, 2001, we changed our name to Biophan Technologies, Inc.

From inception through August 31, 2007, we have incurred cumulative net losses of \$53,423,577. Since December 1, 2000, we have relied almost entirely on sales of our securities and loans to fund our operations.

Our principal executive offices are located at 15 Schoen Place, Pittsford, New York 14534 and our telephone number is (585) 267-4800.

The Offering

Securities offered by the Selling Shareholders	38,102,868 shares
Common stock to be outstanding after the offering	141,226,524 shares *
Use of proceeds	We will not receive any proceeds from the sale of shares by the selling stockholders.
Risk Factors	You should read the "Risk Factors" section of this prospectus for a discussion of factors that you should consider carefully before deciding to invest in shares of our common stock.
OTC Bulletin Board symbol	"BIPH"

The number of shares of our common stock to be outstanding following this offering is based on 103,123,656 shares of our common stock outstanding as of October 22, 2007, and assumes the conversion of an aggregate face amount of \$5,287,756 of our outstanding Senior Secured Convertible Notes due October 11, 2009 into an aggregate of 35,251,707 shares of common stock to be sold by selling stockholders in this offering and (ii) the issuance of 2,851,161 shares of common stock in payment of interest to accrue under the Notes during their term, and to be sold by the selling stockholders in this offering and excludes (i) the exercise of outstanding options under our incentive stock compensation plans, (ii) the issuance of any shares of our common stock to SBI Brightline XI, LLC pursuant to the Stock Purchase Agreement dated as of May 27, 2005 (as amended), and (iii) the exercise of any other options, warrants or other rights to acquire shares of our common stock by any person or entity (including the selling stockholders).

* Includes 4,923,080 shares of our common stock held by Myotech, LLC. Because we have consolidated our financial statements with those of Myotech in accordance with FASB Interpretation No. 46 (Revised December 2003), "Consolidation of Variable Interest Entities" ("FIN 46(R)"), these shares are carried as treasury shares on our Consolidated Balance Sheets as of February 28, 2007 and August 31, 2007 and the Consolidated Statement of Stockholders' Equity as of February 28, 2007. However, because we did not have direct control over the voting or disposition of the shares held by Myotech, these shares are treated as issued and outstanding shares throughout this prospectus except (i) in the section entitled "Selected Financial Data" on page 12 and (ii) in the Financial Statements beginning on page F-1.

SUMMARY CONSOLIDATED FINANCIAL DATA

The tables below summarize our consolidated statements of operations for the six months ended August 31, 2007 and 2006 (Unaudited), and for the years ended February 28, 2007, 2006 and 2005 (Audited) and our consolidated balance sheet data as of February 28, 2007 and 2006 (Audited) and August 31, 2007 (Unaudited). The summary data as of and for the six months ended August 31, 2007 and 2006 (Unaudited) and the summary data as of and for the years ended February 28, 2007 and 2006 (Audited) are derived from our consolidated financial statements and related notes, which are included elsewhere in this prospectus. In the opinion of management, the unaudited interim consolidated financial statements have been prepared on the same basis as the audited consolidated financial statements and include all adjustments necessary for the fair presentation of our financial position and results of operations for these periods. You should read the following information together with the more detailed information contained in "Selected Consolidated Financial Data," "Management's Discussion and Analysis of Financial Condition and Results of Operations" and our consolidated financial statements and the accompanying notes included elsewhere in this prospectus.

CONSOLIDATED
STATEMENTS OF
OPERATIONS DATA:

	Year Ended February 28,			Six Months Ended August 31,	
	2007	2006	2005	2007	2006
Revenues:					
Development payments	\$ -	\$ 225,000	\$ -	\$ -	\$ -
License fees	562,500	479,166	-	125,000	437,500
Grant revenues	-	-	-	75,000	-
Testing services and consulting fees	427,029	340,695	-	132,351	217,521
	989,529	1,044,861	-	332,351	655,021
Operating expenses:					
Research and development	7,190,975	6,829,142	2,629,980	2,817,784	4,529,921
General and administrative	6,824,945	8,451,886	3,337,185	3,290,423	3,659,625
	14,015,920	15,281,028	5,967,165	6,108,207	8,189,546
Operating loss	(13,026,391)	(14,236,167)	(5,967,165)	(5,775,856)	(7,534,525)
Other income(expense):					
Interest income	82,224	70,701	11,869	20,431	11,606
Interest expense	(4,303,543)	(1,140,866)	-	(1,714,326)	(684,407)
Additional expense related to warrants	(7,304,105)	-	-	-	-
Change in fair value of warrant liability	5,318,064	-	-	3,434,017	-
Debt forgiveness	-	-	-	197,614	-
Liquidated damages	-	-	-	(652,500)	-
Loss on extinguishment of debt-related party	(670,053)	-	-	-	-
Other income	161,196	215,789	161,749	33,939	93,701
Other expense	(5,442)	-	-	-	-

Edgar Filing: BIOPHAN TECHNOLOGIES INC - Form S-1

	(6,721,659)	(854,376)	173,618	1,319,175	(579,100)
Loss from continuing operations before minority interest in Myotech, LLC	(19,748,050)	(15,090,543)	(5,793,547)	(4,456,681)	(8,113,625)
Minority interest in Myotech, LLC	2,025,639	606,159	-	725,173	1,215,920
Net loss	\$ (17,722,411)	\$ (14,484,384)	\$ (5,793,547)	\$ (3,731,508)	\$ (6,897,705)
Loss per common share - basic and diluted	\$ (0.23)	\$ (0.19)	\$ (0.08)	\$ (0.05)	\$ (0.09)
Weighted average shares outstanding	77,864,738	75,787,052	69,263,893	81,167,908	77,393,718

CONSOLIDATED BALANCE SHEET DATA:

	As of February 28,		As of August 31,
	2007	2006	2007
Cash and cash equivalents	\$ 2,418,551	\$ 1,477,716	\$ 268,716
Intangible assets, net	\$ 24,396,805	\$ 25,854,850	\$ 23,660,783
Total assets	\$ 28,896,251	\$ 27,968,066	\$ 25,780,474
Total liabilities	\$ 18,966,774	\$ 3,231,158	\$ 7,970,845
Minority interest	\$ 13,139,882	\$ 15,189,109	\$ 12,367,582
Total stockholders' equity (deficiency)	\$ (3,210,405)	\$ 9,547,799	\$ 5,442,047

RISK FACTORS

Investing in our common stock involves a high degree of risk. You should carefully consider the following risk factors, as well as the other information in this prospectus, before deciding whether to invest in our common stock. If any of the following risks actually materializes, our business, financial condition and results of operations would suffer. The trading price of our common stock could decline as a result of any of these risks, and you might lose all or part of your investment in our common stock. You should read the section entitled "Forward-Looking Statements" immediately following these risk factors for a discussion of what types of statements are forward-looking statements, as well as the significance of such statements in the context of this prospectus.

WE MAY BE SUBJECT TO LIABILITY IN THE FORM OF A CLAIM FOR RESCISSION BY CERTAIN SHAREHOLDERS.

As a result of our Forbearance Agreement with certain investors dated February 16, 2007, the Securities and Exchange Commission may take the position that the sale of the \$7,250,000 of senior secured convertible notes had not been completed before we filed the registration statement of which this prospectus is a part and as such we may have issued securities without a valid exemption in violation of Section 5 of the Securities Act of 1933, as amended, for such placement. The \$7,250,000 of senior secured convertible notes were convertible by the investors into 10,820,896 shares of common stock. As additional consideration for the senior secured convertible notes we issued the investors warrants to purchase 10,820,896 shares of our common stock and in connection with the execution of the Forbearance Agreement we issued the investors additional warrants to purchase an aggregate of 60,000 shares of our common stock.

If the Securities and Exchange Commission takes the position that the foregoing was a violation of Section 5 of the Securities Act of 1933, as amended, the investors may be entitled to, among other penalties or fines which may be assessed against us the right to demand rescission of the offering. In that case, we would be required to pay each investor the amount we received as consideration for the securities issued under an invalid exemption, plus any interest accrued with respect to such amount at the applicable rate, and the securities would be cancelled.

WE ARE A BUSINESS WITH A LIMITED OPERATING HISTORY AND ARE NOT LIKELY TO SUCCEED UNLESS WE CAN OVERCOME THE MANY OBSTACLES WE FACE.

We are an early-stage research and development company with limited prior business operations and no material revenues to date. We are presently engaged in the development of certain technologies for use with medical procedures and biomedical devices. Because of our limited operating history, you may not have adequate information on which you can base an evaluation of our business and prospects. To date, our efforts have been devoted primarily to the following:

- organizational activities;
- developing a business plan;
- obtaining funding;
- conducting research and working toward the ultimate successful development of our technologies;
- aggressively patenting our intellectual property;
- licensing technology from third parties related to our business; and

marketing to major biomedical device manufacturers.

In order to establish ourselves in the medical device market, we are dependent upon continued funding and the successful development and marketing of our products. You should be aware of the increased risks, uncertainties, difficulties, and expenses we face as a research and development company and that an investment in our common stock may be worthless if our business fails.

8

IF WE ARE UNABLE TO GENERATE SUFFICIENT REVENUES IN THE FUTURE, WE MAY NOT BE ABLE TO CONTINUE OUR BUSINESS.

We are still in our formative and development stage. As an investor, you should be aware of the difficulties, delays, and expenses normally encountered by an enterprise in its development stage, many of which are beyond our control, including unanticipated research and developmental expenses, employment costs, and administrative expenses. We cannot assure our investors that our proposed business plans as described in this prospectus will materialize or prove successful, or that we will ever be able to finalize development of our products or operate profitably. If we cannot operate profitably, you could lose your entire investment. As a result of the start-up nature of our business, initially we expect to sustain substantial operating expenses without generating significant revenues.

WE HAVE A HISTORY OF LOSSES AND A LARGE ACCUMULATED DEFICIT AND WE EXPECT FUTURE LOSSES THAT MAY CAUSE OUR STOCK PRICE TO DECLINE.

For the six months ended August 31, 2007, we incurred a net loss of \$3,731,508, and for the fiscal years ended February 28, 2007, 2006 and 2005, we incurred net losses of \$17,722,411, \$14,484,384, \$5,793,547, respectively. We have incurred cumulative net losses from inception through August 31, 2007 of \$53,423,577. We expect to continue to incur losses as we spend additional capital to develop and market our technologies and establish our infrastructure and organization to support anticipated operations. We cannot be certain whether we will ever earn a significant amount of revenues or profit, or, if we do, that we will be able to continue earning such revenues or profit. Also, our current financial condition may limit our ability to develop and ultimately market our technologies. Any of these factors could cause our stock price to decline and result in you losing a portion or all of your investment.

THE INABILITY TO RETAIN AND ATTRACT KEY PERSONNEL COULD ADVERSELY AFFECT OUR BUSINESS AND PLAN OF OPERATIONS.

We believe that our future success will depend on the abilities and continued service of certain of our senior management and executive officers, particularly our Chief Executive Officer and those persons involved in the research and development of our products. If we are unable to retain the services of these persons, or if we are unable to attract additional qualified employees, researchers, and consultants, we may be unable to successfully finalize and eventually market our medical devices and other products being developed, which will have a material adverse effect on our business.

OUR RESEARCH AND DEVELOPMENT EFFORTS MAY NOT RESULT IN COMMERCIALY VIABLE PRODUCTS, WHICH COULD RESULT IN A DECLINE OF OUR STOCK PRICE AND A LOSS OF YOUR INVESTMENT.

Our technologies are in the development stage. Further research and development efforts will be required to develop these technologies to the point where they can be incorporated into commercially viable or salable products. We have set forth in this prospectus our proposed research and development program as it is currently conceived. We cannot assure you, however, that this program will be accomplished in the order or in the time frame set forth. We reserve the right to modify the research and development program. We may not succeed in developing commercially viable products from our technologies. Also, our research and development efforts are aimed at technology that will enable certain medical procedures and biomedical devices to become safe and compatible with MRI diagnostics. If MRI diagnostics are replaced by the healthcare industry, our technology and products, if any, may become obsolete. If we are not successful in developing commercially viable products or if such products become obsolete, our ability to generate revenues from our technologies will be severely limited. This would result in the loss of all or part of your investment.

WE MAY NOT BE ABLE TO DEVELOP A MARKET FOR OUR TECHNOLOGY, WHICH WILL LIKELY CAUSE OUR STOCK PRICE TO DECLINE.

The demand and price for our technology and related products will be based upon the existence of markets for the technology and products and the markets for products of others, which may utilize our technology. The extent to which we may gain a share of our intended markets will depend, in part, upon the cost effectiveness and performance of our technology and products when compared to alternative technologies, which may be conventional or heretofore unknown. If the technology or products of other companies provide more cost-effective alternatives or otherwise outperform our technology or products, the demand for our technology or products may be adversely affected. Our success will be dependent upon market acceptance of our technology and related products. Failure of our technology to achieve and maintain meaningful levels of market acceptance would materially and adversely affect our business, financial condition, results of operations, and market penetration. This would likely cause our stock price to decline.

IF WE ARE NOT ABLE TO COMPETE EFFECTIVELY IN THE COMPETITIVE MEDICAL DEVICE INDUSTRY, OUR FUTURE GROWTH AND OPERATING RESULTS WILL SUFFER.

Our future success depends on our ability to compete effectively with manufacturers of medical devices, including major manufacturers of pacemakers and other implantable devices that may have internal development programs. We are an early-stage research and development company engaged exclusively in developing our initial technologies. Products using our technologies have not yet been commercialized and we have generated no material revenue from operations. As a result, we may have difficulty competing with larger, established medical device companies. Most of our potential competitors will be established, well-known companies that have:

- substantially greater financial, technical and marketing resources;
- larger customer bases;
- better name recognition;
- related product offerings; and
- larger marketing areas.

Companies such as Medtronic, Inc., Guidant Corporation, St. Jude Medical, Boston Scientific Corporation, and Johnson & Johnson are major, international providers of medical devices currently with limited compatibility for MRI. Because these companies may possibly develop MRI image compatibility solutions for their own product lines, they may ultimately be in competition with us. These companies represent a wide array of medical devices and products, technologies, and approaches. All of these companies have more resources than we do and, therefore, a greater opportunity to develop comparable products and bring those products to market more efficiently than we can. If we do not compete effectively with current and future competitors, our future growth and operating results will be adversely affected.

WE MAY NOT BE ABLE TO OBTAIN NECESSARY GOVERNMENT APPROVAL TO MARKET OUR TECHNOLOGY WHICH WILL LIKELY CAUSE OUR STOCK PRICE TO DECLINE AND OUR BUSINESS TO FAIL.

Our marketing partners must obtain the approval of the U.S. Food and Drug Administration in order to market our MRI image compatibility technology and Myotech CSS technology. If these approvals are not obtained, or are significantly delayed, our ability to generate revenues may be adversely affected and our development and marketing efforts inhibited. This would most likely cause our stock price to decline and result in the loss of all or part of your

investment.

10

WE MAY NOT BE ABLE TO PROTECT OUR PROPRIETARY RIGHTS AND WE MAY INFRINGE THE PROPRIETARY RIGHTS OF OTHERS. OUR INABILITY TO PROTECT OUR RIGHTS COULD IMPAIR OUR BUSINESS AND CAUSE US TO INCUR SUBSTANTIAL EXPENSE TO ENFORCE OUR RIGHTS.

Proprietary rights are critically important to us. We currently have 49 issued U.S. patents and over 60 U.S. and international patents pending. Although we intend to aggressively pursue additional patent protection for our technologies as we continue to develop them, we cannot assure you that any additional patents will be issued. Although we will seek to defend our patents and to protect our other proprietary rights, our actions may be inadequate to protect our patents and other proprietary rights from infringement by others, or to prevent others from claiming infringement by us of their patents and other proprietary rights.

Policing unauthorized use of our technology is difficult, and some foreign laws do not provide the same level of protection as U.S. laws. Litigation may be necessary in the future to enforce our intellectual property rights, to protect our trade secrets or patents that we may obtain, or to determine the validity and scope of the proprietary rights of others. Such litigation could result in substantial costs and diversion of resources and have a material adverse effect on our future operating results.

FUTURE SALES OF OUR COMMON STOCK WOULD HAVE A DILUTIVE EFFECT ON CURRENT STOCKHOLDERS AND COULD ADVERSELY IMPACT THE MARKET PRICE FOR OUR COMMON STOCK.

Sales of a substantial number of shares of our common stock, or the perception that sales could occur, whether at the then current market price or below the then current market price, could adversely affect prevailing market prices for our common stock. For example, in connection with our issuance of \$7,250,000 of senior secured amortizing convertible notes on October 12, 2006, of which \$5,287,756 in principal is currently outstanding, the holders of the notes may elect to convert the notes at any time into shares of our common stock at a price of \$0.15 per share (the "Conversion Price"). Payments of interest and principal on the notes may be made, at our option, in cash or shares of our common stock registered for resale under the Securities Act, and if we elect to make payments on the notes in shares, those payments will be based on the lower of (i) the Conversion Price or (ii) 90% of the volume weighted trailing average price per share of our common stock for the 20 trading days ending 23 trading days prior to the date we make a payment. As additional consideration to the purchasers of the notes, we issued five-year warrants that currently permit the investors to purchase an aggregate of 18,034,830 shares of our common stock at an exercise price of \$0.23 per share. As further consideration to the purchasers of the notes, we issued one-year warrants to purchase up to 10,820,896 shares of our common stock at a price of \$0.23 per share. If the purchasers elect to exercise this one-year warrant, they will also receive additional five-year warrants to purchase our common stock equal to the number of shares purchased under this one-year warrant, with 50% of the additional warrants having an exercise price of \$0.85 per share and the remaining 50% of the additional five-year warrants having an exercise price of \$0.92 per share. In addition, if we issue additional shares of our common stock for sale in future financings, our stockholders would experience additional dilution.

BECAUSE OUR CEO IS AN AFFILIATE OF OTHER ENTITIES WITH WHOM BIOPHAN HAS SIGNIFICANT BUSINESS RELATIONSHIPS, THERE MAY BE CONFLICTS OF INTEREST THAT YOU SHOULD CONSIDER BEFORE INVESTING IN OUR COMMON STOCK.

John Lanzafame, our interim Chief Executive Officer, is on the Board of NaturalNano, Inc., the largest shareholder of which is Technology Innovations, LLC, which is a 57% equity member of Biomed Solutions LLC, a company engaged in the business of indentifying and acquiring technologies in the biomedical field for exploitation. Biomed is a beneficial owner of 5.17% of our outstanding common stock and holds an aggregate of \$2,250,000 face amount of our convertible promissory note. NaturalNano has entered into a research and development agreement with us for drug eluting technology.

Because of the nature of our business and the business of these other entities, the relationships of Mr. Lanzafame with these other entities may give rise to conflicts of interest with respect to certain matters affecting us. Potential conflicts may not always be resolved in a manner that is favorable to us. We believe it is impossible to predict the precise circumstances under which future potential conflicts may arise and therefore intend to address potential conflicts on a case-by-case basis. Under Nevada law, directors have a fiduciary duty to act in good faith and with a view to the best interests of the corporation.

FORWARD-LOOKING STATEMENTS

This prospectus contains forward-looking statements. All statements other than statements of historical facts contained in this prospectus, including statements regarding our future results of operations and financial position, business strategy and plans and objectives of management for future operations, are forward-looking statements. These statements involve known and unknown risks, uncertainties and other factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements.

In some cases, you can identify forward-looking statements by terms such as "may," "will," "should," "expects," "plans," "anticipates," "could," "intends," "target," "projects," "contemplates," "believes," "estimates," "predicts," "potential" or "continue" or the negative of these terms or other similar words. These statements are only predictions. We have based these forward-looking statements largely on our current expectations and projections about future events and financial trends that we believe may affect our business, financial condition and results of operations. We discuss many of the risks in greater detail under the heading "Risk Factors." Also, these forward-looking statements represent our estimates and assumptions only as of the date of this prospectus. Except as required by law, we assume no obligation to update any forward-looking statements after the date of this prospectus.

This prospectus also contains estimates and other statistical data made by independent parties and by us relating to market size and growth and other industry data. This data involves a number of assumptions and limitations, and you are cautioned not to give undue weight to such estimates. We have not independently verified the statistical and other industry data generated by independent parties and contained in this prospectus and, accordingly, we cannot guarantee their accuracy or completeness. In addition, projections, assumptions and estimates of our future performance and the future performance of the industries in which we operate are necessarily subject to a high degree of uncertainty and risk due to a variety of factors, including those described in "Risk Factors," "Management's Discussion and Analysis of Financial Condition and Results of Operation" and elsewhere in this prospectus. These and other factors could cause results to differ materially from those expressed in the estimates made by the independent parties and by us.

USE OF PROCEEDS

We will not receive any of the proceeds of the sale of shares of common stock by the selling stockholders.

DIVIDEND POLICY

We have never declared or paid any cash dividends on our capital stock and do not expect to pay any cash dividends for the foreseeable future. We intend to use future earnings, if any, in the operation and expansion of our business. In addition, the terms of our credit facility restrict our ability to pay dividends, and any future indebtedness that we may incur could preclude us from paying dividends.

SELECTED CONSOLIDATED FINANCIAL DATA

The following consolidated statements of operations data for the years ended February 28, 2007, 2006 and 2005 and the consolidated balance sheet data as of February 28, 2007 and 2006 have been derived from our audited consolidated financial statements and related notes, which are included elsewhere in this prospectus. The statements of operations data for the years ended February 29, 2004 and February 28, 2003 and the balance sheet data as of February 28, 2005, February 29, 2004 and February 28, 2003 have been derived from our audited consolidated financial statements that do not appear in this prospectus.

Edgar Filing: BIOPHAN TECHNOLOGIES INC - Form S-1

The consolidated statement of operations data for the six months ended August 31, 2007 and 2006 and the consolidated balance sheet as of August 31, 2007 have been derived from our unaudited consolidated financial statements and related notes, which are included elsewhere in the prospectus. In the opinion of management, the unaudited interim consolidated financial statements have been prepared on the same basis as the audited consolidated financial statements and include all adjustments necessary for the fair presentation of our financial position and results of operations for these periods. The consolidated selected financial data set forth below should be read in conjunction with our consolidated financial statements, the related notes and "Management's Discussion and Analysis of Financial Condition and Results of Operations" included elsewhere in this prospectus. The historical results are not necessarily indicative of the results to be expected for any future period.

	Year ended February 28, 2007	Year ended February 28, 2006	Year ended February 28, 2005	Year ended February 29, 2004	Year ended February 28, 2003	Six months ended August 31, 2007 2006	
Operating Data:							
Revenues	\$ 989,529	\$ 1,044,861	\$ -0-	\$ 75,000	\$ -0-	\$ 332,351	\$ 655,021
Research and development expenses	7,190,975	6,829,142	2,629,980	1,240,439	1,373,124	2,817,784	4,529,921
General and administrative expenses	6,824,945	8,451,886	3,337,185	1,911,003	1,792,593	3,290,423	3,659,625
Other income (expense)	(6,721,659)	(854,376)	173,618	(642,128)	(272,535)	1,319,175	(579,100)
Minority interest in Myotech, LLC	2,025,639	606,159	-0-	-0-	-0-	725,173	1,215,920
Net loss	\$ (17,722,411)	\$ (14,484,384)	\$ (5,793,547)	\$ (3,718,570)	\$ (3,438,252)	\$ (3,731,508)	\$ (6,897,705)
Loss per common share - basic and diluted	\$ (.23)	\$ (.19)	\$ (.08)	\$ (.08)	\$ (.11)	\$ (.05)	\$ (.09)
Weighted average shares outstanding	77,864,738	75,787,052	69,263,893	44,017,010	31,731,051	81,167,908	77,393,718

	February 28, 2007	February 28, 2006	February 28, 2005	February 29, 2004	February 28, 2003	August 31, 2007	
Balance Sheet Data:							
Current assets	\$ 2,631,520	\$ 1,880,826	\$ 2,007,181	\$ 2,077,307	\$ 476,353	\$ 552,769	
Intangible assets net	24,396,805	27,968,066	997,738	70,000	70,000	23,660,783	
Total assets	28,896,251	27,968,066	3,181,370	2,231,345	683,056	25,780,474	
Current liabilities	7,418,579	3,231,158	1,462,103	254,058	796,187	6,676,690	
Long-term liabilities	11,548,195	-0-	-0-	-0-	83,333	1,294,155	
Minority interest	13,139,882	15,189,109	-0-	-0-	-0-	12,367,582	
Stockholders' equity(deficiency)	(3,210,405)	9,547,799	1,719,267	1,977,287	(196,464)	5,442,047	
Working capital (deficiency)	(4,787,059)	(1,350,332)	545,078	1,823,249	(319,834)	(6,123,921)	

MANAGEMENT'S DISCUSSION AND ANALYSIS

OF FINANCIAL CONDITION AND PLAN OF OPERATION

The following discussion and analysis of our financial condition and results of operations should be read in conjunction with our consolidated financial statements and related notes that appear elsewhere in this prospectus. In addition to historical consolidated financial information, the following discussion contains forward-looking statements that reflect our plans, estimates and beliefs. Our actual results could differ materially from those discussed in the forward-looking statements. Factors that could cause or contribute to these differences include those discussed below and elsewhere in this prospectus, particularly in “Risk Factors.”

Overview

We are a technology development company with a strong focus on solving real-world technical challenges facing the medical device industry. We currently have 49 issued U.S. patents and over 60 U.S. and international patents pending. We believe that a strong intellectual property portfolio is vital to our ability to achieve and maintain royalties and product sales to major industrial partners across our product lines.

When selecting a market opportunity to address, we generate a wide range of potential technical solutions. We strive to assure that each technical solution we pursue is well-protected by intellectual property to ensure that we have the capability to effectively market our technologies. Whenever practical, we attempt to develop and patent multiple solutions for any given technology requirement. This is done both to strengthen our position against competitors, and to be in a position to offer multiple manufacturers alternative solutions, such as for MRI visibility of vascular stents, as we introduce our technologies to the market. This approach has resulted in the development of a range of core technologies, in various related segments of the medical device market. We are aggressive in development and defense of our intellectual property.

We also continue development of a new circulatory support device, through our relationship with Myotech, LLC. The Myotech Circulatory Support System is a life-saving device that provides benefits and competitive advantages not possible with other cardiac assist devices. In the past, this technology has saved human lives and holds the potential for the treatment of multiple forms of acute and chronic heart failure.

Revenue

We currently derive revenue from sales of intellectual property rights, from development contract payments, license fees from Boston Scientific Scimed and operating revenues from our European subsidiary, consisting primarily of MRI-related testing and consulting services to medical device manufacturers.

Research and Development Expenses

Research and development expenses consist primarily of:

- salaries and related costs for our research and development employees at our U.S. and European sites;
- funding for various research projects, often employing the use of consulting scientists and engineers;
- legal fees to file, renew, and defend our patent estate; and
- license fees for access to certain patent technologies developed by others.

General and Administrative Expenses

General and administrative expenses consist primarily of:

- salaries and related costs of executives, administrative and marketing personnel;
- professional service costs;
- public / investor relations;
- travel and related costs; and
- occupancy and other overhead costs.

Critical Accounting Policies and Estimates

Management does not believe that any recently issued, but not yet effective, accounting standards if currently adopted would have a material effect on the accompanying financial statements.

Revenue Recognition

We earn and recognize revenue under development agreements when the phase of the agreement to which amounts relate is completed and we have no further performance obligation. Completion is determined by the attainment of specified milestones including a written progress report. Advance fees received on such agreements are deferred until recognized. We recognize initial license fees over the term of the related agreement. Revenue related to a performance milestone is recognized upon the achievement of the milestone, as defined in the respective agreements. We also recognize revenues from testing services and consulting fees as services are performed. We recognize income from sales of intellectual property rights at the time upon transfer of title to the rights.

Accounting Requirements Resulting from the Securities Purchase Agreement dated October 11, 2006

The accounting treatment for the \$7,250,000 in Senior Secured Convertible Notes and related warrants issued pursuant to the Securities Purchase Agreement dated October 11, 2006 among Biophan and the Investors named therein (the "Purchase Agreement") was accounted for in accordance with EITF 00-19, Accounting for Derivative Financial Instruments Indexed to, and Potentially Settled in, a Company's Own Stock and EITF 00-27 Application of Issue No. 98-5 to Certain Convertible Instruments. EITF 00-19 requires freestanding contracts that are settled in a company's own stock to be designated as an equity instrument, an asset or a liability. A contract designated as a liability must be carried at fair value with any changes in fair value recorded in results of operations for the current period. We determined that the warrants issued pursuant to the Purchase Agreement, due to the registration rights requirements contained therein, as well as other outstanding warrants, due to the insufficiency of the Company's then current number of authorized and unissued shares of common stock, should be designated as a liability. Accordingly, using the Black-Scholes method to compute the fair value, we recorded a fair value of warrant liability of \$10.5 million. Further, we recognized the allocation of value to the warrants by recording a \$7,250,000 discount against the Notes. The discount is being amortized to Interest Expense over the term of the Note, using the effective interest method.

In addition, on October 11, 2006, in connection with our Securities Purchase Agreement dated October 11, 2006 with Iroquois Master Fund Ltd and other private investors (the "Purchase Agreement"), we amended our January 24, 2006 Line of Credit Agreement (the "Biomed Line of Credit Agreement") with Biomed and the Convertible Promissory Note in the original principal amount of \$5,000,000 issued by us to Biomed on January 24, 2006 pursuant to the Biomed Line of Credit Agreement (the "\$5,000,000 Biomed Note"). The amendment reduced the price at which the \$5,000,000 Biomed Note is convertible into shares of our Common Stock from \$1.46 per share to a conversion price of \$0.67. In connection with the Purchase Agreement, we also entered into a Subordination and Standstill Agreement (the "Subordination Agreement") with Biomed and the investors who are parties to the Purchase Agreement, pursuant to which Biomed agreed (i) to subordinate its rights to payment under the \$5,000,000 Biomed Note and the Convertible Promissory Note in the original principal amount of \$2,000,000 issued by us to Biomed on May 27, 2005 to the rights of the investors under the Notes and (ii) to convert the entire outstanding amount of principal and interest due under the \$5,000,000 Biomed Note in excess of \$700,000 into shares of our common stock upon the effectiveness of an amendment to our Articles of Incorporation to increase the number of our authorized shares which we have agreed, in the Purchase Agreement, to propose to our stockholders. For accounting purposes, these amendments have been treated, in substance, as an extinguishment of the old debt. Accordingly, the remaining unamortized discount on the old debt of \$1,098,442 was written off, a loss on extinguishment of \$670,053 on the old debt was recognized, and a discount of \$175,970 was recorded on the new debt and fully amortized during the year ended February 28, 2007.

The warrants subject to the Subordination Agreement were not reclassified because Biomed agreed not to exercise them until the proposed increase in the number of authorized shares was effective, and Biomed has agreed not to require a cash settlement in the event the number of authorized shares is not increased.

Accounting for Income Taxes

We are a development stage company with accumulated deficits through August 31, 2007 of \$53,423,577. We plan to use our net operating loss carryforwards to offset our future taxable net income until the accumulated net operating losses are exhausted.

Tabular Disclosure of Contractual Obligations

The following table sets forth information, as of February 28, 2007, our most recent fiscal year end, with respect to our known contractual obligations reflected on our Balance Sheet as of such date:

	Total	Payment Due By Period			
		Less Than 1 Year	1-3 Years	3-5 Years	More Than 5 Years
Contractual Obligations:					
Long-Term Debt	\$ 7,250,000	\$ 2,856,061	\$ 4,393,939	\$ —	—
Capital Lease Obligations	27,049	7,445	19,604	—	—
Operating Lease Obligations	2,301,550	102,891	286,094	311,626	1,600,939
Cooperative Research and Development Agreement (CRADA)	112,500	75,000	37,500	—	—
License Agreements	5,447,500	337,500	737,500	690,000	3,682,500
Employment Agreements	313,750	218,750	95,000		
Total	\$ 15,452,349	\$ 3,597,647	\$ 5,569,637	\$ 1,001,626	\$ 5,283,439

Lease Obligation

At February 28, 2007, the Company was obligated under operating leases for office space originally expiring January 30, 2008, which the Company had the right to terminate upon ninety days prior written notice to the landlord. The notice of termination was given to the landlord and we occupied the premises on a month-to-month basis until February 9, 2007. The Company has entered into new operating leases for office space commencing March 2007 and expiring April 30, 2022, subject to our right to terminate at any time after December 31, 2008 upon 90 days' notice.

The following is a schedule of future minimum rental payments, included annual increases, required under the operating lease agreements:

Year Ending February 28,	Amount
2008	\$ 102,891
2009	139,558
2010	146,536
2011	153,636
2012	157,990
Thereafter	1,600,939
	\$ 2,301,550

Rent expense, net of subrentals, charged to operations under these operating lease aggregated \$113,161, \$70,775 and \$58,546 for the years ended February 28, 2007, 2006, and 2005, respectively. Rent expense, net of subrentals, charged to operations for the period from August 1, 1968 (Date of Inception) to February 28, 2007 was \$368,626.

License Agreements

We are obligated under seven license or royalty agreements for patents that expire at various dates through 2025. These agreements may be terminated by us with 60 days written notice. Aggregate minimum future payments over the remaining life of the patents under these agreements total \$5,447,500. License/royalty expense charged to operations was \$152,410, \$594,890, and \$89,880 for the years ended February 28, 2007, 2006 and 2005 respectively.

Employment Agreements

We have employment agreements with our executive officers that renew annually unless terminated by either party. Such agreements, which have been revised from time to time, provide for minimum salary levels, adjusted annually for cost-of-living changes, as well as for incentive bonuses that are payable if specified management goals are attained.

Also, we have an employment contract with an officer that expires November 9, 2007, and Biophan Europe has an employment agreement with a key employee that expires on February 24, 2009. These agreements provide for base salaries, bonuses based on attaining certain milestones, a restricted stock grant and stock options. The aggregate commitment for future base salaries at February 28, 2007, excluding bonuses and other awards approximates \$313,750.

Investment in Myotech, LLC

Effective November 30, 2005, we entered into a Securities Purchase Agreement for the acquisition of an initial 35% interest in Myotech, LLC ("Myotech"), a New York limited liability company, whereby we exchanged 4,923,080 shares of our common stock for 3,768,488 Class A (voting) units of Myotech.

Based upon the terms of the Securities Purchase Agreement, we were obligated to purchase for cash consideration of \$2,225,000 an additional 811,037 Class A units. We may also elect to acquire up to an additional 3,563,097 Class A units for further cash consideration of up to \$9,775,000, over a 24-month period, which may result in our owning a majority interest in Myotech. During the three month period ended February 28, 2006, we provided \$1,185,000 of additional funding for 431,946 additional Class A units of Myotech. During 2007, we provided \$1,040,000 of additional funding satisfying the mandatory \$2,225,000 cash contribution, and received in exchange 379,091 additional Class A units of Myotech. In addition, Biophan has also provided an additional investment of \$1,994,349 to Myotech against milestone 2 in the year ended February 28, 2007 for 726,963 newly issued Class A units, which increased our ownership to 43.7%. Additional investments of \$105,175 against milestone 2 have been made since February 28, 2007 for 38,337 additional newly issued Class A units, which raised our ownership percentage to 43.8% to date.

On October 2, 2007, we entered into a Securities Purchase Agreement with Myotech, pursuant to which we agreed to purchase from Myotech an aggregate of 15,496,547 membership units for an aggregate purchase price of \$3,200,000. Prior to the execution of the agreement we owned 5,408,194 Class A Membership Units of Myotech. In accordance with the agreement, upon execution of the agreement we received 5,000,000 Class A Membership Units and were to receive an additional 4,316,547 Class A Membership Units upon the payment of an aggregate initial purchase price of \$1,200,000. Thereafter, upon the satisfaction of certain conditions, we would purchase an additional 6,180,000 Class A Membership Units of Myotech for a purchase price of \$2,000,000. As a result of this investment the Company's holdings in Myotech will increase to approximately 75% and provide Biophan with control of a majority of the Board of Directors of Myotech.

We have determined that Myotech is a Variable Interest Entity within the meaning of FIN 46(R) and that we are the primary beneficiary (as defined in FIN 46(R)). Consequently, the financial statements of Myotech have been consolidated with our consolidated financial statements for all periods ending on or after November 30, 2005, the date of our initial investment in Myotech.

Additional Expense Related to Warrants.

In accordance with the guidance provided by EITF 00-19, Accounting for Derivative Financial Instruments Indexed to and Potentially Settled in, a Company's Own Stock, we incurred this expense in connection with the issuance of convertible notes and warrants on October 12, 2006 to record the total fair value of derivative liability, originally recorded at \$15,309,980. This amount is adjusted quarterly. The adjustment is recorded under a separate caption "Change in Fair Value of Warrant Liability".

Fair Value of Warrant Liability.

In accordance with the guidance provided by EITF 00-19, Accounting for Derivative Financial Instruments Indexed to and Potentially Settled in, a Company's Own Stock, we have recorded a liability of \$10,157,937 for the fair value of the warrants related to the Senior Secured Convertible Notes at February 28, 2007 in order to provide for the possibility that we may be unable to comply with the registration rights of the lenders as contained in the Securities Purchase Agreement and we currently do not have sufficient available authorized shares to execute a potential conversion of the Notes and related warrants and thus we would be required to settle the contract in cash. In addition, since we currently do not have sufficient available authorized shares to execute a potential conversion of other outstanding warrants if requested to do so by the grantees, we could be required to settle any conversion requests in cash. Therefore, we reclassified warrants with an approximate value of \$756,000 from equity to the warrant liability. The fair value of this amount was \$336,069 at February 28, 2007. The Company has obtained stockholder approval to increase the authorized shares at a Special Meeting held on May 8, 2007. The total fair value of derivative liability, originally recorded at \$15,309,980 on October 12, 2006, was adjusted by \$4,815,974 to \$10,494,006 at February 28, 2007. The fair value of the derivative liability pertaining to the warrants is volatile. For a further explanation on the

factors and assumptions included in the Black-Scholes model to derive the fair values, please refer to the notes to the consolidated financial statements under the heading 'Fair Value of Warrant Liability'.

RESULTS OF OPERATIONS

The following table presents the dollar amount and percentage of changes from period to period of the line-items included in our Condensed Consolidated Statements of Operations for the three months and six months ended August 31, 2007 and 2006:

	Three Months Ended August 31,				Six Months Ended August 31,			
	2007	2006	Incr. (Decr.)	% Change	2007	2006	Incr. (Decr.)	% Change
Revenue	\$ 160,018	\$ 310,099	\$(150,081)	(48.40%)	\$ 332,351	\$ 655,021	\$(322,670)	(49.26%)
Operating expenses:								
Research and development	1,497,837	1,941,513	(443,676)	(22.85%)	2,817,784	4,529,921	(1,712,137)	(37.80%)
General and administrative	1,802,753	1,573,434	229,319	(14.57%)	3,290,423	3,659,625	(369,202)	(10.09%)
Total expenses	3,300,590	3,514,947	(214,357)	(6.10%)	6,108,207	8,189,546	(2,081,339)	(25.41%)
Operating loss	(3,140,572)	(3,204,848)	64,276	(2.01%)	(5,774,856)	(7,534,525)	1,758,669	(23.34%)
Other income (expense)	(1,026,255)	(329,508)	(696,747)	211.45%	1,319,175	(579,100)	1,898,275	(327.80%)
Loss from continuing operations before minority interest in Myotech, LLC	(4,166,827)	(3,534,356)	(632,471)	17.89%	(4,456,681)	(8,113,625)	3,656,944	(45.07%)
Minority interest in Myotech, LLC	253,354	520,095	(266,741)	(51.29%)	725,173	1,215,920	(490,747)	(40.36%)
Net loss	\$(3,913,473)	\$(3,014,261)	\$(899,212)	29.83%	\$(3,731,508)	\$(6,897,705)	\$ 3,166,197	(45.90%)

The following comments discuss the significant factors affecting the consolidated operating results of the Company comparing the three months ended August 31, 2007 to the three months ended August 31, 2006 and the six months ended August 31, 2007 to the six months ended August 31, 2006.

Comparison of the Three Months Ended August 31, 2007 to the Three Months Ended August 31, 2006**Revenues:**

Revenues were \$160,018 for the three months ended August 31, 2007 as compared to \$310,099 for the three months ended August 31, 2006. The decrease was due principally to the agreed-upon schedule of license fee payments and amortization thereof from Boston Scientific Scimed (\$125,000) and decreased operating revenues from our European subsidiary, which consisted primarily of MRI-related testing and consulting services to medical device manufacturers

(\$50,000).

Research and Development Expenses:

Research and development expenses decreased by 23%, or \$444,000. After factoring out an increase in non-cash charges relating to stock options expense (\$450,000) however, expenses decreased by 894,000, 51%. The decrease is attributable generally to our planned reductions in spending on our research and development projects, due to restructuring. The major areas of decreased expenses were Project Funding (\$580,000), Consulting (\$180,000), and Personnel (\$116,000).

General and Administrative Expenses:

General and administrative expenses increased by 15%, or \$229,000. After factoring out an increase in non-cash charges relating to stock options expense (\$450,000) however other expenses decreased by 660,000, or 35%. The decrease is attributable generally to our planned reductions in spending on our research and development projects, due to restructuring. The major areas of decreased expenses were Public Relations (\$263,000), Personnel (\$117,000), Travel (\$76,000), Shareholder Expenses (\$74,000), Office Supply and Expense (\$56,000) and Consulting & Outside Services (\$43,000).

Other income (expense):

The major component of this category is interest expense, accounting for \$1,234,622 of a net total of \$1,026,255 for the three months ended August 31, 2007 compared with \$380,934 of a net total of \$329,508 for the three months ended August 31, 2006. Interest expense increased by \$853,688. The major areas attributable to the increase was due to interest (\$180,000), and discount (905,197) related to the Senior Secured Convertible Notes and a decrease in interest (\$359,000) related to the Biomed Line of Credit.

Minority Interest in Myotech LLC:

The increase in this line-item is a direct effect of allocating the losses incurred by Myotech to the interest of the owners of Myotech other than Biophan.

Comparison of the Six Months Ended August 31, 2007 to the Six Months Ended August 31, 2006

Revenues:

Revenues were \$332,351 for the six months ended August 31, 2007 as compared to \$655,021 for the six months ended August 31, 2006. The decrease was due principally to the agreed-upon schedule of license fee payments and amortization thereof from Boston Scientific Scimed (\$315,500) and decreased operating revenues from our European subsidiary, which consisted primarily of MRI-related testing and consulting services to medical device manufacturers (\$82,000). There was also an increase in Grant revenues (\$75,000).

Research and Development Expenses:

Research and development expenses decreased by 38%, or \$1,712,137. After factoring out an increase in non-cash charges relating to stock options expense (\$267,000) however, expenses decreased by \$2,162,000, 49%. The decrease is attributable generally to our planned reductions in spending on our research and development projects, due to restructuring. The major areas of decreased expenses were Project Funding (\$1,360,000), Consulting (\$432,000), and Personnel (\$127,000).

General and Administrative Expenses:

General and administrative expenses decreased by 10%, or \$369,202. After factoring out an increase in non-cash charges relating to stock options expense (\$889,000) However, other expenses decreased by 1,258,000, or 36%. The decrease is attributable generally to our planned reductions in spending, due to restructuring. The major areas of decreased expenses were Public Relations (\$678,000), Personnel (\$128,000), Travel (\$100,000), Shareholder Expenses (\$70,000), Legal fees (\$142,000), Office Supply and Expense (\$44,000), and Consulting and Outside Services (\$241,000). Also, there was an increase in Accounting fees (\$202,000).

Other income (expense):

The major component of this category is interest expense, accounting for \$1,714,326 of a net other income of \$1,319,175 for the six months ended August 31, 2007 compared with \$684,407 of a net other expense of \$579,100 for the six months ended August 31, 2006. The major areas attributable to the increase were due to interest (\$342,000), discount (\$1,910,000), and a decrease in change in fair value of derivative liability (\$4,339,000) related to the Senior Secured Convertible Notes and a decrease in interest (\$570,000) related to the reduction of the Biomed Line of Credit. Other items attributable to the increase in net other income is the change in the fair value of warrant liability (\$3,434,000) and a decrease due to liquidated damages (\$652,500).

The following table sets forth our results of operations for the fiscal years ended February 28, 2005 through 2007:

	Year Ended February 28,		
	2007	2006	2005
Revenues:			
Development payments	\$ —	\$ 225,000	\$ —
License fees	562,500	479,166	—
Testing services and consulting fees	427,029	340,695	—
	989,529	1,044,861	—
Operating expenses:			
Research and development	7,190,975	6,829,142	2,629,980
General and administrative	6,824,945	8,451,886	3,337,185
Write-down of intellectual property rights	—	—	—
	14,015,920	15,281,028	5,967,165
Operating loss	(13,026,391)	(14,236,167)	(5,967,165)
Other income(expense):			
Interest income	82,224	70,701	11,869
Interest expense	(4,303,543)	(1,140,866)	—
Additional expense related to warrants	(7,304,105)	—	—
Change in fair value of warrant liability	5,318,064	—	—
Loss on extinguishment of debt - related party	(670,053)	—	—
Other income	161,196	215,789	161,749
Other expense	(5,442)	—	—
	(6,721,659)	(854,376)	173,618
Loss from continuing operations before minority interest in Myotech, LLC	(19,748,050)	(15,090,543)	(5,793,547)
Minority interest in Myotech, LLC	2,025,639	606,159	—
Loss from continuing operations	(17,722,411)	(14,484,384)	(5,793,547)
Loss from discontinued operations	—	—	—
Net loss	\$ (17,722,411)	\$ (14,484,384)	\$ (5,793,547)
Loss per common share - basic and diluted	\$ (0.23)	\$ (0.19)	\$ (0.08)
Weighted average shares outstanding	77,864,738	75,787,052	69,263,893

Comparison of the Years Ended February 28, 2007 and 2006

Revenues

Revenues for the year ended February 28, 2007 were \$0.990 million compared to \$1.045 million in 2006. Our 2007 revenues pertain to \$0.563 million in license fees from our licensing agreement with Boston Scientific Scimed, Inc. and \$0.427 million from our MRI testing services and consulting fees in Biophan Europe. Our 2006 revenues pertain to \$0.704 million in development payments and license fees from our licensing agreement with Boston Scientific Scimed, Inc. and \$0.341 million from our MRI testing services and consulting fees in Biophan Europe.

Operating Expenses

Research and Development. These expenses primarily consist of the personnel-related, technical consulting, professional fees for patent attorneys, and license fees. For the year ended February 28, 2007, these expenses increased by 5.3%, or \$0.362 million, to \$7.191 million compared to \$6.829 million for 2006. Because we consolidated Myotech, LLC at November 30, 2005, the fourth quarter of 2006 included \$0.443 million of Myotech operational expenses and \$0.344 million of Myotech intangible assets amortization. We consolidated Myotech LLC for the

fiscal year. The most significant changes in this category of expenses include a decrease in non-cash stock option compensation expense of \$1.5 million due primarily to a 2006 expense of \$ 1.948 million of non-cash expense from the vesting of contingent stock options that vested upon the achievement of specified performance-based milestones, which was partially offset by 0.1 million for additional professional staff and salary increases. In addition, we increased our funding of various research and development projects by \$1.3 million and we incurred \$1.0 million of increased noncash patent amortization expense related to the Myotech intangible assets, which was partially offset by \$0.6 million of decreased spending for outside professional services related to licenses and patent maintenance.

General and Administrative.

General and administrative expenses include the costs of personnel-related expenses for the administrative, legal, finance, information technology, and communications functions. For the year ended February 28, 2007, these expenses declined by 19%, or \$1.627 million to \$6.825 million compared to \$8.452 million for 2006. Because we consolidated Myotech LLC at November 30, 2005, the fourth quarter of 2006 included \$0.165 million of Myotech operational expenses. We consolidated Myotech LLC for the fiscal year 2007. The most significant changes in this category of expenses include a decrease in non-cash stock option compensation expense of \$1.7 million due primarily to a 2006 expense of \$ 2.296 million of non-cash expense from the vesting of contingent stock options that vested upon the achievement of specified performance-based milestones, which was partially offset by 0.5 million for additional professional staff and salary increases; increased outside professional services of \$0.6 million primarily related to audit, first-year Sarbanes Oxley compliance, and financial consulting. These cost increases were offset by decreased spending by \$1.0 million for other expenses.

Other Income (Expense)

Interest Expense. We incurred interest expense amounting to approximately \$4.304 million for the year February 28, 2007 compared to \$1.141 million of expense for the year ended February 28, 2006. The increased expense (noncash) is attributed to \$2.3 million in interest under provisions of the \$7.25 million Senior Secured Convertible Notes held by Iroquois Master Fund Ltd and other investors; the write-off of \$1.1 million of the remaining unamortized discount on a note to Biomed Solutions, LLC; and approximately \$0.9 million of interest payable on borrowings under lines of credit with Biomed Solutions, LLC.

Change in Fair Value of Warrant Liability. We adjusted this liability of \$10.494 million primarily related to the Senior Secured Convertible Notes at February 28, 2007, or a decrease in expense of \$5.318 million from our initial recording of this derivative liability of \$15.309 million at the closing date of October 12, 2006.

Loss on Extinguishment of Debt. We incurred a loss on the extinguishment of the note (noncash) to Biomed Solutions, LLC due to the substantial amendment to the note to Biomed, amounting to \$0.670 million.

Minority Interest in Myotech LLC. The loss of \$2.026 million is a pro rata share of the loss incurred by Myotech, LLC attributable to minority interests for the year ended February 28, 2007. The loss of \$0.606 million is the pro rata share of the loss incurred by Myotech from November 30, 2005 (date of acquisition) through February 28, 2006. As further described under the heading "Business Combinations" in the "Notes to Consolidated Financial Statements" the Company holds a 43.7% interest in Myotech LLC, valued on our balance sheet at February 28, 2007 at \$12.687 million, which we must consolidate as a variable interest entity since the Company is deemed to be the primary beneficiary in the relationship with Myotech.

Comparison of the Years Ended February 28, 2006 and 2005

Revenues

Revenues for the year ended February 28, 2006 were \$1.045 million compared to no revenues in 2005. Our 2006 revenues pertain to \$0.704 million in development payments and license fees from our licensing agreement with Boston Scientific Scimed, Inc. and \$0.341 million from our MRI testing services and consulting fees in Biophan Europe.

Operating Expenses

Research and Development. These expenses primarily consist of the personnel-related, technical consulting, professional fees for patent attorneys, and license fees. For the year ended February 28, 2006, these expenses increased by 160%, or \$4.199 million, to \$6.829 million compared to \$2.630 million for 2005. Because we consolidated Myotech, LLC at November 30, 2005, the fourth quarter included \$0.443 million of Myotech operational expenses and \$0.344 of Myotech intangible assets amortization. Excluding these expenses, the year-to-year comparison would have reflected an increase of 130%, or \$3.411 million. The most significant increase was caused by \$1.948 million in non-cash contingent stock option expense due to the vesting of contingent options that vested upon the achievement of specified performance-based milestones. With the inclusion of the Myotech expenses, we also increased funding of various research and development projects by \$0.846 million; we incurred increased licensing fees by \$0.515 million, and increased expenses for additional professional staff and salary increases for current staff of \$0.538 million.

General and Administrative. General and administrative expenses include the costs of personnel-related expenses for the administrative, legal, finance, information technology, and communications functions. For the year ended February 28, 2006, these expenses rose by 153%, or \$5.115 million to \$8.452 million compared to \$3.337 million for 2005. Because we consolidated Myotech LLC at November 30, 2005, the fourth quarter included \$0.165 million of Myotech operational expenses. The most significant increase in expense was caused by approximately \$2.296 million in non-cash contingent stock option expense due to the vesting of contingent options that vested upon the achievement of specified performance-based milestones. With the inclusion of the Myotech expenses, outside services increased by \$1.666 million, consisting primarily of additional legal and financial consulting and communications expenses, combined with \$0.358 million in added costs for new staff and increased salaries, and \$0.518 million for travel and other administrative expenses.

Other Income (Expense)

Interest Expense. We incurred interest expense amounting to approximately \$1.141 million primarily related to a \$5 million line of credit from Biomed Solutions, LLC ("Biomed"), which included a beneficial conversion feature of approximately \$1.0 million. The discount is being amortized over the term of the line of credit. The Company incurred no interest expense in 2005.

Minority Interest. This amount is the pro rata share of the loss incurred by Myotech LLC for the 4th quarter of fiscal 2006 at which time Myotech is consolidated with the Company. For further information regarding the basis of consolidation of Myotech, please refer to Footnote 3 in the Notes to the Consolidated Financial Statements.

LIQUIDITY AND CAPITAL RESOURCES

Liquidity

On May 27, 2005, we entered into a Line of Credit Agreement with Biomed Solutions, LLC, a related party, whereby Biomed agreed to provide a line of credit facility of up to \$2 million. Borrowings under the line, bear interest at 8% per annum, are payable on demand and are convertible at Biomed's election, into the Company's common stock at 90% of the average closing price for the 20 trading days preceding the date of borrowings under the line. In June 2005, the Company borrowed the entire \$2 million under the line in two separate draws of \$1 million each. In accordance with the agreement, Biomed received warrants to purchase 500,000 shares of the Company's common stock at an exercise price of 110% of the average closing price for the 20 trading days preceding the date of execution of the credit agreement. The Company recorded a discount on the borrowings of \$958,160 due to the beneficial conversion feature of the note as well as for the value of the warrants. The discount was amortized as additional interest expense over the term of the note. In August 2005, Biomed elected to convert \$1 million of the note plus

accrued interest into 480,899 shares of common stock at which time, the remaining discount related to the \$1 million portion of the loan was fully expensed. On October 7, 2005, we repaid \$500,000 of principal and all accrued interest on the loan. The balance of borrowings on the line was \$500,000 at August 31, 2007.

On January 24, 2006, we entered into an additional Line of Credit Agreement (the "Line of Credit Agreement") with Biomed Solutions, LLC, pursuant to which Biomed committed to make advances to us, in an aggregate amount of up to \$5,000,000. Under the Line of Credit Agreement, advances may be drawn down in such amounts and at such times as we determine upon 15 days prior notice to Biomed, except that we may not draw down more than \$1,500,000 in any 30-day period. Amounts borrowed bear interest at the rate of 8% per annum and were convertible into shares of our Common Stock at the rate of \$1.46 per share. Biomed's obligation to lend to us under the Line of Credit Agreement expires on June 30, 2007, on which date the entire amount borrowed by us (and not converted into shares of our Common Stock) becomes due and payable. In connection with the establishment of the credit facility, we issued to Biomed a warrant to purchase up to 1,198,630 shares of our Common Stock at an exercise price of \$1.89 per share. The Company recorded a discount on the borrowings of \$1,678,425 due to the beneficial conversion feature of the note as well as for the value of the warrant.

On October 11, 2006, in connection with our Securities Purchase Agreement dated October 11, 2006 with Iroquois Master Fund Ltd and other private investors (the "Purchase Agreement"), we amended our January 24, 2006 Line of Credit Agreement (the "Biomed Line of Credit Agreement") with Biomed and the Convertible Promissory Note in the original principal amount of \$5,000,000 issued by us to Biomed on January 24, 2006 pursuant to the Biomed Line of Credit Agreement (the "\$5,000,000 Biomed Note"). The amendment reduced the price at which the \$5,000,000 Biomed Note is convertible into shares of our Common Stock from \$1.46 per share to a conversion price of \$0.67. In connection with the Purchase Agreement, we also entered into a Subordination and Standstill Agreement (the "Subordination Agreement") with Biomed and the investors who are parties to the Purchase Agreement, pursuant to which Biomed agreed (i) to subordinate its rights to payment under the \$5,000,000 Biomed Note and the Convertible Promissory Note in the original principal amount of \$2,000,000 issued by us to Biomed on May 27, 2005 to the rights of the investors under the Notes and (ii) to convert the entire outstanding amount of principal and interest due under the \$5,000,000 Biomed Note in excess of \$700,000 into shares of our common stock upon the effectiveness of an amendment to our Articles of Incorporation to increase the number of our authorized shares which was effective May 9, 2007. On July 19, 2007, Biomed converted \$2,180,000 of principal and \$195,899 of accrued interest into a total of 3,546,118 shares of our common stock leaving a balance outstanding at August 31, 2007 of \$1,750,000.

On October 11, 2006, we entered into a Securities Purchase Agreement (the "Purchase Agreement") with 10 private investors led by Iroquois Master Fund Ltd ("Iroquois"). Pursuant to the Purchase Agreement, on October 12, 2006 we issued \$7,250,000 of Senior Secured Convertible Notes (the "Notes") to the investors and received proceeds of \$6,219,880 after paying estimated fees and expenses of \$1,030,120 related to the transaction. The holders of the Notes may elect to convert the Notes at any time into shares of our common stock based upon a price of \$0.67 per share (the "Conversion Price"). Interest on the outstanding principal amount under the Notes is payable quarterly at a rate equal to the six-month London InterBank Overnight Rate plus 500 basis points, with a minimum rate of 10% per annum and a maximum rate of 12% per annum, payable at our option in cash or shares of our common stock registered for resale under the Securities Act of 1933, as amended (the "Securities Act"). If we elect to make an interest payment in common stock, the number of shares issuable by us will be based upon the lower of (i) 90% of the 20-day trailing average volume weighted average price per share as reported on Bloomberg LP (the "VWAPS") or (ii) the Conversion Price. Principal on the Notes amortizes and payments are due in 33 equal monthly installments commencing four months following issuance of the Notes, and may be made at our option in cash or shares of our common stock registered for resale under the Securities Act. If we elect to make a principal payment in common stock, the number of shares issuable by us will be based upon the lower of (i) 87.5% of the 15-day trailing VWAPS prior to the principal payment date or (ii) the Conversion Price. Our obligations under the Notes are secured by a first priority security interest in substantially all of our assets pursuant to a Security Agreement dated as of October 11, 2006 among us, the investors and Iroquois, as agent for the investors (the "Security Agreement").

As further consideration to the investors, we issued to the investors one-year warrants to purchase an aggregate of 10,820,896 shares of our common stock at a price of \$0.67 per share. If the investors elect to exercise these one-year warrants, they will also receive additional five-year warrants to purchase the shares of our common stock equal to the

number of shares purchased under the one-year warrants, with 50% of the additional warrants having an exercise price of \$.85 per share, and the remaining 50% of the additional five-year warrants having an exercise price of \$.92 per share. We also issued to the investors five-year warrants to purchase an aggregate of 10,820,896 shares of our common stock. The first five-year warrants allow for the purchase of 5,410,448 shares of our common stock at an exercise price of \$0.81 per share, and the second five-year warrants allow for the purchase of 5,410,448 shares of our common stock at an exercise price of \$0.89 per share. The warrants contain anti-dilution protection that, should we issue equity or equity-linked securities at a price per common share below the exercise price of the five-year warrants, it will automatically adjust the exercise price of the warrants to the price at which we issue such equity or equity-linked securities. The total fair value of the warrants was \$14,554,105. The Company recorded a discount on the Notes of \$7,250,000 for the fair value of the related warrants. The excess of the fair value of the warrants over the carrying value of the notes, which amounted to \$7,304,105, was recognized as additional expense related to warrants in the statement of operations for the year ended February 28, 2007. The discount on the Notes is being amortized over the life of the Notes using the effective interest method. The discount amortization for the three months and six months ended August 31, 2007 amounted to \$905,197 and \$1,910,971 respectively, and is included in interest expense in the accompanying statements of operations.

We further agreed to register for resale under the Securities Act the common stock issuable upon the exercise of the warrants and any shares of common stock we may issue to the holders of the Notes in connection with payments of interest and principal, or which we are obligated to issue upon any conversion of the Notes at the option of the holders. Because we were unable to comply with various provisions of the registration requirements of the Purchase Agreement we incurred liquidated damages amounting to \$652,500 that have been accrued and was charged to operations during the three months ended May 31, 2007.

On February 21, 2007, we entered into a Forbearance Agreement (the "Forbearance Agreement") with the investors pursuant to which the investors agreed that, during the period commencing on February 16, 2007 and ending on the earlier of (i) March 31, 2007 or (ii) the date on which any Termination Event (as defined in the Forbearance Agreement) first occurs (the "Forbearance Period"), they will forbear from exercising any and all of the rights and remedies which they may have against us or any of our assets under the Notes or the Purchase Agreement or at law or in equity as a result of any default under the Notes or as a result of the occurrence of certain events with respect to the Purchase Agreement. In exchange for entering into the Forbearance Agreement, we issued pro rata to the investors three-year warrants for the purchase of an aggregate of 60,000 shares of our common stock at an exercise price of \$0.51 per share (the "Fee Warrants").

Upon the issuance of the Fee Warrants, the exercise prices of the five-year warrants issued to the investors pursuant to the Purchase Agreement (the "Original Warrants") for the purchase of an aggregate of 10,820,896 shares of our common stock were automatically adjusted from \$0.81 per share and \$0.89 per share, respectively, to \$0.51 per share, and the number of shares of our common stock issuable upon exercise of the Original Warrants was automatically adjusted, proportionately, to an aggregate of 18,034,830 shares. In the Forbearance Agreement, the investors waived, with respect to the issuance of the Fee Warrants, application of similar anti-dilution adjustments contained in the Notes and in a third series of warrants for the purchase, on or before October 12, 2007, of an aggregate of 10,820,896 additional shares of our common stock at an exercise price of \$0.67 per share (the "One Year Warrants"). C.E. Unterberg Towbin, which holds a warrant for the purchase of 865,672 shares of our common stock at an exercise price of \$0.67 per share, issued to it in connection with its services as exclusive placement agent under the Purchase Agreement, separately agreed to waive, with respect to the issuance of the Fee Warrants, application of the anti-dilution provisions set forth in that warrant. Because the anti-dilution adjustment to the Original Warrants is accounted for as a modification of the Original Warrants, we recorded an expense for this modification in the period ended February 28, 2007.

On October 3, 2007, we entered into Amendment No. 1 to the Securities Purchase Agreement, Senior Secured Convertible Notes, Warrants and Security Agreement with the independent private investors. Pursuant to the Amendment, we agreed to amend the Notes to provide that even if the we elect to make a monthly installment payment in cash, the holder will have the right to convert any portion of the Note into common stock of the Company and apply the number of shares the holder would have received had we elected to make payment in common stock. In addition, the Conversion Price was reduced to \$0.15. The Amendment also amended the warrants to reduce the exercise prices of the various warrants to \$0.23. In exchange for the foregoing, the investors released certain intellectual property for the Security Agreement, allowing the Company to transfer and sell such intellectual property. Further, in the Amendment, we agreed to certain spending covenants in connection with the proceeds we will receive from the sale of the intellectual property under the Intellectual Property Assignment Agreement dated as of August 6, 2007 by and between Biophan and Medtronic, Inc. As of October 22, 2007 an aggregate of \$5,287,756 in principal was outstanding with respect to these Notes.

Effective November 30, 2005, we entered into a Securities Purchase Agreement for the acquisition of an initial 35% interest in Myotech, LLC ("Myotech"), a New York limited liability company, whereby we exchanged 4,923,080 shares of our common stock, par value \$.005, for 3,768,488 Class A (voting) units of Myotech.

Based upon the terms of the Securities Purchase Agreement, we were obligated to purchase for cash consideration of \$2.225 million an additional 811,037 Class A units. We may elect to acquire up to an additional 3,563,097 Class A units for further cash consideration of up to \$9.775 million, over a 24-month period, which may result in the Company owning a majority interest in Myotech. During the three month period ended February 28, 2006, Biophan provided \$1,185,000 of additional funding for 431,946 newly issued Class A units of Myotech. During the year ended February 28, 2007, Biophan has provided \$1,040,000 of additional funding satisfying the cash consideration of \$2.225 million cited above, for 379,091 newly issued Class A units of Myotech. In addition, Biophan has also provided an additional investment of \$1,994,349 to Myotech against milestone 2 in the year ended February 28, 2007 for 726,963 newly issued Class A units, which increased our ownership to 43.7%. Additional investments of \$395,685 were made during the six months ended August 31, 2007 for 144,232 additional newly issued Class A units, which raised our ownership percentage to 44.1%.

We have determined that Myotech is a Variable Interest Entity within the meaning of FIN 46(R) and that we are the primary beneficiary (as defined in FIN 46(R)). Consequently, the financial statements of Myotech have been consolidated with our consolidated financial statements for all periods ending on or after November 30, 2005, the date of our initial investment in Myotech.

On October 2, 2007, we entered into a revised Securities Purchase Agreement with Myotech pursuant to which the Company agreed to purchase from Myotech an aggregate of 15,496,547 membership units for an aggregate purchase price of \$3,200,000. Prior to the execution of the Agreement Biophan owned 5,408,194 Class A Membership Units of Myotech. In accordance with the Agreement, upon execution of the Agreement Biophan received 5,000,000 Class A Membership Units and was to receive an addition 4,316,547 Class A Membership Units upon the payment of an aggregate initial purchase price of \$1,200,000. Thereafter, upon the satisfaction of certain conditions, Biophan will purchase an additional 6,180,000 Class A Membership Units of Myotech for a purchase price of \$2,000,000. As a result of these investments, our ownership percentage in Myotech will increase to approximately 75%.

On August 6, 2007, we entered into an Intellectual Property Assignment Agreement with Medtronic, Inc., a Minnesota corporation, pursuant to which we agreed to transfer and sell to Medtronic all of our interest in and to certain intellectual property owned by us for an aggregate purchase price of \$11,000,000, which amount would have been reduced to \$10,500,000 if the closing did not occur within 60 days of the execution of the agreement. On October 5, 2007, we closed the transaction contemplated by the Intellectual Property Assignment Agreement, sold the foregoing intellectual property to Medtronic and received an aggregate of \$11,000,000 as the sale price.

As of the date of our Quarterly Report on Form 10-Q for the three months ended May 31, 2007, we disclosed and discussed certain information pertaining to our ability to continue as a going concern. We have been in the development stage since inception, incurring recurring losses from operations and, as of August 31, 2007, the Company's current liabilities exceeded its current assets by \$6,123,921. In addition, as of August 31, 2007, we were in default of our obligations to make payments of principal, interest and liquidated damages to holders of our Senior Secured Convertible Notes. These factors raise potential doubt about the Company's ability to continue as a going concern.

However, as explained previously, on October 3, 2007, we entered into Amendment No. 1 to the Securities Purchase Agreement, Senior Secured Convertible Notes, Warrants and Security Agreement with the independent private investors. Pursuant to the Amendment and related agreements, the aforementioned defaults were cured. In addition, the investors released certain intellectual property for the Security Agreement, allowing the Company to transfer and sell certain intellectual property to Medtronic, Inc.. Further, in the Amendment, we agreed to certain spending

covenants in connection with the proceeds we will received from the sale of the intellectual property under the Intellectual Property Assignment Agreement dated as of August 6, 2007 by and between Biophan and Medtronic. On October 5, 2007, we closed the transaction contemplated by the Intellectual Property Assignment Agreement, sold the foregoing intellectual property to Medtronic and received an aggregate of \$11,000,000 as the sale price.

25

In order to further address the current liquidity situation, management has instituted a cost reduction program that includes a reduction in quarterly operating expenses from approximately \$1,950,000 at this time last year to a cap of \$600,000 per quarter currently. In addition, the Company has reduced its investments in several product lines and pursued alternative funding vehicles in support of other projects.

We have also reorganized our efforts on funding the development of the Myotech Cardiac Support System device. On October 2, 2007, we entered into a revised Securities Purchase Agreement with Myotech, LLC in which we hold a 44% interest as of August 31, 2007. Pursuant to the Agreement, we agreed to purchase from Myotech an aggregate of 15,496,547 membership units for an aggregate purchase price of \$3,200,000. In accordance with the Agreement, we received an additional 5,000,000 Class A Membership Units and an additional 4,316,547 Class A Membership Units upon the payment of an aggregate initial purchase price of \$1,200,000. Thereafter, upon the satisfaction of certain conditions, Biophan will purchase an additional 6,180,000 Class A Membership Units of Myotech for a purchase price of \$2,000,000. As a result of these investments, our ownership percentage in Myotech will increase to approximately 75%.

The proceeds from the sale of intellectual property rights to Medtronic, along with the receipt in December 2007 of our third \$250,000 annual minimum payment under our license agreement with Boston Scientific Scimed, will provide adequate working capital resources for the funding of the Myotech device development and other operations for an estimated twenty-six months.

Capital Resources

Our current strategic plan does not indicate a need for material capital expenditures in the conduct of research and development activities. We currently employ fourteen full-time individuals, twelve in the U.S. and two in Europe.

BUSINESS

OVERVIEW

Biophan Technologies, Inc. is a technology development company with a strong market focus. We were co-founded by Michael Weiner and Wilson Greatbatch, inventor of the first successfully implanted cardiac pacemaker, which he licensed to Medtronic. We went public in December 2000. We have assembled a veteran management team, with extensive experience in technology development, product development, intellectual property management and business-to-business technology licensing.

MRI Related Technologies

Our technologies for MRI safety and image compatibility apply to a broad segment of the medical device marketplace. The limitations of existing devices are becoming increasingly significant as MRI continues to grow as a premier imaging modality due to its exceptional soft tissue contrast, ability to provide functional data and its lack of ionizing radiation, which separates MRI from fluoroscopy and CT imaging.

The limitations of existing medical devices with MRI are two-fold. Some devices have safety limitations - patients with these types of implants would be in danger if they were placed in an MRI machine. These devices are currently contraindicated for use with MRI, preventing patients with these implants from having potentially life saving diagnostic MRI procedures performed. Devices that are currently contraindicated for use with MRI include pacemakers, implantable cardioverter defibrillators (ICDs) and neurostimulators. Biophan developed and sold a suite of patents related to MRI safety to Medtronic in August 2007.

Other types of medical devices are safe for use with MRI, but interfere with the MRI image, creating an image artifact (distortion) when viewed under MRI. This limited MRI image compatibility prevents imaging either within the implant or in the area immediately around the implant. Devices that have limited MRI image compatibility include stents, heart valves, vena cava filters, occluders and certain types of catheters and guidewires.

Biophan has solutions to the problems of MRI image compatibility that enable:

26

MRI image compatible stents which allow for the detection of in-stent restenosis and thrombus detection with a non-invasive MRI procedure rather than a much more invasive angiogram or intravenous ultrasound procedure;

MRI image compatible vena cava filters, which allow for visualization within the filter for the detection of thrombi caught in the filter, enabling the physician to determine when it is safe to remove the device;

MRI image compatible stent-based heart valves, which can be placed under MRI guidance and enable non-invasive follow up and evaluation of the function of the valve; and

Catheters and guidewires designed to operate in an MRI environment safely and effectively, enabling much broader adoption of MRI guided interventional procedures which benefit from improved soft tissue contrast and reduce the exposure of both the patient and physician to the radiation associated with fluoroscopy and CT imaging.

Biophan has aggressively protected its technologies with broad patent protection. Our total U.S. portfolio of patents owned as well as exclusively licensed inclusive 49 issued patents and over 60 applications at various stages of examination at the U.S. Patent and Trademark Office.

Biophan is well positioned to take advantage of this market opportunity, with proven technologies and broad intellectual property protection. We employ internal research facilities, combined with outsourcing to contract laboratories and universities with appropriate expertise, leveraging our core competencies with a network of strategic partnerships. This approach eliminates the need to build unnecessary infrastructure.

Biophan's marketing efforts are focused on business-to-business sales of our technology. Since we are focused on working with the leaders in each market segment, the number of prospective partners is approximately 25 medical device companies. Biophan's marketing and sales efforts rely on a select group of experienced business development and technology licensing executives.

Biophan entered into its first significant license agreement with Boston Scientific Scimed Corporation in 2005 covering a range of products in exclusive and non-exclusive product segments. Boston Scientific renewed its license in January 2007, with a \$250,000 payment.

MYOTECH Circulatory Support System (CSS)

Biophan has also taken a majority equity position in Myotech, LLC, to help Myotech develop and market a novel circulatory support system. The Company has determined that Myotech is a variable interest entity in accordance with FIN 46(R). The Company has further concluded that it is the primary beneficiary as defined by FIN 46(R) and, as a result, the Company is required to consolidate Myotech as of the date of acquisition of November 30, 2005. Therefore, the consolidated financial statements of the Company include the accounts of Myotech, LLC.

Myotech was formed in July 2003 to commercialize a mechanical circulatory support system called the Myotech CSS which is based upon a family of technologies known as Direct Mechanical Ventricular Actuation (DMVA). The Myotech CSS is aimed at one of the largest and fastest growing medical market segments, the treatment of heart failure. ABN-AMRO Morgan Stanley has forecast worldwide sales of ventricular assist devices (VAD) to grow from its 2003 level of \$400 million to \$7.1 billion by 2009, reflecting an anticipated compounded annual growth rate of 61%.

Existing cardiac assist devices, such as VADs, have serious limitations that include clotting and stroke, infection, bleeding, repeat major surgery, and high mortality rates. The devices are available only at a limited number of transplant and specialized cardiac centers and are very expensive to use, often costing in excess of \$200,000 per procedure.

The Myotech CSS is a comprehensive circulatory support system that has features designed to provide safer and more effective support to a wide array of acute and chronic heart failure conditions. As shown in trials of early prototypes of DMVA technology at Duke University in the 1990s, such a device can be installed quickly to stabilize and provide short term support to patients suffering from acute heart failure to help the heart to recover and ultimately allow the device to be removed. The Myotech CSS offers the following additional competitive advantages:

27

No contact with circulating blood which reduces the problems of clotting and stroke, bleeding, repeat surgery, and infection - problems that plague existing VADs;

Technically simple, rapid installation (approximately three minutes) that does not require highly specialized cardiothoracic surgeons; and

The ability to completely restore blood flow from the diseased or failed heart. The Myotech CSS provides systolic (emptying) and diastolic (filling) support to both ventricles. Current VADs typically provide only systolic support to one ventricle.

Future versions are expected to include designs with therapeutic capabilities, such as drug delivery designed to enable the Myotech CSS to treat a wide variety of acute and chronic heart failure conditions. We also plan to make the Myotech CSS available in multiple sizes to treat more heart failure patients, including women.

Healthcare leaders in the U.S. government and private sector also recognize this resulting in an allocation of \$1 million in 2007 to accelerate the availability of the Myotech CSS in forward combat treatment stations as well as suburban and rural hospitals.

The short term goal is to develop and introduce a first generation (Gen-1) product. We will initially focus on the commercialization of the Gen-1 Myotech CSS product, which is designed to address sudden cardiac arrest and acute myocardial infarction complicated with cardiogenic shock. Additional R&D will be conducted in parallel to develop the technological capabilities required for the Company to expand the use of the Gen-1 product.

It is anticipated that the Gen-1 Myotech CSS could enter into clinical studies in fiscal year 2009. The Myotech CSS is targeted to be marketed and distributed by entering into a strategic relationship with a major medical device company.

MARKET OPPORTUNITY

MRI Related Technologies

Some medical devices have limitations related to MRI safety, and may be contraindicated for use with MRI (such as pacemakers and neurostimulators). Patients with these types of implants cannot have MRI exams performed even if the exams are needed for life threatening conditions, such as cancer detection or diagnosis of aneurysms.

Many devices are already safe for use with MRI, but have limited MRI image compatibility. This includes devices such as stents, vena cava filters, and some types of catheters and guidewires. Some of these devices are simply not well imaged under MRI, while other devices have properties that interfere with the MRI image by causing an image artifact (distortion) in the area in and around the device, limiting the effectiveness of MRI for placement or diagnostic follow-up on these implants.

Biophan has solutions to these problems. Biophan's internally developed technology and patents, in combination with exclusive in-licensed technologies provide comprehensive intellectual property coverage for Biophan's MRI image compatibility solutions.

Management believes that the most significant product opportunity in MRI image compatibility is the coronary stent market, which is dominated by drug eluting stents. This market was estimated by Lehman Brothers Equity Research in its 2006 Medical Device Outlook to exceed \$5.5 billion in 2006. Biophan's technology for coronary stents is licensed exclusively to Boston Scientific, one of the leaders in the coronary stent market. Biophan has non-exclusively licensed some of the other product segments (such as catheters and guidewires) and has not yet licensed some other product segments, such as an MRI compatible vena cava filter.

STRATEGY

MRI Related Technologies

Management believes that the target market for Biophan's MRI related technologies, represented by the number of medical devices and implants that have limitations related to MRI image compatibility, is in excess of \$5 billion.

Biophan has developed the following strategy and operating philosophy:

- o Position Biophan as the leading innovator in applying technologies for MRI image compatibility to medical implants and interventional devices;

Continue to focus on developing and marketing solutions to enable MRI image compatible products and implants; and

Seek new and novel market applications for the Company's primary technologies;

- o Utilize an experienced business-to-business sales and technology licensing team to market the Company's technologies;

- o Protect current and future technology developments by establishing and maintaining a strong patent position; and

- o Continue to call on development and marketing partners to bring these technologies to the market in a broad range of products, focusing on the leading 20 to 25 medical device manufacturers, with specific targeting of the top three in each major product category.

MYOTECH Circulatory Support System (CSS)

With regard to the Myotech CSS technology, we recognize the following:

Mechanical cardiac assist devices provide many benefits for heart failure patients relative to existing treatment procedures;

The potential of the VAD market alone is estimated to be approximately \$7 to \$8 billion and growing at a rate of 50-60% annually;

Conventional VADs have distinct disadvantages including invasiveness to the patient, clotting and stroke, bleeding, repeat surgery, and infection;

There are currently no other equally capable solutions on the market and none are anticipated. This position is based upon the following:

Searches of the medical market;

Review of U.S. and foreign patents and patent activity;

Review of the literature and activity within the scientific community;

Our Scientific Advisory Board's knowledge of relevant industry activities; and

Participation in relevant tradeshows;

We possess a substantial intellectual property portfolio which protects current and future developments of its technology in the U.S. and other major international markets; and

29

The expertise, depth, and experience of its management team.

Based on the above and management's knowledge of its markets, Biophan, along with MYOTECH, has developed the following strategy and operating philosophy:

- o Initially focus on the development and approval of a Gen-1 product for sudden cardiac arrest;

- o On an longer term basis, focus on next-generation products for the therapeutic recovery ;

- o Enhance awareness of the Myotech CSS by:

 - Utilizing the Scientific Advisory Board;

 - Engaging industry thought leaders;

 - Publication of the results of pre-clinical and clinical

 - activities; and

 - Participation at major medical and scientific forums;

- o Interface with the FDA on a pre-approval basis to help ensure rapid approval of Myotech CSS product;

- o Market and distribute the Myotech CSS by entering into a strategic relationship with a leading medical device company with an appropriate sales and marketing infrastructure;

- o Utilize well-recognized manufacturing companies currently producing products for the major medical device companies, to minimize entry costs and shorten time to market. Utilize this manufacturing capacity until such time as product manufacturing is brought in house or taken over by the strategic partner;

- o Protect current and future technology developments by establishing a strong trademark and patent position;

- o Recruit additional, expert-level subject matter expertise where it compliments core team capabilities; and

- o Rapidly develop and introduce a first generation product to establish an early revenue stream, while conducting parallel R&D to demonstrate the ability of the technologies to meet the needs of additional market segments.

TECHNOLOGY

Technologies for MRI Image Compatibility

Biophan has developed and in licensed a number of technologies for improving MRI image compatibility of interventional devices and implants. These technologies fall into two main categories:

- o Resonator Technology

 - o Incorporating a resonant circuit, tuned to the resonant frequency of the MRI machine, to enhance the MRI signal and overcome the image artifact (distortion).

Product Opportunities for Improved MRI Imaging

These product opportunities include the following:

- o MRI visible stents

30

- o MRI visible vena cava filters
- o MRI visible stent based heart valve
- o Guidewires
- o Catheters

MRI Visible Stents

A stent is a device that is implanted to hold open a blood vessel that has become too narrow due to atherosclerosis. When imaged under MRI, stents create a large image artifact which prevents viewing of blockages or clotting within the stent. Biophan has developed a solution to this problem.

The image artifact (a large dark area on the MRI image in the area where the stent is located) prevents the physician from seeing the critical area in and around the stent. This is caused by the fact that a metallic stent behaves as a Faraday Cage due to its geometry and material, and the stent additionally creates a magnetic susceptibility artifact due to the material of manufacture of the stent.

To overcome this limitation, Biophan has developed a resonator technology, which uses tuned circuits to increase the RF signal, and overcome the Faraday Cage effect, making it possible to image within and around a stent.

Biophan's technology allows imaging of a blood clot or restenosis within a stent. Currently, measuring restenosis within a stent requires either angiography or intravenous ultrasound, both of which involve complex and invasive catheterization procedures and have a higher chance of complications to the patient than a simple, non-invasive MRI scan.

MRI Visible Vena Cava Filters

A vena cava filter is a device inserted into a major vein to prevent a thrombus (blood clot) from entering the lungs, which could cause a pulmonary embolism. This device will trap the blood clot in a "cage" before it reaches the lungs.

Similar to the problems associated with imaging a stent, vena cava filters create an image artifact when imaged by MRI. Biophan's resonator technology allows for overcoming this interference. This technology has significant implications for the future of medical imaging. The ability to effectively visualize would allow a physician to determine the degree of clotting within the filter and to know when it is safe to remove the device, or if it is necessary to take other actions.

MRI Visible Stent-Based Heart Valve

A stent based heart valve enables replacement of the aortic valve without the requirement of an open-heart surgery. In cases of calcification of the aortic valve, the function of the valve is no longer efficient. The standard clinical procedure would be to replace the valve in an open-heart surgery. This is a complicated and expensive procedure.

Our technology allows the procedure to be performed via percutaneous access through a peripheral vessel, with the procedure performed over a guide wire for placement. The procedure may be performed under fluoroscopy using contrast media injections, or under MRI guidance. For this procedure, there is no need to stop the heart, and no need to put the patient on a heart-lung bypass machine during the operation.

With an MRI visible stent-based heart valve, the physician can utilize MRI imaging, with its 3D-orientation and excellent image quality. It is possible to perform the planning and the implementation of the interventions without the side effects of exposure to x-rays, including harmful radiation exposure for both the patients and the physician, and the need for nephrotoxic contrast media. In addition, the ability to accurately visualize the function of the valve under MRI with Biophan's resonator technology can allow less invasive follow up to assess valve function on a regular basis.

Guidewires and Catheters

Viewing interventional devices, such as catheters and guidewires, under MRI is a challenge if the objects are smaller or thinner than the resolution of the MRI system or if the objects are made of materials that are less well contrasted under MRI. Biophan's patented technologies overcome this, enabling surgical procedures under MRI that would have been difficult or impossible previously.

SALES AND MARKETING

MRI Related Technologies

These technologies are applicable to a broad array of products, including stents, vena cava filters, heart valves, occluders, and catheters.

Biophan's technology supplies an important feature for these devices, but the devices and systems are complex and have a significant hurdles in terms of design, development, manufacturing and regulatory approval. As a result, Biophan plans to license these technologies to leading medical device manufacturers who have the experience, capabilities and sales force to market products with these features and benefits.

Biophan's marketing efforts are focused on business-to-business sales of our technology. Since we are focused on working with the leaders in each market segment (which we define as the top three in terms of market share for each target product), the number of prospective partners is approximately 25 medical device companies.

COMPETITION

In the area of devices that can be imaged non-invasively under MRI, such as imaging restenosis inside stents, or visualizing blood flow in heart valves, the Company holds fundamental issued patents on its solutions, including resonant circuits (which overcome Faraday cage effects of stents). Other companies have filed patents on alternative designs, but Biophan and its licensors have the only known solutions demonstrated to enable visualizing inside stents and heart valves under MRI.

In the area of cardiovascular support, there are several manufacturers of circulatory support systems, including Abiomed, Thoratec, World Heart, and others. In the area of acute heart failure, where restoration of cardiac output is needed for an arrested heart, there are no circulatory systems known to the Company that can provide full systolic and diastolic support to an arrested heart, without blood contact, as quickly as the Myotech circulatory support system. PPA Technologies AG, in Germany, is developing a device that provides non-blood contacting support, their patents are not widely filed outside of Germany and do not cover many of the features and full range of capabilities of the Myotech CSS.

In the area of power systems powered by body heat, vs. chemical batteries, the Company knows of at least one competitor, Research Technologies Institute in North Carolina, which has spun off a company to develop materials with improved energy conversion properties, and has identified implantable medical devices as a target market. There are other research activities in this area underway at several research organizations within universities. Biophan's TE-Bio subsidiary holds exclusive licenses to several implantable biothermal battery patents. The TE-Bio subsidiary was co-founded with the original patent owner, Biomed Solutions, prior to Biophan entering the power systems business. NASA is also working in the area, and is collaborating with Biophan under the Space Act program. Biophan recently won an SBIR grant for using the technology for Homeland Security, which is helping to further the collaboration and development. Biophan has certain rights to NASA related developments.

INTELLECTUAL PROPERTY

MRI Related Technologies

32

Biophan controls, directly or through exclusive licenses, 49 issued U.S. patents, and over 60 pending applications at various stages of examination. These cover a broad range of technologies, including MRI image compatibility technologies, biothermal power supply technologies and photonics-related technologies.

Trademarks

The name "Biophan" is a registered trademark of the Company. We have filed for registration of the following trademarks: Nanolution, Nanolute and Nanoview.

Myotech's intangible assets currently consist primarily of trademarks and patent applications.

Myotech has filed for registration of the following trademarks: Myotech, MYO-VAD, Your Heart Your Life, and We take therapy to heart.

Myotech's first patent application "Sensor-Equipped and Algorithm-Controlled Direct Mechanical Ventricular Assist Device" has published worldwide; national filing has begun in Europe, Canada, Japan, China, and India. The second patent application "Therapeutic Agent Delivery Apparatus with Direct Mechanical Ventricular Assist Capability" has published in the US, and has been filed worldwide as a PCT. These applications are being followed by five divisionals and CIP applications. A provisional application "Method and Apparatus for Minimally Invasive Direct Mechanical Ventricular Actuation" has been filed. Utility and foreign applications will follow. Work has begun on a comprehensive application focused on the biochemical and physiological aspects of the treatment of acute and chronic heart.

Employees

As of October 22, 2007, we had 14 full-time employees, 12 of whom are in the US and two of whom are in Europe. We believe that we have a good relationship with our employees.

Facilities

Our headquarters are located at 15 Schoen Place, Pittsford, New York 14534 with approximately 4,470 square feet of office space and approximately 1,000 square feet of laboratory space. Our lease for this facility extends to April 30, 2022, subject to our right to terminate at any time after January 31, 2009 upon 90 days' notice. For the lease years commencing May 1, 2007 and 2008, we will pay an annual base rent of \$89,558. For each year commencing on May 1, 2009 and continuing through April 30, 2011, the base rent will increase by 5% over the previous year's rent. For each year commencing on May 1, 2011 and continuing through April 30, 2017, the base rent will increase by 3% over the previous year's rent. The landlord will be responsible for all real property taxes for the first 38 months of the lease term; thereafter, the landlord will absorb the first 3% of any increase in the real property taxes on the premises in which our facility is located and two-thirds of the remaining 97% of any such increase, while we will reimburse the landlord for our proportionate share (48%) of the remaining one-third of such 97%. We will bear our own gas, electric, water and other utility charges and our proportionate share of utility charges for the premises' interior common areas. We believe that this facility will be adequate for our current and anticipated future needs through the lease expiration date.

Legal Proceedings

Except as noted below, we are not a party to any material legal proceedings and there are no material legal proceedings pending with respect to our property, except as noted below. We are not aware of any legal proceedings contemplated by any governmental authorities involving either us or our property. None of our directors, officers or affiliates is an adverse party in any legal proceedings involving us or our subsidiaries, or has an interest in any

proceeding which is adverse to us or our subsidiaries.

The Company is pursuing legal claims against one of its former law firms and certain of its attorneys. Review of the firm's work product and bills recently revealed questions about the firm's billing practices and other activities. The amount of potential damages has not yet been quantified. Also, the law firm has asserted claims seeking payment of additional legal fees, which claims the Company has denied. The litigation is in an early stage. While, as with any legal proceedings, no assurance can be given as to ultimate outcome, management believes that the outcome of the litigation will not have a material adverse effect upon the Company's financial condition. Accordingly, adjustments, if any that might result from the resolution of this matter have not been reflected in the financial statements.

33

On April 5, 2007, SBI Brightline LLC and SBI Brightline XI, LLC brought suit against us and Biomed Solutions, LLC in the Superior Court of Orange County, California. The suit alleges, among other things, that in September 2006 we entered into an oral agreement to terminate the Stock Purchase Agreement dated as of May 27, 2005 and amended on January 8, 2006, between us and SBI Brightline XI, LLC, and seeks unspecified monetary damages and an order by the Court deeming the Stock Purchase Agreement to be terminated. We believe the allegations made by SBI are without basis in fact and we intend to defend the lawsuit vigorously. Because of the potential costs of litigation and the anticipated demands that our defense may place on the time and attention of our management our defense of this matter, regardless of the outcome, could have a material adverse effect on our business and operations.

MANAGEMENT

EXECUTIVE OFFICERS AND DIRECTORS

The following table sets forth information regarding our executive officers and directors. Each of our executive officers has been elected by our board of directors and serves until his or her successor is duly elected and qualified:

Name	Age	Position
John F. Lanzafame	40	Chief Executive Officer
Guenter H. Jaensch	68	Director and Chairman of the Board
Theodore A. Greenberg	47	Director
Bonita L. Labosky	65	Director
Stan Yakatan	65	Director
Robert J. Wood	68	Chief Financial Officer
Stuart G. MacDonald	58	Vice-President -- Research and Development

The principal occupations and business experience for at least the past five years of each director and executive officer is as follows.

John F. Lanzafame joined Biophan in 2004 and has served as interim Chief Executive Officer since September 2007, and previously served as Chief Operating Officer since 2006. He leads operations and business development for the Company. He has served as Vice President- Business Development and President of Nanolution, LLC, the drug delivery division of Biophan. In 2006, Mr. Lanzafame was promoted to Chief Operating Officer. From 1989 to 2004, Mr. Lanzafame was employed by STS Biopolymers, Inc., a privately held medical device company that marketed high performance polymer-based coatings for the medical device industry, including drug eluting surfaces for devices such as coronary stents and indwelling catheters, serving in a variety of positions from 1989 to 2003 and as President beginning in 2003. Mr. Lanzafame left STS Biopolymers in 2004, following sale of the company to Angiotech Pharmaceuticals. Mr. Lanzafame is a member of the Board of Directors of NaturalNano, Inc.

Guenter H. Jaensch, Ph.D. is the former Chairman and CEO of Siemens Pacesetter, Inc., a manufacturer of cardiac pacemakers. During his more than twenty-five years at Siemens, Dr. Jaensch held various senior executive positions prior to running Siemens Pacesetter, including President of Siemens Communications Systems, Inc. from August 1983 to March 1985, Chairman and President of Siemens Corporate Research and Support, Inc., from April 1982 to September 1991 and Chairman and CEO of Siemens Pacesetter, Inc. and Head of the Cardiac Systems Division of Siemens AG Medical Engineering Group from October 1991 to September 1994. In 1994, upon the acquisition of Pacesetter by St. Jude Medical, Inc., he joined St. Jude Medical as Chairman and CEO of Pacesetter, Inc. and retired in 1995 to manage his personal investments. Since December 1997 he has been a director of MRV Communications, a publicly traded company in the fiber optic technology business. Dr. Jaensch has been a director of Biophan since March 2002.

Theodore A. Greenberg is Chief Investment Officer, Chief Financial Officer, Secretary, and is a member of the Board of Directors of Infinity Capital Group, Inc., a business development company which he joined in 2005. Since 2004 he has been, and continues to be, a project consultant and advisor and has provided services to various companies. In 1999, Mr. Greenberg co-founded Park Avenue Equity Partners, LP, a \$100 million middle market private equity fund and he was a general partner until 2003. From 1998 to 1999, Mr. Greenberg was the Chief Financial Officer of Development Capital, LLC. Mr. Greenberg has been a director of Biophan since April 2006.

Bonita L. Labosky has, since December 2006, been President and CEO of Cardiac Concepts, Inc., a Minneapolis-based company developing new medical device technologies. From 2000 until December 2006, she was Group Vice President and member of the Executive Committee of Welch Allyn, Inc., a provider of innovative medical diagnostic devices, patient monitoring systems, and external defibrillators. During her tenure at Welch Allyn, Inc., Ms. Labosky also served as a member of the firm's Executive Committee. From 1993 until 2000, she was a Vice President of Medtronic, Inc., serving as General Manager for Heart Failure Management from 1997 through 2000, General Manager for Micro Interventional Systems from 1996 through 1997, and General Manager of the Promeon Division from 1993 through 1997. From 1989 through 1993, she was a research and development director at Medtronic and from 1978 through 1988 she held various management positions (including Vice President and General Manager) with SPSS, Inc. Ms. Labosky joined our Board of Directors in March 2007.

Stan Yakatan is Chairman and Chief Executive Officer of Katan Associates, a private company which he founded in May 1989 that provides advisory services and strategic planning for companies in the life sciences industry. From June 2003 to August 2005, Mr. Yakatan was Chairman and Chief Executive Officer of Grant Life Sciences, a publicly-traded company engaged in the research, development, marketing, and sale of diagnostic kits for the screening, monitoring, and diagnosis of diseases with emphasis on women's health, infectious diseases, and cancers. Mr. Yakatan continues to serve as a Director of Grant Life Sciences. He is also a Director of Response Biomedical Corp. and LifePoint, Inc. and of several privately-held companies in the life sciences industry. From 1968 until he founded Katan Associates in 1989, Mr. Yakatan held various senior executive positions with New England Nuclear Corporation (a division of E.I. DuPont), ICN Pharmaceuticals, Inc., New Brunswick Scientific Co., Inc. and Biosearch. Mr. Yakatan is the Chairman of Biocomm Inc., a venture capital firm, and has founded and served as Chief Executive Officer of numerous entrepreneurial ventures in the biomedical and healthcare sectors. He has served as a strategic advisor to government agencies in Canada and Australia.

Robert J. Wood has served as interim Chief Financial Officer since July 2007. Mr. Wood was our Chief Financial Officer, Vice-President, Treasurer and Secretary until his retirement in January 2006. Mr. Wood subsequently continued in a part-time role as a financial consultant to the Company. Mr. Wood is a Certified Public Accountant with extensive experience in public accounting and business consulting. He began his career as Price Waterhouse & Co. in 1962 after graduating from St. John Fisher College with a B.B.A. in Accounting. From 1973 to 2000, he was consecutively owner/partner of Metzger, Wood & Sokolski, CPAs (through December 1985), Mengel, Metzger, Barr & Co., LLP (through December 1990), and Wood & Company, CPAs, P.C. (through November 2000), all in Rochester, New York. In December 2000, his practice was acquired by a regional CPA firm, Eldredge, Fox and Porretti, LLP, and he was engaged in business consulting until joining Biophan as full time Chief Financial Officer in August 2001.

Stuart G. MacDonald has been Biophan's Vice-President-Research and Development since January 2001. From January 1995 through December 2000, Mr. MacDonald was employed at Ortho-Clinical Diagnostics, a Johnson & Johnson company, holding the position of Director-Engineering from 1996 to mid-1997 and Vice-President, Clinical Lab Instrumentation R&D from mid-1997 through December 2000. He worked at Eastman Kodak Company from 1971 to 1994, rising to the position of Assistant Director, Clinical Diagnostic Research Labs. A portion of Mr. MacDonald's time is spent assisting with the research programs of Biomed Solutions, LLC and Myotech, LLC, related companies, for which Biophan is reimbursed.

There are no family relationships among any of our directors or executive officers.

35

Corporate Governance Guidelines

Our Board has long believed that good corporate governance is important to ensure that we are managed for the long-term benefit of our stockholders. Our common stock is currently quoted on the OTC Bulletin Board. The OTC Bulletin Board currently does not have any corporate governance rules similar to the NASDAQ Stock Market, Inc., the American Stock Exchange, Inc. or any other national securities exchange or national securities association. However, our Board believes that the corporate governance rules of NASDAQ and AMEX represent good governance standards and, accordingly, during the past year, our Board has continued to review our governance practices in light of the Sarbanes-Oxley Act of 2002, the new rules and regulations of the Securities and Exchange Commission and the new listing standards of NASDAQ and AMEX, and it has implemented certain of the foregoing rules and listing standards during this past fiscal year. Biophan has also adopted a Code of Ethics for Senior Financial Officers that is applicable to our principal executive officer, principal financial officer, principal accounting officer or controller, or persons performing similar functions. Our Board is also considering adopting during this current fiscal year additional corporate governance guidelines to assist it in the exercise of its duties and responsibilities and to serve the best interests of Biophan and its stockholders.

Board Determination of Independence

Under NASDAQ and AMEX rules, generally speaking, a director will only qualify as an "independent director" if, in the opinion of our Board, that person does not have a relationship which would interfere with the exercise of independent judgment in carrying out the responsibilities of a director. Our Board has determined that each of Dr. Jaensch, Mr. Greenberg, Mr. Yakatan, and Ms. Labosky does not have a relationship which would interfere with the exercise of independent judgment in carrying out the responsibilities of a director and that, consequently, each of these directors is an "independent director" as defined under Rule 4200(a)(15) of the NASDAQ Marketplace Rules and similar AMEX rules.

The Board held nine (9) meetings during our fiscal year ended February 28, 2007. The standing committees of the Board are the Audit Committee and the Compensation Committee. The Board does not currently have a nominating committee and has not established any specific procedure for selecting candidates for director. Directors are currently nominated by a majority vote of the Board. There is also no established procedure for stockholder communications with members of the Board or the Board as a whole. However, stockholders may communicate with our investor relations department, and such communications are either responded to immediately or are referred to the president or chief financial officer for a response. During fiscal 2007, each of the incumbent directors, during his period of service, attended at least 75% of the total number of meetings held by the Board.

Audit Committee.

The Audit Committee is composed of Dr. Jaensch and Mr. Greenberg. The responsibilities of the Audit Committee as more fully set forth in the Audit Committee Charter adopted in July 2003 and posted on our website at www.biophan.com, include appointing, retaining, replacing, compensating and overseeing the work of the independent accountants, who report to, and are directly accountable to, the Committee. The Audit Committee reviews with the independent accountants the results of the audit engagement, approves professional services provided by the accountants including the scope of non-audit services, if any, and reviews the adequacy of our internal accounting controls. The Audit Committee met formally five (5) times during our fiscal year ended February 28, 2007. During that fiscal year, the Audit Committee was composed at various times of Dr. Jaensch, Mr. Bramson, Mr. Kenzie, Mr. Greenberg, Mr. Yakatan and Mr. Katz. On the occasion of two of the four meetings held by the Committee during his tenure, Mr. Yakatan was absent. Otherwise, each member of the Audit Committee attended all of the meetings. The Board has determined that each of Dr. Jaensch and Mr. Greenberg meets the qualifications as an "audit committee financial expert". Each member of the Audit Committee is "independent" as such term is used in Section 10A(m)(3) of the Securities and Exchange Act of 1934, as amended.

Compensation Committee.

The Compensation Committee is composed of Ms. Labosky and Mr. Yakatan. The responsibilities of the Compensation Committee as more fully set forth in the Compensation Committee Charter adopted in June 2005 and posted on our website at www.biophan.com, include reviewing our compensation policies, establishing executive officer compensation, and administering our stock option plans. The Compensation Committee met informally several times during our fiscal year ended February 28, 2007. During that fiscal year, the Compensation Committee was composed at various times of Dr. Jaensch, Mr. Kenzie, Mr. Bramson, Mr. Yakatan and Mr. Katz. Each member of the Compensation Committee attended all of the meetings during his or her tenure on the Committee. All of the members of the Committee are deemed to be non-employee directors for purposes of Section 162(m) and Rule 16b-3 of the Exchange Act. None of our executive officers serves as a member of the Board or Compensation Committee, or other committee serving an equivalent function, of any other entity that has one or more of its executive officers serving as a member of our Board or Compensation Committee. None of the members of our Compensation Committee has ever been our employee.

Director Compensation

Directors who are also our employees do not receive additional compensation for serving on the Board or its committees. Non-employee directors, for their services as directors, receive an annual cash fee of \$8,000. Dr. Jaensch receives an additional \$30,000 for serving as Chairman of the Board. In addition, non-employee directors receive options under our 2006 Incentive Stock Plan. All directors receive reimbursement for their reasonable expenses incurred in attending Board meetings. An additional \$3,000 per year is paid to the Chairman of the Audit Committee. Otherwise, no additional compensation is paid to any director for serving as a member of any committee of the Board. We maintain directors and officers liability insurance.

The following table shows compensation to directors for the fiscal year ended February 28, 2007:

Name	DIRECTOR COMPENSATION (1)			Total (\$)
	Fees Earned or Paid in Cash (\$)	Option Awards \$(2)	All Other Compensation (\$)	
Guenter H. Jaensch	38,000 (3)	24,834 (9)	0	62,834
			183,500	
Steven Katz	8,000 (4)	24,834 (10)	(16)	216,334
Theodore A. Greenberg	6,000 (5)	24,834 (11)	0	30,834
Stan Yakatan	2,000 (6)	5,165 (12)	0	7,165
Michael Friebe	0 (7)	0 (13)	27,984 (17)	27,984
Robert S. Bramson	2,000 (7)	0 (14)	34,607 (18)	36,607
Ross B. Kenzie	6,000 (8)	24,834 (15)	0	30,834

(1) Certain columnar information required by Item 402(k)(2) of Regulation S-K has been omitted for categories where there was no compensation awarded to, or paid to, the named directors during the fiscal year ended February 28, 2007.

(2) The reported amounts reflect the dollar amounts recognized for financial statement reporting purposes for the fiscal year ended February 28, 2007, in accordance with FAS 123R, of awards pursuant to our Stock Incentive Plan and may include amounts from awards granted both in and prior to the fiscal year ended February 28, 2007. As required, the amounts shown exclude the impact of any forfeitures related to service-based vesting conditions. The actual amount realized by the director will likely vary based on a number of factors, including the Company's performance, stock price fluctuations and applicable vesting.

(3) Includes a \$30,000 fee for service as Chairman of the Board and an \$8,000 fee for service on the Board.

(4) Resigned in March 2007.

(5) Elected to the Board in April 2006.

(6) Elected to the Board in December 2006.

(7) Term expired in July 2006.

(8) Resigned in October 2006.

(9) An option for the purchase of 40,000 shares of common stock at an exercise price of \$1.06 per share was granted to Dr. Jaensch on July 18, 2006. This option becomes fully vested and exercisable on the earlier of (i) completion of one year of service as a director measured from the date of grant or (ii) continuation of such service through the day immediately preceding the first annual shareholders meeting following the date of grant. This option has a termination date of July 18, 2016. At February 28, 2007, Dr. Jaensch held options for the purchase of an aggregate of 715,000 shares of common stock, of which options for the purchase of 627,500 shares were exercisable.

(10) An option for the purchase of 40,000 shares of common stock at an exercise price of \$1.06 per share was granted to Mr. Katz on July 18, 2006. This option becomes fully vested and exercisable on the earlier of (i) completion of one year of service as a director measured from the date of grant or (ii) continuation of such service through the day immediately preceding the first annual shareholders meeting following the date of grant. This option has a termination date of July 18, 2016. At February 28, 2007, Mr. Katz held options for the purchase of an aggregate of 420,000 shares of common stock, of which options for the purchase of 332,500 shares were exercisable.

(11) An option for the purchase of 40,000 shares of common stock at an exercise price of \$1.06 per share was granted to Mr. Greenberg on July 18, 2006. This option becomes fully vested and exercisable on the earlier of (i) completion of one year of service as a director measured from the date of grant or (ii) continuation of such service through the day immediately preceding the first annual shareholders meeting following the date of grant. This option has a termination date of July 18, 2016. At February 28, 2007, Mr. Greenberg held options for the purchase of an aggregate of 40,000 shares of common stock, none of which were exercisable.

(12) An option for the purchase of 40,000 shares of common stock at an exercise price of \$0.45 per share was granted to Mr. Yakatan on December 1, 2006. This option becomes fully vested and exercisable on the earlier of (i) completion of one year of service as a director measured from the date of grant or (ii) continuation of such service through the day immediately preceding the first annual shareholders meeting following the date of grant. This option has a termination date of December 1, 2016. At February 28, 2007, Mr. Yakatan held options for the purchase of an aggregate of 40,000 shares of common stock, none of which were exercisable.

(13) Dr. Friebe held no options at February 28, 2007.

(14) At February 28, 2007, Mr. Bramson held options for the purchase of an aggregate of 365,000 shares, of which options for the purchase of 277,500 shares were exercisable.

(15) An option for the purchase of 40,000 shares of common stock at an exercise price of \$1.06 per share was granted to Mr. Kenzie on July 18, 2006. This option required (i) completion of one year of service as a director measured from the date of grant or (ii) continuation of such service through the day immediately preceding the first annual shareholders meeting following the date of grant. Because Mr. Kenzie resigned on October 31, 2006 before satisfaction of the vesting requirements, this option terminated without becoming exercisable. At February 28, 2007, Mr. Kenzie held options for the purchase of an aggregate of 245,000 shares of common stock, of which options for the purchase of 197,500 shares were exercisable.

(16) Other compensation consists of fees for consulting services performed by Mr. Katz.

(17) Other compensation consists of salary as an employee of our subsidiary, Biophan Europe GmbH, through May 2006 and fees for consulting services through September 2006.

(18) Other compensation consists of fees for legal services provided by Bramson & Pressman, of which Mr. Bramson is a partner.

CODE OF ETHICS

The Company has adopted a Code of Ethics for Senior Financial Officers that is applicable to our principal executive officer, principal financial officer, principal accounting officer or controller, or persons performing similar functions.

POTENTIAL CONFLICTS OF INTEREST

Messrs. MacDonald, Helfer, and other of our employees from time to time spend a portion of their time on the business affairs of Biomed or its affiliates, for which Biomed reimburses us a percentage of their salary and benefits. Our Board of Directors reviews this arrangement on a regular basis. Currently, Biomed reimburses us for less than 50% of the payroll costs of Messrs. MacDonald, Helfer, and others. The Board of Directors does not believe that any conflicts of interest arise as a result of this policy, but it monitors the relationship on an ongoing basis.

Messrs. MacDonald and Helfer serve on the board of managers of Myotech, LLC, an entity in which Biomed is a 12.53% owner and Biophan is a 68% owner. Myotech is developing a biomedical device that does not compete with those being developed by us.

Mr. Lanzafame is on the Board of NaturalNano, Inc., the principal owner of which is Technology Innovations, LLC. NaturalNano has entered into a research and development agreement with us for drug eluting technology.

Biomed has agreed that all intellectual property developed by the employees of Biomed that is in the area of MRI Safe and/or Image Compatible Technology (MRI Technology) and HIV Antisense will be assigned to us. Per this agreement, MRI Technology means the technology necessary to enable medical devices to be resistant to radio frequency and static and gradient electromagnetic fields produced by MRI machines. HIV Antisense is a method of treating HIV.

LIMITATION OF LIABILITY AND INDEMNIFICATION

As permitted by the Nevada General Corporation Law, we have adopted provisions in our certificate of incorporation and by-laws to be in effect at the closing of this offering that limit or eliminate the personal liability of our directors. Consequently, a director will not be personally liable to us or our stockholders for monetary damages or breach of fiduciary duty as a director, except for liability for:

- o any breach of the director's duty of loyalty to us or our stockholders;
- o any act or omission not in good faith or that involves intentional misconduct or a knowing violation of law;
- o any unlawful payments related to dividends or unlawful stock repurchases, redemptions or other distributions; or
- o any transaction from which the director derived an improper personal benefit.

These limitations of liability do not alter director liability under the federal securities laws and do not affect the availability of equitable remedies such as an injunction or rescission.

In addition, our by-laws provide that:

- o we will indemnify our directors, officers and, in the discretion of our board of directors, certain employees to the fullest extent permitted by the Nevada General Corporation Law; and

o we will advance expenses, including attorneys' fees, to our directors and, in the discretion of our board of directors, to our officers and certain employees, in connection with legal proceedings, subject to limited exceptions.

We also maintain general liability insurance that covers certain liabilities of our directors and officers arising out of claims based on acts or omissions in their capacities as directors or officers, including liabilities under the Securities Act of 1933, as amended. Insofar as indemnification for liabilities arising under the Securities Act may be permitted to directors, officers, or persons controlling the registrant pursuant to the foregoing provisions, we have been informed that in the opinion of the Securities and Exchange Commission such indemnification is against public policy as expressed in the Securities Act and is therefore unenforceable.

These provisions may discourage stockholders from bringing a lawsuit against our directors for breach of their fiduciary duty. These provisions may also have the effect of reducing the likelihood of derivative litigation against directors and officers, even though such an action, if successful, might otherwise benefit us and our stockholders. Furthermore, a stockholder's investment may be adversely affected to the extent we pay the costs of settlement and damage awards against directors and officers pursuant to these indemnification provisions. We believe that these provisions, the indemnification agreements and the insurance are necessary to attract and retain talented and experienced directors and officers.

At present, there is no pending litigation or proceeding involving any of our directors or officers where indemnification will be required or permitted. We are not aware of any threatened litigation or proceeding that might result in a claim for such indemnification.

COMPENSATION DISCUSSION AND ANALYSIS

General Compensation Philosophy

The objectives of the Company's executive compensation policies are (i) to be competitive with pay practices of other companies of comparable size and status, including those in the biotechnology industry and (ii) to attract, motivate and retain key executives who are vital to the long-term success of the Company. The Company's executive compensation currently consists of both fixed annual salary and stock based compensation which align the interests of the Company's executives with the interests of its stockholders.

Executive Compensation Guiding Principles

Our general compensation philosophy is further guided by the following principles specific to our executives:

- o A strong link between pay and Company performance
- o Executives aligned with stockholders and managing from the perspective of owners with a meaningful equity stake in Biophan in the form of grants of stock options and restricted stock.
- o A competitive compensation package that will enable the Company to attract and motivate high-performing talent and that is strongly competitive with other biotechnology companies in our industry.
- o A simple and cost-efficient program design

The Compensation Committee of our Board of Directors determines the base salary (and any bonus and equity-based compensation) for each executive officer annually. John F. Lanzafame, our Chief Executive Officer, confers with members of the Compensation Committee, and makes recommendations, regarding the compensation of all executive officers other than himself. He does not participate in the Compensation Committee's deliberations regarding his own compensation. In determining the compensation of our executive officers, the Compensation Committee consults the annual Bioworld Executive Compensation Report, but does not engage in any benchmarking of total compensation or any material element of compensation.

The Compensation Committee believes that it is important that the interests of our executive officers be aligned as closely as possible with those of our shareholders, and in that regard reviews on an annual basis the number of stock options and other equity interests held by each of our executive officers.

Components of Biophan's Compensation Program

The compensation program for our Named Executive Officers consists of:

- (1) Base salary;
- (2) Long-term incentive compensation, including:
 - (i) Stock Options, Restricted Stock, and Restricted Stock Units,
 - (ii) Stock Appreciation Rights, and Other Stock-Based Awards,
 - (iii) Broad-based Employee Benefits

(1) Base Salary

With respect to annual compensation, the fundamental objective in setting base salary levels for the Company's senior management is to pay competitive rates to attract and retain high quality, competent executives. Competitive pay levels are determined based upon proxy disclosures, individual leadership, level of responsibility, management skills and industry activities. The Company does not currently have a bonus program for its executives.

(2) Long Term Incentive Compensation

- (i) Stock Options, Restricted Stock, and Restricted Stock Units.

The Company has two equity-based compensation plans, entitled Biophan Technologies, Inc. 2001 Stock Option Plan and Biophan Technologies, Inc. 2006 Incentive Stock Plan (the "Plans"), which are stockholder approved. The Plans provide for the grant of incentive and non-qualified stock options to employees, and the grant of non-qualified options to consultants and to directors and advisory board members. In addition, various other types of stock-based awards, such a stock appreciation rights, may be granted under the Plans. The Plans are administered by the Compensation Committee of our Board of Directors, which determines the individuals eligible to receive options or other awards under the Plans, the terms and conditions of those awards, the applicable vesting schedule, the option price and term for any granted options, and all other terms and conditions governing the option grants and other awards made under the Plans. Under the 2006 Plan, non-employee directors receive automatic grants of options for the purchase of 40,000 shares of common stock (i) upon the initial election to the Board of Directors and (ii) at each successive Annual Meeting at which they are re-elected to the Board. Under the 2001 Plan, 13,000,000 shares of our common stock were reserved for issuance pursuant to options or restricted stock awards; at February 28, 2007, 597,981 shares were available for future option grants and awards. Under the 2006 Plan, 7,500,000 shares of our common stock were reserved for issuance pursuant to options or restricted stock awards; at February 28, 2007, 7,265,003 shares were available for future option grants and awards.

To date, awards have been solely in the form of non-qualified stock options granted under the Plans. The Compensation Committee grant these stock-based incentive awards from time to time for the purpose of attracting and retaining key executives, motivating them to attain the Company's long-range financial objectives, and closely aligning their financial interests with long-term stockholder interests and share value.

Restricted stock awards entitle recipients to acquire shares of common stock, subject to our right to repurchase all or part of such shares from the recipient in the event that the conditions specified in the applicable award are not satisfied prior to the end of the applicable restriction period established for such award. Restricted stock unit awards entitle the recipient to receive shares of common stock to be delivered in the future subject to such terms and conditions on the

delivery of the shares as the Board of Directors may determine.

Restricted stock and restricted stock unit awards granted under the 2006 Plan may vest (a) solely on the basis of passage of time, (b) solely based on achievement of specified performance criteria or (c) upon the passage of time, subject to accelerated vesting if specified performance criteria are met. The Board of Directors may determine, at the time of grant, that restricted stock or restricted stock unit award being made to an officer will vest solely upon achievement of specified performance criteria designed to qualify for deduction under Section 162(m) of the Code. The performance criteria for each restricted stock or restricted stock unit award intended to so qualify for purposes of Section 162(m) of the Code will be based on one or more of the following measures: sales, earnings per share, return on net assets, return on equity, and customer service levels.

Except as noted below, (a) restricted stock and restricted stock units that vest solely on the basis of passage of time may vest no faster than ratably over three years; and (b) restricted stock and restricted stock units that vest based on achievement of specified performance criteria, or provide for accelerated vesting based upon achievement of specified performance criteria, may not vest earlier than the first anniversary of the date of grant. These vesting restrictions do not apply to restricted stock and restricted stock unit awards collectively with respect to up to 5% of the total number of shares of common stock covered by the 2006 Plan. In addition, the Board of Directors may make exceptions to the vesting limitations described above in the event of the recipient's death, a change in control or other extraordinary circumstances specified in the 2006 Plan.

(ii) Stock Appreciation Rights and Other Stock-Based Awards

A stock appreciation right, or SAR, is an award entitling the holder on exercise to receive, at the election of the Board of Directors, an amount in cash or common stock or a combination thereof determined in whole or in part by reference to appreciation, from and after the date of grant, in the fair market value of a share of common stock. SARs may be based solely on appreciation in the fair market value of common stock or on a comparison of such appreciation with some other measure of market growth such as (but not limited to) appreciation in a recognized market index. Under the 2006 Plan, the Board of Directors has the right to grant other awards of common stock or awards otherwise based upon common stock or other property, including without limitation rights to purchase shares of common stock, having such terms and conditions as the board may determine.

The Company believes that, through the use of stock options, restricted stock, restricted stock units, stock appreciation rights, and other stock-based awards, executives' interests are directly tied to enhanced stockholder value. The Compensation Committee has the flexibility of awarding any of these incentives to executives. This flexibility enables the Company to fine-tune its grants in order to maximize the alignment of the interests of the stockholders and management.

(iii) Broad-based Employee Benefits

As employees, our Named Executive Officers have the opportunity to participate in a number of benefits programs that are generally available to all eligible employees. These benefits include:

- o Healthcare Plans— includes medical benefits, dental benefits, behavioral health program, vision and hearing care program, and wellness programs.
- o Disability Plans— includes short-term and long-term disability income plans.
- o Investing Plans— includes a 401(k) plan.

Qualified Retirement Plan

We maintain a tax-qualified retirement plan that provides all eligible employees with an opportunity to save for retirement on a tax-advantaged basis. Under the 401(k) Plan, participants may elect to defer a portion of their compensation on a pre-tax basis and have it contributed to the Plan subject to applicable annual Internal Revenue Code limits. Pre-tax contributions are allocated to each participant's individual account and are then invested in selected investment alternatives according to the participants' directions. Employee elective deferrals are 100% vested at all times. The 401(k) Plan allows for matching contributions to be made by us. As a tax-qualified retirement plan, contributions to the 401(k) Plan and earnings on those contributions are not taxable to the employees until distributed from the 401(k) Plan and all contributions are deductible by us when made.

For eligible employees, our Investing Plans likewise use base and lump-sum merit pay as components of "eligible compensation" under the applicable plans (incentive plan awards are not part of "eligible compensation"). In addition, our "qualified" plans are subject to applicable IRS limits.

SUMMARY COMPENSATION TABLE (1)

The table set forth below summarizes the compensation paid to our named executive officers during the year ended February 28, 2007.

Name and Principal Position	Year	Salary (\$)	Bonus (\$)(2)	Stock	Option Awards (\$)(4)	All	Total (\$)
				Awards (\$)(3)		Other Compensation (\$)	
Michael L. Weiner (6) President	2007	260,000	0	0	0	11,758	271,758
Darryl L. Canfield (7) CFO	2007	180,000	0	0	0	0	180,000
John F. Lanzafame (8) Vice-President and COO	2007	188,077	0	0	0	0	188,077
Stuart G. MacDonald Vice-President-Research	2007	175,000	0	0	0	0	175,000
Jeffrey L. Helfer Vice-President-Engineering	2007	180,000	0	0	0	0	180,000

(1) Certain columnar information required by Item 402(c)(2) of Regulation S-K has been omitted for categories where there has been no compensation awarded to, or paid to, the named executive officers required to be reported in the table during fiscal year ended February 28, 2007.

(2) No bonus was paid to any named executive officer. The Company does not have a formal bonus plan, but the Compensation Committee has, from time to time on the recommendation of management, awarded cash bonuses to employees in recognition of exceptional service.

(3) The Company did not issue any stock awards to named executive officers in the fiscal year ended February 28, 2007.

(4) The Company did not issue any options awards to named executive officers in the fiscal year ended February 28, 2007.

(5) Unless otherwise indicated, the aggregate amount of perquisites and other personal benefits given to each of the named executive officers valued at the actual cost to the Company was less than \$10,000. These amounts consist of contributions made by the Company to the 401(k) Plan and premiums for long-term disability for each of the officers.

(6) Resigned in October 2007.

(7) Resigned in June 2007.

(8) Was appointed as Chief Executive Officer in September 2007.

Grants of Plan Based Awards

The Company did not grant stock options or stock awards to the named executive officers during the fiscal year ended February 28, 2007.

Outstanding Equity Awards at Fiscal Year End

The following table presents the number and values of exercisable and unexercisable options at February 28, 2007:

43

Option Awards (1)

Name	Number of Securities Underlying Unexercised Options		Option Exercise Price (\$/Sh)	Option Expiration Date
	Exercisable (#) (Vested)	Unexercisable (#) (Unvested)		
Michael L. Weiner	250,000 (2)	0	0.50	01/01/2011
	250,000 (3)	0	0.43	07/16/2012
	300,000 (4)	0	0.18	10/31/2013
	800,000	200,000 (5)	0.97	05/10/2014
Darryl Canfield	300,000	300,000 (6)	1.87	11/09/2015
John F. Lanzafame	75,000	25,000 (7)	0.67	07/19/2014
	112,500	37,500 (8)	0.74	09/03/2014
	240,000	60,000 (9)	1.80	3/15/2015
	91,667	183,333 (10)	1.56	01/06/2016
Stuart G. MacDonald	100,000 (11)	0	0.50	01/01/2011
	100,000 (12)	0	0.43	07/16/2012
	200,000 (4)	0	0.18	10/31/2013
	340,000	85,000 (13)	0.97	05/10/2014
	25,000 (14)	0	2.60	05/27/2015
Jeffrey L. Helfer	100,000 (15)	0	0.50	01/01/2011
	100,000 (3)	0	0.43	07/16/2012
	200,000 (4)	0	0.18	10/31/2013
	340,000	85,000 (13)	0.97	05/10/2014
	25,000 (14)	0	2.60	05/27/2015

(1) Certain columnar information required by Item 402(f) (2) of Regulation S-K has been omitted for categories where there has been no compensation awarded to, or paid to, the named executive officers required to be reported in the table during fiscal year ended February 28, 2007.

(2) These stock options were granted on January 1, 2001, with 100,000 vesting and becoming exercisable immediately. The remaining options vested and became exercisable in three equal annual installments with the first installment vesting on January 1, 2002.

(3) These stock options were granted on July 16, 2002. This option vested and became exercisable in three equal annual installments with the first installment vesting on December 31, 2002.

(4) These stock options were granted on October 31, 2003. This option vested and became exercisable in four equal annual installments with the first installment vesting on October 31, 2003.

(5) These stock options were granted on May 10, 2004. This option becomes vested and exercisable after the following contingencies are met.

a. 400,000 options upon completion of a financing deal,

b. 400,000 options upon completion of a substantial licensing and/or strategic transaction, and

c. 200,000 options upon completion of a listing on a major exchange.

(6) These stock options were granted on November 9, 2005. This option becomes vested and exercisable in six equal annual installments with the first installment vesting on November 9, 2005.

(7) These stock options were granted on July 19, 2004. This option becomes vested and exercisable in four equal annual installments with the first installment vesting July 19, 2004.

(8) These stock options were granted September 3, 2004. This option becomes vested and exercisable in four equal annual installments with the first installment vesting September 3, 2004.

(9) These stock options were granted on March 10, 2005. This option becomes vested and exercisable after the following contingencies are met.

- a. 90,000 options upon completion of a financing deal vest and become exercisable in three equal semi-annual installments with the first installment vesting March 15, 2005,
- b. 150,000 options upon completion of a substantial licensing and/or strategic transaction vest and become exercisable in three equal semi-annual installments with the first installment vesting March 15, 2005, and
- c. 60,000 options upon completion of a listing on a major exchange vest and become exercisable in three equal semi-annual installments with the first installment vesting on the date of completion.

(10) These stock options were granted on January 6, 2006. This option becomes vested and exercisable in three equal annual installments with the first installment vesting on January 6, 2007.

(11) These stock options were granted January 1, 2001. This option vested and became exercisable in five equal annual installments with the first installment vesting January 1, 2002.

(12) These stock options were granted July 16, 2002. This option vested and became exercisable on December 31, 2002.

(13) These stock options were granted on May 10, 2004. This option becomes vested and exercisable after the following contingencies are met.

- a. 127,500 options upon completion of a financing deal,
- b. 212,500 options upon completion of a substantial licensing and/or strategic transaction, and
- c. 85,000 options upon completion of a listing on a major exchange.

(14) These stock options were granted May 27, 2005. This option vested and became exercisable on May 27, 2005.

(15) These stock options were granted October 15, 2001. This option vested and became exercisable in five equal annual installments with the first installment vesting October 15, 2002.

Options Exercised and Stock Vested

No named executive officer exercised options in the fiscal year ended February 28, 2007. Options held by the following named executive officer vested during the year ended February 28, 2007 as follows:

Darryl L. Canfield 200,000
John F. Lanzafame 154,127
Stuart G. MacDonald 50,000
Jeffrey L. Helfer 50,000

Employment Agreements

Each of John F. Lanzafame, interim Chief Executive Officer; Stuart G. MacDonald, Vice President of Research and Development; and Jeffrey L. Helfer, Vice President and General Manager of Cardiovascular Products; has entered into an employment agreement with Biophan.

The employment agreements for Messrs. MacDonald, Helfer and Lanzafame are terminable by either us or the employee upon 30 days' notice or immediately by us for cause (as defined in their employment agreements) or upon the death or disability of the employee. However, Messrs. MacDonald and Lanzafame are entitled to receive severance equal to six months' base salary, payable in three equal installments within fifteen (15), thirty (30) and sixty (60) days following termination in the event that the employee is terminated by us within ninety (90) days following a change in control. In addition, under such circumstances each of them will be immediately vested in any options, warrants, retirement plan or agreements then in effect. Mr. Helfer is entitled to receive severance equal to six months' base salary, payable in six equal monthly installments for Voluntary Termination with Good Reason. Each will receive benefit continuation for the period equal to their severance.

For purposes of the employment agreements for Messrs. MacDonald, Helfer and Lanzafame "change in control" means (1) on the date of the merger or consolidation of Biophan with another entity where the members of the Board of Directors, immediately prior to the merger or consolidation, would not, immediately after the merger or consolidation, constitute a majority of the Board of Directors of the entity issuing cash or securities in the merger or consolidation; (2) on the date Michael L. Weiner is terminated as President of the Company (Mr. Weiner resigned on October 3, 2007); or (3) on the date of the sale or other disposition of all or substantially all of the assets of Biophan.

In the event of termination for cause, all unexercised warrants and options held by the applicable employee, whether or not vested, will be canceled and the employee will not be eligible for severance payments. In the event of voluntary termination, all vested warrants and options remain exercisable for the life of the applicable agreement.

Termination and Change in Control Tables

The tables below outline the potential payments to our Named Executive Officers upon the occurrence of certain termination triggering events. For the purposes of the table, below are the standard definitions for the various types of termination, although exact definitions may vary by agreement and by person.

"Voluntary termination" means a termination initiated by the executive officer.

"Voluntary termination for Good Reason" generally means termination initiated by the executive officer (i) following a change in control as defined above (ii) due to a material breach by the Company under the employment agreement or (iii) a significant change in the executive officer's duties.

"Involuntary Termination--Disability" means entitlement to long-term disability benefits under the Company Disability Income Plan, as amended and any successor plan, or a determination of a permanent and total disability under a state workers compensation statute.

"Involuntary Termination-- For Cause" means the occurrence of one or more of the following events (i) the Executive willfully refuses to obey reasonable and lawful orders of the President or the Board of Directors; (ii) the Executive has willfully breached or habitually neglected his duty and has failed to correct his behavior within five (5) days following receipt of written notice of such concerns; (iii) the Executive has been convicted in a court of law of a crime or offense which involves dishonesty or fraud; (iv) the Executive has breached any of the Executive's obligations pursuant to this Agreement; or (v) the Executive has committed an intentional tort against the Company or its Executives.

"Involuntary Termination-- Not for Cause" means an involuntary termination for reasons other than "For Cause" as defined above.

"Involuntary Termination for Change-in-Control" occurs when a named executive is terminated after the completion of change in control as described above in Employment Contracts.

No Named Executive Officer is entitled to a payment in connection with Involuntary Termination--For Cause.

Only Mr. Helfer is entitled to a payment in connection with a Voluntary Termination for Good Reason.

Michael L. Weiner
President, Director

	Voluntary Termination		Involuntary Termination
Executive Benefits and Payments Upon	Good Reason or	Disability or	Change in

Edgar Filing: BIOPHAN TECHNOLOGIES INC - Form S-1

Termination (1) Compensation	Retirement	Death	For Cause	Not For Cause	Control
Severance (2)	0 \$	260,000	0	\$ 260,000	\$ 260,000
Benefits and Perquisites (3)					
401(k) Match (4)	0	9,000	0	9,000	9,000
Health Insurance (5)	0	10,200	0	10,200	10,200
Long-Term Disability premiums (5)	0	1,360	0	1,360	1,360

Darryl L. Canfield
Vice President, Treasurer,
Secretary, Chief Financial Officer

Executive Benefits and Payments Upon	Voluntary Termination		Involuntary Termination		Change in
	Good Reason or	Disability or	For Cause	Not For Cause	
Termination (1) Compensation	Retirement	Death	For Cause	Not For Cause	Control
Severance (2)	0	0	0	0 \$	90,000
Benefits and Perquisites (3)					
401(k) Match (4)	0	0	0	0	3,600
Health Insurance (5)	0	0	0	0	1,930
Long-Term Disability premiums (5)	0	0	0	0	810

John F. Lanzafame
Vice -President - Business
Development, Chief Operating
Officer

Executive Benefits and Payments Upon	Voluntary Termination		Involuntary Termination		Change in
	Good Reason or	Disability or	For Cause	Not For Cause	
Termination (1) Compensation	Retirement	Death	For Cause	Not For Cause	Control
Severance (2)	0	0	0	0 \$	90,000
Benefits and Perquisites (3)					
401(k) Match (4)	0	0	0	0	3,600
Health Insurance (5)	0	0	0	0	4,500
Long-Term Disability premiums (5)	0	0	0	0	240

Stuart MacDonald
Vice-President - Research and Development

Executive Benefits and Payments Upon	Voluntary Termination		Involuntary Termination		Change in
	Good Reason or	Disability or	For Cause	Not For Cause	
Termination (1) Compensation	Retirement	Death	For Cause	Not For Cause	Control

Edgar Filing: BIOPHAN TECHNOLOGIES INC - Form S-1

Severance (2)	0	0	0	0	\$ 87,500
Benefits and Perquisites (3)					
401(k) Match (4)	0	0	0	0	3,500
Health Insurance (5)	0	0	0	0	1,600
Long-Term Disability premiums (5)	0	0	0	0	640

Jeffrey L. Helfer

Vice-President and General

Manager-Cardiovascular Products

Executive Benefits and Payments Upon	Voluntary Termination		Involuntary Termination		Change in Control
	Good Reason or Retirement	Disability or Death	For Cause	Not For Cause	
Termination (1) Compensation					
Severance (2)	\$ 90,000	0	0	0	0
Benefits and Perquisites (3)					
401(k) Match (4)	3,600	0	0	0	0
Health Insurance (5)	4,500	0	0	0	0
Long-Term Disability premiums (5)	550	0	0	0	0

(1) For purposes of this analysis, we assume that the named Executive Officer's compensation is as follows: John Lanzafame and Jeffrey Helfer's current base salaries are \$180,000; Stuart MacDonald's current base salary is \$175,000.

(2) Severance is calculated as follows: John Lanzafame and Stuart MacDonald receive six (6) months of base salary for Involuntary Termination-Change in Control; Jeffrey Helfer receives six (6) months for Voluntary Termination-Good Reason.

- (3) Payments associated with benefits and perquisites are limited to the items listed. No other continuation of benefits or perquisites occurs under the termination scenarios listed.
- (4) 401(k) Employer Match is calculated on salary paid as per Safe Harbor provision of the 401(k) Plan up to the maximum allowable contribution.
- (5) Health Insurance and Long-Term Disability continuation is calculated as follows: each of John Lanzafame, Stuart MacDonald, and Jeffrey Helfer at six (6) months.

LIMITATION OF LIABILITY AND INDEMNIFICATION

As permitted by the Nevada General Corporation Law, we have adopted provisions in our certificate of incorporation and by-laws to be in effect at the closing of this offering that limit or eliminate the personal liability of our directors. Consequently, a director will not be personally liable to us or our stockholders for monetary damages or breach of fiduciary duty as a director, except for liability for:

- o any breach of the director's duty of loyalty to us or our stockholders;
- o any act or omission not in good faith or that involves intentional misconduct or a knowing violation of law;
- o any unlawful payments related to dividends or unlawful stock repurchases, redemptions or other distributions; or
- o any transaction from which the director derived an improper personal benefit.

These limitations of liability do not alter director liability under the federal securities laws and do not affect the availability of equitable remedies such as an injunction or rescission.

In addition, our by-laws provide that:

- o we will indemnify our directors, officers and, in the discretion of our board of directors, certain employees to the fullest extent permitted by the Nevada General Corporation Law; and
- o we will advance expenses, including attorneys' fees, to our directors and, in the discretion of our board of directors, to our officers and certain employees, in connection with legal proceedings, subject to limited exceptions.

We also maintain general liability insurance that covers certain liabilities of our directors and officers arising out of claims based on acts or omissions in their capacities as directors or officers, including liabilities under the Securities Act of 1933, as amended. Insofar as indemnification for liabilities arising under the Securities Act may be permitted to directors, officers, or persons controlling the registrant pursuant to the foregoing provisions, we have been informed that in the opinion of the Securities and Exchange Commission such indemnification is against public policy as expressed in the Securities Act and is therefore unenforceable.

These provisions may discourage stockholders from bringing a lawsuit against our directors for breach of their fiduciary duty. These provisions may also have the effect of reducing the likelihood of derivative litigation against directors and officers, even though such an action, if successful, might otherwise benefit us and our stockholders. Furthermore, a stockholder's investment may be adversely affected to the extent we pay the costs of settlement and damage awards against directors and officers pursuant to these indemnification provisions. We believe that these provisions, the indemnification agreements and the insurance are necessary to attract and retain talented and experienced directors and officers.

At present, there is no pending litigation or proceeding involving any of our directors or officers where indemnification will be required or permitted. We are not aware of any threatened litigation or proceeding that might result in a claim for such indemnification.

BENEFICIAL OWNERSHIP OF COMMON STOCK BY DIRECTORS, OFFICERS AND PRINCIPAL STOCKHOLDERS

The following table sets forth the beneficial ownership information of our common stock at October 22, 2007, for:

o each person known to us to be the beneficial owner of more than 5% of our common stock (other than selling stockholders, whose beneficial ownership is disclosed on page 54);

o each named executive officer;

o each of our directors; and

o all of our executive officers and directors as a group.

We have determined beneficial ownership in accordance with the rules of the SEC. Except as indicated by the footnotes below, we believe, based on the information furnished to us, that the persons and entities named in the table below have sole voting and investment power with respect to all shares of common stock reflected as beneficially owned. We have based our calculation of the percentage of beneficial ownership on 103,123,656 shares of common stock outstanding on October 22, 2007.

In computing the number of shares of common stock beneficially owned by a person and the percentage ownership of that person, we deemed outstanding shares of common stock subject to options or warrants held by that person that are currently exercisable or exercisable within 60 days of October 22, 2007. We did not deem these shares outstanding, however, for the purpose of computing the percentage ownership of any other person. Beneficial ownership representing less than 1% is denoted with an asterisk (*).

Name of Beneficial Owner	Shares Beneficially Owned	Percentage Ownership
Guenter H. Jaensch 16065 Bristol Isle Way Delray Beach, FL 33446	1,521,000 (1)	1.46%
Theodore A. Greenberg 530 F Grand Street, Apt. 8FG New York, NY 10002	109,000 (2)	*
Bonita L. Labosky 3067 East Lake Road Skaneateles, NY 13152	66,000 (2)	*
Stan Yakatan 245 33 rd Street Hermosa Beach, CA 90254	310,000 (3)	*
John F. Lanzafame 10 Alameda Drive Fairport, NY 14450	1,476,667 (2)	1.41%
Stuart G. MacDonald 4663 East Lake Road Pultneyville, NY 14538	1,400,000 (4)	1.34%

Robert J. Wood 12 Peachtree Lane Pittsford, NY 14534	1,205,000 (2)	1.16%
Biomed Solutions, LLC 15 Schoen Place Pittsford, NY 14534	5,585,705 (5)	5.17%
Technology Innovations, LLC 15 Schoen Place Pittsford, NY 14534	5,886,349 (6)	5.45%
Michael L. Weiner 3349 Monroe Ave, Unit 350 Rochester, NY 14618	7,693,710 (8)	7.02%
All Directors and Executive Officers as a Group (7 persons)	6,087,667 (7)	5.60%

* Less than 1%

(1) Includes 1,521,000 shares issuable upon exercise of currently-exercisable options. Also includes 225,000 shares owned by Dr. Jaensch's wife; Dr. Jaensch disclaims beneficial ownership of the shares held by his wife.

(2) Issuable upon exercise of currently exercisable options.

(3) Includes 300,000 shares issuable upon exercise of currently exercisable options.

(4) Includes 1,310,000 shares issuable upon exercise of currently exercisable options.

(5) Includes 4,928,949 shares issuable upon exercise of currently-exercisable warrants and conversion of outstanding convertible promissory notes and accrued interest thereon.

(6) Includes (i) 656,756 shares owned by Biomed Solutions, LLC and (ii) 4,928,949 shares issuable to Biomed Solutions, LLC upon exercise of currently-exercisable warrants and conversion of outstanding convertible promissory notes and accrued interest thereon. Technology Innovations, LLC is the beneficial owner of 57% of the outstanding membership interests of Biomed Solutions, LLC; it disclaims ownership of these shares except to the extent of its pecuniary interest in Biomed Solutions, LLC.

(7) Includes shares issuable upon exercise of options as described in notes 1 through 6 above. Also includes shares as to which beneficial ownership is disclaimed, as described in note 1 above.

(8) Includes (i) 656,756 shares owned by Biomed Solutions LLC and an aggregate of 4,928,949 shares issuable to Biomed Solutions LLC upon exercise of currently-exercisable warrants and conversion of outstanding convertible promissory notes and accrued interest, and (ii) 300,644 shares owned by Technology Innovations LLC. Mr. Weiner is deemed to have voting and investment control over these shares by reason of his status as Manager of Biomed Solutions LLC and Technology Innovations LLC. He disclaims beneficial ownership of these shares except to the extent of his pecuniary interest in Biomed Solutions LLC and Technology Innovations LLC. Also includes 1,600,000 shares issuable upon exercise of currently-exercisable options held by Mr. Weiner.

Plan category	Number of securities to be issued upon exercise of	Weighted average exercise price of outstanding options	Number of securities remaining available for future issuance under
---------------	--	--	--

	outstanding options, warrants and rights (a)		(b)	equity compensation plans (excluding securities reflected in column (a) (c)
Equity compensation plans approved by security holders	9,428,062	\$.96	7,862,984
Equity compensation plans not approved by security holders	-0-		-0-	-0-
Total	9,428,062	\$.96	7,862,984

49

CERTAIN RELATIONSHIPS AND RELATED PARTY TRANSACTIONS

Michael L. Weiner, who was our President until his resignation on October 3, 2007, is the Manager and a 42.7% equity member of Technology Innovations, LLC., a 57% equity member of Biomed Solutions, LLC. Mr. Weiner is also the Manager of Biomed. Biomed is the record owner of 656,756 shares of our common stock and Technology Innovations is the record owner of 300,644 shares of our common stock. As Manager of Technology Innovations and Biomed, Mr. Weiner has control over these entities. Mr. Weiner is also on the board of Nanoset, LLC, an entity owned in part by Biomed Solutions, and with which we have entered into a technology license agreement. Mr. Weiner was also on the Board of Myotech, LLC which is the owner of 4,923,080 shares of our common stock. We beneficially own 68% of Myotech, LLC.

On December 1, 2000, we issued to Biomed Solutions, LLC 10,759,101 shares of our common stock in exchange for Biomed's shares of LTR Antisense Technology, Inc.

On December 1, 2000, Biomed Solutions transferred its MRI-compatible pacemaker patent pending and related technology to Biophan for a future payment of \$500,000. This obligation bore interest at 8% per annum from February 28, 2002. On February 10, 2004, Biomed transferred \$300,000 of this obligation to SBI Brightline Consulting, LLC and converted the remaining balance of \$200,000 into shares of our common stock. On the same date, SBI converted the \$300,000 obligation transferred to it into 3,000,000 shares of our common stock.

On June 4, 2002, we executed a line of credit agreement with Biomed providing for borrowings up to \$250,000. On August 19, 2002, the line was increased by \$100,000 and the expiration date thereof for that portion of the line was set at August 19, 2003. The payment date of amounts borrowed under the original line was extended to December 1, 2002. It was later extended to June 1, 2004. On February 10, 2004, all outstanding balances under the line of credit were converted to common stock in accordance with the terms of the credit agreement.

On May 27, 2005, we entered into an unsecured loan agreement with Biomed, whereby Biomed agreed to provide us with a line of credit facility of up to \$2 million. Borrowings under the line bear interest at 8% per annum (compounded monthly) and are payable on demand on or after November 27, 2005. In June 2005 the entire facility was drawn down. The outstanding principal and interest are convertible into shares of our Common Stock at 90% of the average market closing price per share of our Common Stock for the 20 trading days preceding the date of borrowings under the line (\$2.12 per share for the first \$1 million and \$2.19 per share for the second \$1 million). Additionally, Biomed received warrant coverage of 500,000 shares, with the warrants priced at 110% of the average market closing price per share of our Common Stock for the 20 trading days preceding the date of execution of the loan agreement (\$2.49 per share). On August 31, 2005, Biomed elected to convert \$1,000,000 of the outstanding debt plus accrued interest into 480,899 shares of our Common Stock. On October 7, 2005, we repaid \$500,000 of the outstanding debt plus the entire accrued interest to date, leaving an outstanding principal balance of \$500,000. The loan agreement requires us to use our best efforts to include the shares issued and issuable upon conversion of the loan in any registration statement we file covering resale of shares of our Common Stock.

On January 24, 2006, we entered into a Line of Credit Agreement (the "Line of Credit Agreement") with Biomed pursuant to which Biomed has committed to make advances to us, in an aggregate amount of up to \$5,000,000. Our obligations with respect to borrowings under the credit facility are governed by a Convertible Promissory Note issued by us to Biomed on January 24, 2006. Under the Line of Credit Agreement, advances may be drawn down in such amounts and at such times as we determine upon 15 days' prior notice to Biomed, except that we may not draw down more than \$1,500,000 in any 30-day period. As of February 28, 2007, we had borrowed an aggregate of \$3,930,000 under the Line of Credit Agreement. Amounts borrowed bear interest at the rate of 8% per annum and were originally convertible into shares of our Common Stock at the rate of \$1.46 per share. On October 11, 2006, in connection with Biomed's agreement to subordinate its rights under the Convertible Promissory Note to the interests of the investors acquiring the Notes described under the heading "Transactions with Selling Stockholders" on Page 47, we amended

the Line of Credit Agreement to reduce the conversion price to \$0.67 per share. Any amounts drawn down and repaid may be reborrowed at any time (subject to a requirement of 15 days' notice and the limitation that not more than \$1,500,000 may be drawn down during any 30-day period). Biomed's obligation to lend to us under the Line of Credit Agreement expires on June 30, 2007, on which date the entire amount borrowed by us (and not converted into shares of our Common Stock) becomes due and payable. In connection with the establishment of the credit facility under the Line of Credit Agreement, on January 24, 2006 we issued to Biomed a Stock Purchase Warrant (the "Warrant") entitling Biomed to purchase up to 1,198,630 shares of our Common Stock at an exercise price of \$1.89 per share. Biomed's purchase rights under the Warrant expire on January 23, 2011.

On October 2, 2007, we entered into a Securities Purchase Agreement with Myotech, pursuant to which we agreed to purchase from Myotech an aggregate of 15,496,547 membership units for an aggregate purchase price of \$3,200,000. Prior to the execution of the agreement we owned 5,408,194 Class A Membership Units of Myotech. In accordance with the agreement, upon execution of the agreement we received 5,000,000 Class A Membership Units and were to receive an additional 4,316,547 Class A Membership Units upon the payment of an aggregate initial purchase price of \$1,200,000. Thereafter, upon the satisfaction of certain conditions, we would purchase an additional 6,180,000 Class A Membership Units of Myotech for a purchase price of \$2,000,000. As a result of this investment the Company's holdings in Myotech will increase to approximately 75% and provide Biophan with control of a majority of the Board of Directors of Myotech.

We have affiliations with three entities, Biomed, Technology Innovations, and Myotech (through November 30, 2005) that are related by virtue of common senior management personnel and stock ownership. During the years ended February 28, 2007, 2006, and 2005, the Company charged Biomed and Myotech (through November 30, 2005) for services of certain Company personnel. The total of these charges was \$197,362, \$156,647 and \$161,014, respectively. We also charge Biomed, TI and Myotech (through November 30, 2005) for expenses allocable to and paid on their behalf. During the years ended February 28, 2007, 2006, and 2005, expenses paid by the Company on their behalf were approximately \$175,220, \$647,000 and \$240,000, respectively. At February 28, 2007, the combined balances due from these related parties was \$16,301. The amounts do not bear interest and the Company received payment within forty-five days.

During the years ended February 28, 2007, 2006 and 2005, we were billed \$35,290, \$93,000 and \$9,000 respectively, for legal services provided by Bramson & Pressman. Robert S. Bramson, at the time a member of our Board of Directors, is a partner in Bramson & Pressman.

During the year ended February 28, 2006, we were billed \$110,500 for consulting services provided by Steven Katz, at the time a member of our Board of Directors. During the year ended February 28, 2007, we were billed \$183,500 for consulting services provided by Mr. Katz. These services, and the amount of fees billed by Mr. Katz for each, are described below:

Service	Fee
Assistance with audit of Biophan Europe GmbH	\$ 7,500
Assistance with acquisition of interest in Myotech LLC	32,500
Assistance with October 2006 convertible note and warrant financing	131,000
General management assistance	12,500

Pursuant to a policy adopted by resolution of our Board of Directors, all transactions with affiliates must be approved by the disinterested members of our Board of Directors, based on a determination that such transactions are on terms no less favorable to us than would prevail in arms-length transactions with unaffiliated parties under similar circumstances. All transactions with our affiliates during the fiscal year ended February 28, 2007 were approved in accordance with this policy.

TRANSACTIONS WITH SELLING STOCKHOLDERS

On October 11, 2006, we entered into a Securities Purchase Agreement (the "Purchase Agreement") with ten private investors led by Iroquois Master Fund Ltd ("Iroquois"). The investors party to the Purchase Agreement are selling stockholders in this offering.

Pursuant to the Purchase Agreement, on October 12, 2006 we issued \$7,250,000 of Senior Secured Convertible Notes (the "Notes") to the investors and received proceeds of \$6,219,880 after paying estimated fees and expenses of

\$1,030,120 related to the transaction. The holders of the Notes may elect to convert the Notes at any time into shares of our common stock based upon a price of \$0.67 per share (the "Conversion Price"). Interest on the outstanding principal amount under the Notes is payable quarterly at a rate equal to the six-month London InterBank Overnight Rate plus 500 basis points, with a minimum rate of 10% per annum and a maximum rate of 12% per annum, payable at our option in cash or shares of our common stock registered for resale under the Securities Act of 1933, as amended (the "Securities Act"). If we elect to make an interest payment in common stock, the number of shares issuable by us will be based upon the lower of (i) 90% of the 20-day trailing average volume weighted average price per share as reported on Bloomberg LP (the "VWAPS") or (ii) the Conversion Price. Principal on the Notes amortizes and payments are due in 33 equal monthly installments commencing four months following issuance of the Notes, and may be made at our option in cash or shares of our common stock registered for resale under the Securities Act. If we elect to make a principal payment in common stock, the number of shares issuable by us will be based upon the lower of (i) 87.5% of the 15-day trailing VWAPS prior to the principal payment date or (ii) the Conversion Price. Our obligations under the Notes are secured by a first priority security interest in substantially all of our assets pursuant to a Security Agreement dated as of October 11, 2006 among us, the investors and Iroquois, as agent for the investors (the "Security Agreement").

As further consideration to the investors, we issued one-year warrants to purchase an aggregate of 10,820,896 shares of our common stock at a price of \$0.67 per share. If the investors elect to exercise these one-year warrants, they will also receive additional five-year warrants to purchase shares of our common stock equal to the number of shares purchased under the one-year warrants, with 50% of the additional warrants having an exercise price of \$0.85 per share, and the remaining 50% of the additional five-year warrants having an exercise price of \$0.92 per share. We also issued to the investors two series of five-year warrants to purchase an aggregate of 10,820,896 shares of our common stock. The first five-year warrants allow for the purchase of 5,410,448 shares of our common stock at an exercise price of \$0.81 per share, and the second five-year warrants allow for the purchase of 5,410,448 shares of our common stock at an exercise price of \$0.89 per share. The warrants contain anti-dilution protection that, should we issue equity or equity-linked securities at a price per common share below the exercise price of the five-year warrants, will automatically adjust the exercise price of the warrants to the price at which we issue such equity or equity-linked securities.

On February 21, 2007, we entered into a Forbearance Agreement (the "Forbearance Agreement") with the selling investors pursuant to which the investors agreed that, during the period commencing on February 16, 2007 and ending on the earlier of (i) March 31, 2007 or (ii) the date on which any Termination Event (as defined in the Forbearance Agreement) first occurs (the "Forbearance Period"), they will forbear from exercising any and all of the rights and remedies which they may have against us or any of our assets under the Notes or the Purchase Agreement or at law or in equity as a result of any default under the Notes or as a result of the occurrence of certain events with respect to the Purchase Agreement. In exchange for entering into the Forbearance Agreement, we issued pro rata to the investors three-year warrants for the purchase of an aggregate of 60,000 shares of our common stock at an exercise price of \$0.51 per share (the "Fee Warrants").

Upon the issuance of the Fee Warrants, the exercise prices of five-year warrants issued to the investors pursuant to the Purchase Agreement to the Note Holders (the "Original Warrants") for the purchase of an aggregate of 10,820,896 shares of our common stock were automatically adjusted from \$0.81 per share and \$0.89 per share, respectively, to \$0.51 per share, and the number of shares of Common Stock issuable upon exercise of the Original Warrants was automatically adjusted, proportionately, to an aggregate of 18,034,830 shares. In the Forbearance Agreement, the investors waived, with respect to the issuance of the Fee Warrants, application of similar anti-dilution adjustments contained in the Notes and in a third series of warrants for the purchase, on or before October 12, 2007, of an aggregate of 10,820,896 additional shares of our common stock at an exercise price of \$0.67 per share (the "One Year Warrants").

Pursuant to the Forbearance Agreement, we also agreed that we would not, without the prior written consent of investors then holding Notes representing, in the aggregate, at least sixty percent (60%) of the face amount of all outstanding Notes, incur expenses (other than the accrual of interest, penalties and liquidated damages on the Notes or under the Purchase Agreement) in excess of \$500,000 during any thirty-day period commencing on February 16, 2007 and terminating on the date on which the Registration Statement to which this prospectus relates was declared effective by the Securities and Exchange Commission.

C.E. Unterberg, Towbin acted as the exclusive placement agent in the offering. We paid the placement agent a cash fee of \$580,000 and issued to it a five-year warrant to purchase an aggregate of 865,672 shares of our common stock at a price of \$0.67 per share. The placement agent is a selling stockholder in this offering.

In connection with the Forbearance Agreement, C.E. Unterberg Towbin separately agreed to waive, with respect to the issuance of the Fee Warrants, application of the anti-dilution provisions set forth in its warrant.

On October 3, 2007, the Company entered into Amendment No. 1 to the Securities Purchase Agreement, Senior Secured Convertible Notes, Warrants and Security Agreement (the "Amendment"). Pursuant to the Amendment, the Company agreed to amend the Notes to provide that even if the Company elects to make a monthly payment in cash, the holder will have the right to convert any portion of the Note into common stock of the Company and apply the number of shares the holder would have received had the Company elected to make payment in common stock. In addition, the Conversion Price was reduced to \$0.15. The Amendment also amended the warrants to reduce the exercise prices of the various warrants to \$0.23. In exchange for the foregoing the investors released certain intellectual property, allowing the Company to transfer and sell such intellectual property.

Pursuant to the Amendment the Company also agreed to certain spending covenants in connection with the proceeds it will receive from the sale of the intellectual property under the Intellectual Property Assignment Agreement dated as of August 6, 2007 by and between Biophan and Medtronic, Inc. The Amendment also granted certain additional rights to the investors related to Biophan's majority owned subsidiary Myotech including the right to consent to the appointment of Biophan's representatives to the Board of Directors.

The Registration Statement to which this prospectus relates was filed by us pursuant to an agreement with the selling stockholders to register for resale under the Securities Act the common stock issuable upon the exercise of all of the warrants and any shares of common stock that we may issue at our option to the holders of the Notes in connection with payments of interest and principal, or that we are obligated to issue upon any conversion of the Notes at the option of the holders. We further agreed to propose to our shareholders an amendment to our Articles of Incorporation in order to increase to at least 250,000,000 the number of authorized shares of our common stock (the "Charter Amendment") in order to make available a sufficient number of shares to permit the exercise if full of the warrants issued to the investors under the Purchase Agreement and the conversion in full of the Notes.

SELLING STOCKHOLDERS

The following table sets forth the beneficial ownership information of our common stock at October 22, 2007, and as adjusted to reflect the sale of the shares of common stock in this offering, for each selling stockholder.

Certain selling stockholders may be affiliates of broker-dealers. To our knowledge, each selling stockholder purchased the shares of our stock in the ordinary course of business and, at the time of acquiring the securities to be resold, the selling stockholder had no agreements or understandings, directly or indirectly, with any person to distribute the securities.

We have determined beneficial ownership in accordance with the rules of the SEC. Except as indicated by the footnotes below, we believe, based on the information furnished to us, that the persons and entities named in the table below have sole voting and investment power with respect to all shares of common stock reflected as beneficially owned. We have based our calculation of the percentage of beneficial ownership on 103,123,656 shares of common stock outstanding on October 22, 2007, assuming (i) the conversion of an aggregate face amount of \$5,287,756 of our outstanding Senior Secured Convertible Notes due October 11, 2009 into an aggregate of 35,251,707 shares of common stock of which 28,880,636 shares are to be sold by selling stockholders in this offering, (ii) the exercise of warrants to purchase an aggregate of 11,686,568 shares of common stock, (iii) the issuance of an aggregate of 2,929,984 shares of common stock in payment of interest accruing under the Notes to be sold by selling stockholders

in this offering, and (iv) the issuance to the selling stockholders of additional warrants to purchase an aggregate of 36,069,660 shares of common stock. Our calculation does not include an aggregate of 60,000 of common stock issuable to the selling stockholders upon exercise of warrants which may not be exercised.

In computing the number of shares of common stock beneficially owned by a person and the percentage ownership of that person, we deemed outstanding shares of common stock subject to options or warrants held by that person that are currently exercisable or exercisable within 60 days of October 22, 2007. We did not deem these shares outstanding, however, for the purpose of computing the percentage ownership of any other person. Beneficial ownership representing less than 1% is denoted with an asterisk (*).

Edgar Filing: BIOPHAN TECHNOLOGIES INC - Form S-1

Beneficial Owner	Shares Beneficially Owned Prior to the Offering		Shares Offered	Shares Beneficially Owned After the Offering	
	Number	Percent		Number	Percent
BridgePoint Master Fund Ltd (2) 1125 Sanctuary Parkway, Suite 275 Alpharetta, GA 30004	11,595,174	4.99%	4,191,172	7,404,002	4.99%
CAMOFI Master LDC (3) c/o Centrecourt Asset Management LLC 550 Madison Avenue, 8th Floor New York, New York 10017	15,460,240	4.99%	5,588,238	9,872,002	4.99%
Castlerigg Master Investments (4) c/o Sandell Asset Management Corp. 40 W. 57th Street, 26th Floor New York, New York 10019	15,460,240	4.99%	5,588,238	9,872,002	4.99%
Cranshire Capital, L.P.(5) 3100 Dundee Rd., Suite 703 Northbrook, IL 60062	11,595,174	4.99%	4,191,172	7,404,002	4.99%
Crescent International Ltd. (6) c/o Cantara (Switzerland) S.A. 84 Avenue Louis-Casai CH-1216 Cointrin/Geneva, Switzerland	7,730,107	4.99%	2,794,106	4,936,001	4.87%
Harborview Master Fund LP (7) Harbour House, Second Floor Waterfront Drive, Road Town Tortola, British Virgin Islands	7,730,107	4.99%	2,794,106	4,936,001	4.87%
Highbridge International LLC (8) c/o Highbridge Capital Management, LLC 9 West 57th Street, 27th Floor New York, New York 10019	7,511,391	4.99%	2,575,390	4,936,001	4.87%
Iroquois Master Fund Ltd (9) 641 Lexington Avenue, 28th Floor New York, New York 10022	17,363,607	4.99%	5,023,604	12,340,003	4.99%
Rockmore Investment Master Fund Ltd. (10) 150 East 58th Street, 28th Floor	7,498,737	4.99%	2,562,736	4,936,001	4.87%

New York, New York 10155

Truk Opportunity Fund, Ltd, LLC

(11)

One East 52nd Street, 6th Floor New York, New York 10022	7,730,107	4.99%	2,794,106	4,936,001	4.87%
---	-----------	-------	-----------	-----------	-------

	109,674,884		38,102,868	71,572,016	
--	-------------	--	------------	------------	--

54

(1) Includes shares of common stock issuable upon exercise of warrants which, by their terms, may not be exercised if and to the extent that the total number of shares of our common stock then beneficially owned by the holder of such warrants and its affiliates and any other persons whose beneficial ownership of common stock would be aggregated with such holder's for purposes of Section 13(d) of the Exchange Act, would exceed 4.999% of the total number of shares of our common stock then outstanding.

(2) Eric S. Swartz, in his capacity as manager of Roswell Capital Partners, LLC, the investment advisor to BridgePointe Master Fund Ltd., has voting control and investment discretion over the shares owned by BridgePointe Master Fund Ltd. Mr. Swartz disclaims beneficial ownership of such shares.

(3) Richard Smithline exercises investment and voting control over the securities owned by CAMOFI Master LDC. Mr. Smithline disclaims beneficial ownership of the securities owned by CAMOFI Master LDC.

(4) Sandell Asset Management Corp. ("SAMC"), is the investment manager of Castlerigg Master Investments Ltd ("Master"). Thomas Sandell is the controlling person of SAMC and may be deemed to share beneficial ownership of the shares beneficially owned by Master. Castlerigg International Ltd. ("Castlerigg International") is the controlling shareholder of Castlerigg International Holdings Limited ("Holdings"). Holdings is the controlling shareholder of Master. Each of Holdings and Castlerigg International may be deemed to share beneficial ownership of the shares beneficially owned by Castlerigg Master Investments. SAMC, Mr. Sandell, Holdings and Castlerigg International each disclaims beneficial ownership of the securities with respect to which indirect beneficial ownership is described.

(5) Mitchell P. Kopin, the president of Downview Capital, Inc., the general partner of Cranshire Capital, L.P, has sole voting control and investment discretion over securities held by Cranshire Capital, L.P. Each of Mitchell P. Kopin and Downview Capital, Inc. disclaims beneficial ownership of the shares held by Cranshire Capital, L.P.

(6) Maxi Brezzi and Bachir Taleb-Ibrahimi, in their capacity as managers of Cantara (Switzerland) SA, the investment advisor to Crescent International Ltd., have voting control and investment discretion over the shares owned by Crescent International Ltd. Messrs. Brezzi and Taleb-Ibrahimi disclaim beneficial ownership of such shares.

(7) Harborview Master Fund L.P. is a master fund in a master-feeder structure whose general partner is Harborview Advisors LLC. Richard Rosenblum and David Stefansky are the managers of Harborview Advisors LLC and have ultimate responsibility for trading with respect to Harborview Master Fund L.P. Messrs. Rosenblum and Stefansky disclaim beneficial ownership of the shares being registered hereunder.

(8) Highbridge Capital Management, LLC is the trading manager of Highbridge International LLC and consequently has voting control and investment discretion over securities held by Highbridge International LLC. Glenn Dubin and Henry Swieca control Highbridge Capital Management, LLC and have voting control and investment discretion over the securities held by Highbridge International LLC. Each of Highbridge Capital Management, LLC, Glenn Dubin and Henry Swieca disclaims beneficial ownership of the securities held by Highbridge International LLC.

(9) Joshua Silverman has voting control and investment decision over securities held by Iroquois Capital, LP. Mr. Silverman disclaims beneficial ownership of the shares held by Iroquois Capital, LP.

(10) Rockmore Capital, LLC ("Rockmore Capital") and Rockmore Partners, LLC ("Rockmore Partners"), each a limited liability company formed under the laws of the State of Delaware, serve as the investment manager and general partner, respectively, to Rockmore Investments (US) LP, a Delaware limited partnership, which invests all of its assets through Rockmore Investment Master Fund Ltd., an exempted company formed under the laws of Bermuda ("Rockmore Master Fund"). By reason of such relationships, Rockmore Capital and Rockmore Partners may be deemed to share dispositive power over the shares of our common stock owned by Rockmore Master Fund. Rockmore Capital and Rockmore Partners disclaim beneficial ownership of such shares of our common stock. Rockmore

Partners has delegated authority to Rockmore Capital regarding the portfolio management decisions with respect to the shares of common stock owned by Rockmore Master Fund and, as of December 8, 2006, Bruce T. Bernstein and Brian Daly, as officers of Rockmore Capital, are responsible for the portfolio management decisions of the shares of common stock owned by Rockmore Master Fund. By reason of such authority, Messrs. Bernstein and Daly may be deemed to share dispositive power over the shares of our common stock owned by Rockmore Master Fund. Messrs. Bernstein and Daly disclaim beneficial ownership of such shares and neither of such persons has any legal right to maintain such authority. No other person has sole or shared voting or dispositive power with respect to the shares of our common stock owned by Rockmore Master Fund (as those terms are used for purposes under Regulation 13D-G of the Securities Exchange Act of 1934, as amended). No person or "group" (as that term is used in Section 13(d) of the Securities Exchange Act of 1934, as amended, or the SEC's Regulation 13D-G) controls Rockmore Master Fund.

(11) Michael E. Fein and Stephen E. Saltzstein, as principals of Atoll Asset Management, LLC, the Managing Member of Truk Opportunity Fund, LLC, exercise investment and voting control over the securities owned by Truk Opportunity Fund, LLC. Both Mr. Fein and Mr. Saltzstein disclaim beneficial ownership of the securities owned by Truk Opportunity Fund, LLC.

(12) Andrew Arno, in his capacity as Chief Executive Officer of C.E. Unterberg, Towbin LLC, has voting control and investment discretion over the shares owned by C.E. Unterberg, Towbin LLC. Mr. Arno disclaims beneficial ownership of such shares.

PLAN OF DISTRIBUTION

The selling stockholders may, from time to time, sell any or all of their shares of common stock on any stock exchange, market or trading facility on which the shares are traded or in private transactions. These sales may be at fixed or negotiated prices. The selling stockholders may use any one or more of the following methods when selling shares:

- o ordinary brokerage transactions and transactions in which the broker-dealer solicits purchasers;
- o block trades in which the broker-dealer will attempt to sell the shares as agent but may position and resell a portion of the block as principal to facilitate the transaction;
- o purchases by broker-dealer as principal and resale by the broker-dealer for its account;
- o an exchange distribution in accordance with the rules of the applicable exchange;
- o privately negotiated transactions;
- o settlement of short sales;
- o broker-dealer may agree with the selling stockholders to sell a specified number of such shares at a stipulated price per share;
- o a combination of any such methods of sale; and
- o any other method permitted pursuant to applicable law.

The selling stockholders may also sell shares under Rule 144 under the Securities Act, if available, rather than under this prospectus.

The selling stockholders may also engage in short sales against the box, puts and calls and other transactions in our securities or derivatives of our securities and may sell or deliver shares in connection with these trades.

Broker-dealers engaged by the selling stockholders may arrange for other broker-dealers to participate in sales. Broker-dealers may receive commissions or discounts from the selling stockholders (or, if any broker-dealer acts as agent for the purchaser of shares, from the purchaser) in amounts to be negotiated. The selling stockholders do not expect these commissions or discounts to exceed what is customary in the types of transactions involved. Any profits on the resale of shares of common stock by the broker-dealer acting as principal might be deemed to be underwriting discounts or commissions under the Securities Act. Discounts, concessions, commissions and similar selling expenses, if any, attributable to the sale of shares will be borne by a selling stockholder. The selling stockholders may agree to indemnify any agent, dealer or broker-dealer that participates in transactions involving sales of the shares if liabilities

are imposed on that person under the Securities Act.

56

The selling stockholders may from time to time pledge or grant a security interest in some or all of the shares of common stock owned by them and, if they default in the performance of their secured obligations, the pledgees or secured parties may offer and sell the shares of common stock from time to time under this prospectus after we have filed an amendment to this prospectus under Rule 424(b)(3) or other applicable provision of the Securities Act of 1933 amending the list of selling stockholders to include the pledgee, transferee or other successors in interest as selling stockholders under this prospectus.

The selling stockholders also may transfer the shares of common stock in other circumstances, in which case the transferees, pledgees or other successors in interest will be the selling beneficial owners for purposes of this prospectus and may sell the shares of common stock from time to time under this prospectus after we have filed an amendment to this prospectus under Rule 424(b)(3) or other applicable provision of the Securities Act of 1933 amending the list of selling stockholders to include the pledgee, transferee or other successors in interest as selling stockholders under this prospectus.

The selling stockholders and any broker-dealer or agents that are involved in selling the shares of common stock may be deemed to be "underwriters" within the meaning of the Securities Act in connection with such sales. In such event, any commissions received by such broker-dealers or agents and any profit on the resale of common stock purchased by them may be deemed to be underwriting commissions or discounts under the Securities Act.

We are required to pay all fees and expenses incident to the registration of the shares of common stock. We have agreed to indemnify the selling stockholders against certain losses, claims, damages and liabilities, including liabilities under the Securities Act.

The selling stockholders have advised us that they have not entered into any agreements, understandings or arrangements with any underwriters or broker-dealers regarding the sale of their shares of common stock, nor is there an underwriter or coordinating broker acting in connection with a proposed sale of shares of common stock by any selling stockholder. If we are notified by any selling stockholder that any material arrangement has been entered into with a broker-dealer for the sale of shares of common stock, if required, we will file a supplement to this prospectus.

The anti-manipulation rules of Regulation M under the Securities Exchange Act of 1934 may apply to sales of our common stock and activities of the selling stockholders.

Because the selling stockholders may be deemed underwriters, they will be subject to the prospectus delivery requirements of the Securities Act.

DESCRIPTION OF CAPITAL STOCK

General

As of October 22, 2007, our authorized capital consists of 250,000,000 shares of common stock, par value \$.005 per share.

Common Stock

As of October 22, 2007, we had 103,123,656 shares of common stock outstanding. Each share of our common stock is entitled to one vote at all meetings of our stockholders. Our stockholders are not permitted to cumulate votes in the election of directors. All shares of our common stock are equal to each other with respect to liquidation rights and dividend rights. There are no preemptive rights to purchase any additional shares of our common stock. In the event of our liquidation, dissolution or winding up, holders of our common stock will be entitled to receive, on a pro rata basis, all of our assets remaining after satisfaction of all liabilities and preferences of outstanding preferred stock, if any.

Neither our Articles of Incorporation nor our Bylaws contain any provisions which limit or restrict the ability of another person to take over our company; however, our Bylaws do permit our Board of Directors to be classified.

57

Options and Warrants

As of October 22, 2007, we had outstanding options to purchase an aggregate of 8,601,565 shares of our common stock pursuant to our 2001 Stock Option Plan (as amended) and outstanding options to purchase an aggregate of 6,472,328 shares of our common stock pursuant to our 2006 Incentive Stock Plan. The exercise prices for these options range from \$.10 per share to \$2.97 per share, and the weighted-average exercise price for all of the options is \$.96 per share. These options are held by directors, officers, key employees and consultants. As of October 22, 2007, options to purchase 13,718,060 shares were exercisable.

As of October 22, 2007, we also had outstanding warrants to purchase 75,177,609 shares of our common stock. The exercise prices for these warrants range from \$.10 per share to \$2.49 per share, and the weighted-average exercise price for all of the warrants is \$0.264 per share.

Certain Statutory Provisions of the Nevada Revised Statutes

Sections 78.411 through 78.444 of the Nevada Revised Statutes provide, in general, that a stockholder acquiring more than 10% of the outstanding voting shares of a publicly-held Nevada corporation subject to the statutes "Interested Stockholder" may not engage in certain "Combinations" with the corporation for a period of three years subsequent to the date on which the stockholder became an Interested Stockholder.

Section 78.416 defines the term "Combination" to encompass a wide variety of transactions with or caused by an Interested Stockholder in which the Interested Stockholder receives or could receive a benefit on other than a pro rata basis with other stockholders, including mergers, certain asset sales, certain issuances of additional shares to the Interested Stockholder or transactions in which the Interested Stockholder receives certain other benefits.

These provisions could have the effect of delaying, deferring or preventing a change of control of our company. Our stockholders, by adopting an amendment to our Articles of Incorporation or Bylaws, may elect not to be governed by these provisions. Neither our Articles of Incorporation nor Bylaws currently excludes us from these restrictions.

The Nevada Revised Statutes permit a corporation to indemnify its directors and officers against expenses, judgments, fines and amounts paid in settlement in cases brought against the director or officer in his capacity as such, provided the director or officer acted in good faith and in a manner he reasonably believed to be in or not opposed to the best interests of the corporation. The exceptions include a breach of the director's duty of loyalty, acts or omissions not in good faith or which involve intentional misconduct or knowing a violation of law, and improper personal benefit. Our Bylaws contain a provision implementing this statute.

Nasdaq Trading Symbol

Our common stock is traded in the over-the-counter markets and is reported on the Nasdaq OTC Bulletin Board under the trading symbol "BIPH."

Transfer Agent and Registrar

The transfer agent and registrar for our common stock is Continental Stock Transfer & Trust Company, 17 Battery Place, New York, NY 10004.

LEGAL MATTERS

Sichenzia Ross Friedman Ference LLP has passed upon the validity of the shares of common stock offered hereby.

EXPERTS

The consolidated financial statements as of February 28, 2007 and 2006 and for each of the three years in the period ended February 28, 2007 included in this prospectus have been so included in reliance on the report of Goldstein Golub Kessler LLP, an independent registered public accounting firm, given on the authority of that firm as experts in auditing and accounting.

CHANGE IN ACCOUNTANTS

On September 10, 2007, we dismissed Goldstein Golub Kessler LLP as our principal independent accountants effective as of that date and engaged Freed Maxick & Battaglia, CPAs, PC as our new principal independent accountants.

No accountant's report issued by Goldstein Golub Kessler LLP on our financial statements for either of the past two fiscal years or any subsequent interim period contained an adverse opinion or a disclaimer of opinion, or was qualified or modified as to uncertainty, audit scope, or accounting principles, except for the following:

a) an explanatory paragraph was included in Goldstein Golub Kessler LLP's report dated May 4, 2007 regarding our ability to continue as a going concern as referenced to Note 2 of our financial statements for the year ended February 28, 2007.

b) our financial statements at February 28, 2006 and for the year then ended were restated and a paragraph noting this restatement was included in Goldstein Golub Kessler LLP's report dated April 26, 2006, except for Note 8 as to which the date was May 12, 2006 and Note 7 as to which the date was January 23, 2007. In addition, Goldstein Golub Kessler's report dated January 23, 2007 (as restated) on the effectiveness of our internal control over financial reporting as of February 28, 2006, based on criteria established in Internal Control - Integrated Framework issued by the Committee of Sponsoring Organizations of the Treadway Commission, expressed an adverse opinion thereon.

The decision to retain Freed Maxick & Battaglia, CPAs, PC was unanimously approved by our Board of Directors.

During the last two fiscal years ended February 28, 2007 and 2006 and through September 10, 2007, there were no disagreements, whether or not resolved, between us and Goldstein Golub Kessler LLP on any matter of accounting principles or practices, financial statement disclosures, or auditing scope or procedures, which, if not resolved to Goldstein Golub Kessler LLP's satisfaction, would have caused Goldstein Golub Kessler LLP to make reference to the subject matter of the disagreement in connection with its report.

Prior to engaging Freed Maxick & Battaglia, CPAs, PC, Freed Maxick & Battaglia, CPAs, PC has not provided us with either written or oral advice that was an important factor considered by our company in reaching a decision to change our company's new principal independent accountants from Goldstein Golub Kessler LLP to Freed Maxick & Battaglia, CPAs, PC.

WHERE YOU CAN FIND MORE INFORMATION

We have filed with the SEC a registration statement on Form S-1 (File Number 333-138632) under the Securities Act with respect to the shares of common stock we and the selling stockholders are offering by this prospectus. This prospectus does not contain all of the information included in the registration statement. For further information

pertaining to us and our common stock, you should refer to the registration statement and to its exhibits. Whenever we make reference in this prospectus to any of our contracts, agreements or other documents, the references are not necessarily complete, and you should refer to the exhibits attached to the registration statement for copies of the actual contract, agreement or other document.

We are subject to the informational requirements of the Securities Exchange Act of 1934 and file annual, quarterly and current reports, proxy statements and other information with the SEC. You can read our SEC filings, including the registration statement, over the Internet at the SEC's website at www.sec.gov. You may also read and copy any document we file with the SEC at its public reference facility at 100 F Street, N.E., Room 1580, Washington, D.C. 20549.

You may also obtain copies of the documents at prescribed rates by writing to the Public Reference Section of the SEC at 100 F Street, N.E., Washington, D.C. 20549. Please call the SEC at 1-800-SEC-0330 for further information on the operation of the public reference facilities.

BIOPHAN TECHNOLOGIE, INC.

INDEX TO FINANCIAL STATEMENTS

Quarterly Financial Information

Condensed Consolidated Balance Sheets, August 31, 2007 (Unaudited) and February 28, 2007	F-1
Condensed Consolidated Statement of Operations, Three Months and Six Months Ended August 31, 2007 and 2006 (Unaudited), and from August 1, 1968 (Date of Inception) through August 31, 2007 (Unaudited)	F-2
Condensed Consolidated Statement of Cash Flows Six Months Ended August 31, 2007 and 2006 (Unaudited), and from August 1, 1968 (Date of Inception) through August 31, 2007 (Unaudited)	F-3
Notes to Condensed Consolidated Financial Statements	F-6

Annual Financial Information

Report of Independent Registered Public Accounting Firm	F-1
Consolidated Balance Sheets, February 28, 2007 and 2006	F-2
Consolidated Statement of Operations, Year Ended February 28, 2007, 2006 and 2005, and from August 1, 1968 (Date of Inception) through February 28, 2007	F-3
Consolidated Statement of Stockholders' Equity from August 1, 1968 (Date of Inception) through February 28, 2007	F-4
Consolidated Statement of Cash Flows, Year Ended February 28, 2007, 2006 and 2005, and from August 1, 1968 (Date of Inception) through February 28, 2007	F-8
Notes to Consolidated Financial Statements	F-11

Pro Forma Information

Unaudited Pro Forma Condensed Consolidated Balance Sheet	F-1
Unaudited Pro Forma Condensed Consolidated Statement of Operations	F-2

PART I. FINANCIAL INFORMATION**ITEM 1. FINANCIAL STATEMENTS****BIOPHAN TECHNOLOGIES, INC. AND SUBSIDIARIES**
(A DEVELOPMENT STAGE COMPANY)**CONDENSED CONSOLIDATED BALANCE SHEETS**

	August 31, 2007 (Unaudited)	February 28, 2007
ASSETS		
Current assets:		
Cash and cash equivalents	\$ 268,716	\$ 2,418,551
Accounts receivable	40,325	21,448
Prepaid expenses	197,344	166,171
Other current assets	46,384	25,350
Total current assets	552,769	2,631,520
Property and equipment, net	369,322	418,362
Other assets:		
Intangible assets, net of amortization		
Myotech, LLC	22,385,252	23,074,028
Other	1,275,531	1,322,777
Deferred financing costs, net of amortization of \$434,816 and \$186,350, respectively	1,097,394	1,345,860
Investment in New Scale Technologies, Inc.	100,000	100,000
Deposits	206	3,704
Deferred tax asset, net of valuation allowance of \$14,350,000 and \$12,784,000 respectively	—	—
	24,858,383	25,846,369
	\$ 25,780,474	\$ 28,896,251
LIABILITIES AND STOCKHOLDERS' EQUITY (DEFICIENCY)		
Current liabilities:		
Current portion of capital lease obligation	\$ 14,680	\$ 7,445
Current portion of senior secured convertible notes, net of discount of \$1,671,612 and \$2,183,580, respectively	1,090,294	672,481
Accounts payable and accrued expenses	1,965,020	1,942,033
Liquidated damages payable	652,500	—
Note payable	57,969	78,007
Line of credit - related party	2,250,000	4,430,000
Due to related parties	62,894	80,280
Deferred revenues	583,333	208,333
Total current liabilities	6,676,690	7,418,579
Long-term debt:		
Capital lease obligation	15,534	19,604
Senior secured convertible notes payable, less discount of \$1,960,351 and \$3,359,354, respectively	1,278,621	1,034,585
Fair value of warrant liability	—	10,494,006

Edgar Filing: BIOPHAN TECHNOLOGIES INC - Form S-1

Total liabilities	7,970,845	18,966,774
Minority interest	12,367,582	13,139,882
Stockholders' equity (deficiency):		
Common stock \$.005 par value		
Authorized, 250,000,000 and 125,000,000 shares, respectively		
Issued, 98,375,689 and 83,431,699 shares, respectively	491,878	417,158
Additional paid-in capital	66,841,444	54,532,204
	67,333,322	54,949,362
Less treasury stock, 4,923,080 shares	(8,467,698)	(8,467,698)
	58,865,624	46,481,664
Deficit accumulated during the development stage	(53,423,577)	(49,692,069)
Total stockholders' equity (deficiency)	5,442,047	(3,210,405)
	\$ 25,780,474	\$ 28,896,251

See Notes to Condensed Consolidated Financial Statements

F-1

BIOPHAN TECHNOLOGIES, INC. AND SUBSIDIARIES
(A DEVELOPMENT STAGE COMPANY)

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
(UNAUDITED)

	Three Months Ended August 31,		Six Months Ended August 31,		Period from August 1, 1968 (date of inception) to August 31, 2007
	2007	2006	2007	2006	
Revenues:					
Development payments	\$ —	\$ —	\$ —	\$ —	\$ 300,000
License fees	62,500	187,500	125,000	437,500	1,166,666
Grant revenues	25,000	—	75,000	—	75,000
Consulting fees	72,518	122,599	132,351	217,521	900,075
	160,018	310,099	332,351	655,021	2,441,741
Operating expenses:					
Research and development	1,497,837	1,941,513	2,817,784	4,529,921	23,028,177
General and administrative	1,802,753	1,573,434	3,290,423	3,659,625	28,056,740
Write-down of intellectual property rights	—	—	—	—	530,000
	3,300,590	3,514,947	6,108,207	8,189,546	51,614,917
Operating loss	(3,140,572)	(3,204,848)	(5,775,856)	(7,534,525)	(49,173,176)
Other income(expense):					
Interest income	4,990	5,263	20,431	11,606	231,803
Interest expense	(1,234,622)	(380,934)	(1,714,326)	(684,407)	(9,794,855)
Additional expense related to warrants	—	—	—	—	(7,304,105)
Change in fair value of warrant liability	—	—	3,434,017	—	9,657,278
Loss on extinguishment of debt - Related party	—	—	—	—	(670,053)
Debt forgiveness	197,614	—	197,614	—	197,614
Liquidated damages	—	—	(652,500)	—	(652,500)
Other income	5,763	46,163	33,939	93,701	887,331
Other expense	—	—	—	—	(70,528)
	(1,026,255)	(329,508)	1,319,175	(579,100)	(7,518,015)
Loss from continuing operations before minority interest in Myotech, LLC	(4,166,827)	(3,534,356)	(4,456,681)	(8,113,625)	(56,691,191)
Minority interest in Myotech, LLC	253,354	520,095	725,173	1,215,920	3,356,971
Loss from continuing operations	(3,913,473)	(3,041,261)	(3,731,508)	(6,897,705)	(53,334,220)
Loss from discontinued operations	—	—	—	—	(89,357)
Net loss	\$ (3,913,473)	\$ (3,041,261)	\$ (3,731,508)	\$ (6,897,705)	\$ (53,423,577)
Net loss per common share:					
Basic and diluted	\$ (0.047)	\$ (0.040)	\$ (0.046)	\$ (0.090)	

Weighted average shares outstanding	83,827,197	77,893,673	81,167,908	77,393,718
--	------------	------------	------------	------------

See Notes to Condensed Consolidated Financial Statements

F-2

BIOPHAN TECHNOLOGIES, INC. AND SUBSIDIARIES
(A DEVELOPMENT STAGE COMPANY)

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
(Unaudited)

	Six Months Ended		Period from
	August 31,		August 1, 1968
	2007	2006	(date of inception) to August 31, 2007
Cash flows used for operating activities:			
Net income (loss)	\$ (3,731,508)	\$ (6,897,705)	\$ (53,423,577)
Adjustments to reconcile net income (loss) to net cash used in operating activities:			
Amortization of intangible assets	736,022	729,022	2,599,508
Amortization of deferred financing costs	248,466	—	434,816
Depreciation and amortization	60,618	31,194	295,420
(Gain) loss on disposal of equipment	—	1,162	10,599
Additional expenses related to warrants	—	—	7,304,105
Change in fair value of derivative liability	(4,339,214)	—	(9,657,278)
Realized and unrealized losses on marketable securities	—	—	66,948
Loss on debt extinguishment - related party	—	—	670,053
Accrued interest on note converted to common stock	736,138	—	767,642
Amortization of discount on convertible notes payable	1,910,971	—	4,668,987
Write-down of intellectual property rights	—	—	530,000
Amortization of discount on payable to related party	—	498,424	2,887,555
Issuance of common stock for services	79,229	—	486,177
Issuance of common stock for interest	—	—	468,823
Grant of stock options for services	1,944,630	839,096	9,952,988
Expenses paid by stockholder	—	—	2,640
Minority interest	(772,301)	(1,260,002)	(3,358,144)
Changes in operating assets and liabilities:			
(Increase) decrease in accounts receivable	(18,877)	103,139	(32,825)
(Increase) decrease in due from related parties	—	(40,080)	(59,300)
(Increase) decrease in prepaid expenses	(31,173)	6,739	(197,344)
(Increase) decrease in other current assets	(21,034)	26,736	(5,046)
(Increase) decrease in deposits	3,498	—	2,043
Increase (decrease) in accounts payable and accrued expenses	22,988	874,266	1,405,015
Increase (decrease) in liquidated damages	652,500	—	652,500
Increase (decrease) in due to related parties	(17,386)	(25,824)	19,398
Increase (decrease) in deferred revenues	375,000	(437,500)	583,333
Net cash used in operating activities	(2,161,433)	(5,551,333)	(32,924,964)
Cash flows used for investing activities:			
Purchases of property and equipment	(4,392)	(91,366)	(609,036)
Sales of marketable securities	—	—	2,369,270
Purchase of investment	—	—	(100,000)

Edgar Filing: BIOPHAN TECHNOLOGIES INC - Form S-1

Acquisition costs of intangible assets	—	—	(466,583)
Cash paid for investment in Myotech, net of cash received of \$19,408	—	—	(280,594)
Cash paid for acquisition of Biophan Europe, net of cash received of \$107,956	—	—	(258,874)
Purchases of marketable securities	—	—	(2,436,218)
Net cash used in investing activities	(4,392)	(91,366)	(1,782,035)

See Notes to Condensed Consolidated Financial Statements.

F-3

BIOPHAN TECHNOLOGIES, INC. AND SUBSIDIARIES
(A DEVELOPMENT STAGE COMPANY)

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
(Unaudited)

	Six Months Ended August 31,		Period from August 1, 1968 (date of inception) to August 31, 2007
	2007	2006	
Cash flows provided by financing activities:			
Proceeds of bridge loans	—	—	986,500
Loan from stockholder	—	—	143,570
Line of credit borrowing from related party	—	3,630,000	7,980,950
Line of credit payments	—	(2,000,000)	(2,072,500)
Proceeds of convertible notes payable	—	—	7,250,000
Notes payable	(20,038)	58,748	(142,031)
Principal payments on capital lease obligation	(4,021)	—	(4,021)
Proceeds from sales of common stock	40,049	3,050,000	19,478,898
Exercise of options	—	8,678	658,467
Exercise of warrants	—	—	1,142,451
Swing profits	—	—	696,087
Deferred financing costs	—	—	(1,030,120)
Deferred equity placement costs	—	—	(112,536)
Net cash provided by financing activities	15,990	4,747,426	34,975,715
Net increase(decrease) in cash and equivalents	(2,149,835)	(895,273)	268,716
Cash and equivalents, beginning	2,418,551	1,477,716	—
Cash and equivalents, ending	\$ 268,716	\$ 582,443	\$ 268,716
Supplemental schedule for cash paid for:			
Interest	\$ 2,558	30,000	\$ 207,439
Supplemental schedule of non cash investing and financing activities:			
Allocation of proceeds from line of credit - related party to beneficial conversion feature and warrants	\$ —	\$ 272,945	\$ 2,812,555
Allocation of proceeds from notes and warrants	\$ —	\$ —	\$ 7,250,000
Change in fair value of warrants reclassified from equity to warrants liability	\$ —	\$ —	\$ 755,876
Reclassification of warrants from warrant liability to equity	\$ 5,964,729	\$ —	\$ 5,964,729
Capital lease obligation	\$ 6,318	\$ —	\$ 33,367
Issuance of common stock upon conversion of line of credit loans	\$ 2,180,000	\$ —	\$ 4,158,450
Issuance of common stock for payment of principal and interest on Senior Secured Notes payable	\$ 1,789,361	\$ —	\$ 1,249,122
Issuance of common stock for the acquisition of a 35% interest in Myotech, LLC	\$ —	\$ —	\$ 8,467,698
Issuance of common stock in satisfaction of accounts payable	\$ 79,229	\$ —	\$ 213,229
Common stock issued for subscription receivable	\$ —	\$ —	\$ —

See Notes to Condensed Consolidated Financial Statements.

F-4

BIOPHAN TECHNOLOGIES, INC. AND SUBSIDIARIES
(A DEVELOPMENT STAGE COMPANY)

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
(Unaudited)

	Six Months Ended		Period from
	August 31,		August 1, 1968
	2007	2006	(date of
			inception) to
			August 31, 2007
Liabilities assumed in conjunction with acquisition of 51% interest in Biophan Europe and certain intellectual property rights:			
Fair value of assets acquired			\$ 1,105,714
Cash paid			(366,830)
Promissory note issued			(200,000)
Restricted stock issued			(134,000)
Payables incurred			(226,500)
Liabilities assumed	\$ —	\$ —	—\$ 178,384
Issuance of common stock upon conversion of bridge loans	\$ —	\$ —	—\$ 1,142,068
Acquisition of intellectual property	\$ —	\$ —	—\$ 425,000
Intellectual property acquired through issuance of capital stock and assumption of related party payable	\$ —	\$ —	—\$ 175,000

See Notes to Condensed Consolidated Financial Statements.

BIOPHAN TECHNOLOGIES, INC. AND SUBSIDIARIES
(A DEVELOPMENT STAGE COMPANY)

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
August 31, 2007

INTERIM FINANCIAL STATEMENTS:

The condensed consolidated financial statements as of August 31, 2007 and for the three and six months ended August 31, 2007 and 2006 are unaudited. However, in the opinion of management of the Company, these financial statements reflect all adjustments, consisting solely of normal recurring adjustments, necessary to present fairly the financial position and results of operations for such interim periods. The results of operations for the interim periods presented are not necessarily indicative of the results to be obtained for a full year. These unaudited condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements and notes thereto included in the Company's Annual Report on Form 10-K for the fiscal year ended February 28, 2007.

BASIS OF CONSOLIDATION:

The consolidated financial statements include the accounts of Biophan Technologies, Inc. ("Biophan"), its wholly owned subsidiaries, LTR Antisense Technology, Inc. ("Antisense") and Nanolution Technologies, Inc., formerly MRIC Drug Delivery Systems, LLC, ("Nanolution"), its majority owned subsidiaries Biophan Europe GmbH ("Biophan Europe"), formerly aMRIs GmbH, and TE Bio LLC ("TE Bio"), and Myotech, LLC ("Myotech"), a variable interest entity, collectively referred to as the "Company". All significant inter-company accounts and transactions have been eliminated in consolidation.

COMPANY HISTORY:

The Company was incorporated under the laws of the State of Idaho on August 1, 1968 and on January 12, 2000, changed its domicile to Nevada by merging into a Nevada corporation, and on July 19, 2001, changed its name to Biophan Technologies, Inc. From the inception of the current line of business on December 1, 2000, the Company has not generated any material revenues and operating profits. Therefore, the Company is in the development stage and will remain so until the realization of significant revenues and operating profits. The Company's ability to continue in business is dependent upon maintaining sufficient financing or attaining future profitable operations.

PRINCIPAL BUSINESS ACTIVITIES:

The primary mission is to develop and commercially exploit technologies for improving the performance, and as a result, the competitiveness of biomedical devices manufactured by third party companies. The Company possesses technologies for enabling biomedical devices, both implantable and those used in diagnostic and interventional procedures, to be safe (do not harm the patient or physician) and image compatible (allow effective imaging of the device and its surrounding tissue) with MRI (magnetic resonance imaging). The Company is also developing and marketing a system for generating power for implantable devices from body heat, and a series of implantable devices including MRI-visible vascular implants such as a vena cava filter, a heart valve and an occluder for the treatment of atrial septal defects, a hole in the wall separating the left and right chambers of the heart. The Company's first licensee for several of these technologies is Boston Scientific (NYSE: BSX). The Company is also an owner of a substantial minority interest, with rights to take a majority interest, in Myotech, (accounted for as a variable interest entity) developer of the Myotech Circulatory Support System, a cardiac assist device that does not contact circulating blood and utilizes technology that has the potential to become a standard of care in the device market for treating multiple types of acute and chronic heart failure including congestive heart failure and sudden cardiac arrest.

DEFERRED TAXES:

Deferred tax assets and liabilities are recognized for future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases. Deferred tax assets and liabilities are measured using enacted rates expected to apply when the differences are expected to be realized. A valuation allowance is recognized if it is anticipated that some or all of the deferred tax asset may not be realized.

In June 2006, the Financial Accounting Standards Board ("FASB") issued FASB Interpretation No. 48, "Accounting for Uncertainty in Income Taxes - an interpretation of FASB Statement No. 109" ("FIN 48"). FIN 48 clarifies the accounting for uncertainty in income taxes recognized in a company's financial statements in accordance with SFAS No. 109, "Accounting for Income Taxes." FIN 48 prescribes a recognition threshold and measurement attribute for the financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return. The Company adopted FIN 48 effective March 1, 2007. The Company does not believe that FIN 48 had a material effect on its consolidated financial position or results of operations as the Company has no unrecognized tax benefits and has not incurred any interest or penalties in any of its tax jurisdictions. Should any such interest or penalties be assessed, they will be charged to interest expense and other expense as incurred. The Company has open tax years beginning in fiscal years ended year February 28, 2004 through 2007. None of the Company's tax returns has been examined by federal or state jurisdictions during these periods.

F-6

REGISTRATION RIGHTS AGREEMENT:

In December 2006, the FASB issued Staff Position No. EITF 00-19-2 ("FSP"). This FSP addresses an issuer's accounting for registration payment arrangements and specifies that the contingent obligation to make future payments or otherwise transfer consideration under a registration payment arrangement should be separately recognized and measured in accordance with FASB No. 5. The guidance in this FSP amends FASB Statements 133 and 150 and FASB Interpretation No. 45 to include scope exceptions for registration payment arrangements. This FSP further clarifies that a financial instrument subject to a registration payment arrangement should be accounted for without regard to the contingent obligation to transfer consideration pursuant to the registration payment arrangement. This guidance is effective for financial statements issued for fiscal years beginning after December 15, 2006. The Company has adopted this FSP in the current fiscal year as it pertains to the issuance of the Senior Secured Convertible Notes and related warrants as explained in the Note captioned "Senior Secured Convertible Notes".

RECENT ACCOUNTING PRONOUNCEMENTS:

Management does not believe that any recently issued, but not yet effective accounting standards, if currently adopted, would have a material effect on the accompanying financial statements.

INVESTMENT IN MYOTECH, LLC:

Effective November 30, 2005, we entered into a Securities Purchase Agreement for the acquisition of an initial 35% interest in Myotech, LLC ("Myotech"), a New York limited liability company, whereby we exchanged 4,923,080 shares of our common stock, par value \$.005, for 3,768,488 Class A (voting) units of Myotech.

Based upon the terms of the Securities Purchase Agreement, we were obligated to purchase for cash consideration of \$2.225 million an additional 811,037 Class A units. We may elect to acquire up to an additional 3,563,097 Class A units for further cash consideration of up to \$9.775 million, over a 24-month period, which may result in the Company owning a majority interest in Myotech. During the three month period ended February 28, 2006, Biophan provided \$1,185,000 of additional funding for 431,946 newly issued Class A units of Myotech. During the year ended February 28, 2007, Biophan has provided \$1,040,000 of additional funding satisfying the cash consideration of \$2.225 million cited above, for 379,091 newly issued Class A units of Myotech. In addition, Biophan has also provided an additional investment of \$1,994,349 to Myotech against milestone 2 in the year ended February 28, 2007 for 726,963 newly issued Class A units, which increased our ownership to 43.7%. Additional investments of \$395,685 were made during the six months ended August 31, 2007 for 144,232 additional newly issued Class A units, which raised our ownership percentage to 44.1%.

We have determined that Myotech is a Variable Interest Entity within the meaning of FIN 46(R) and that we are the primary beneficiary (as defined in FIN 46(R)). Consequently, the financial statements of Myotech have been consolidated with our consolidated financial statements for all periods ending on or after November 30, 2005, the date of our initial investment in Myotech.

On October 2, 2007, we entered into a revised Securities Purchase Agreement with Myotech pursuant to which the Company agreed to purchase from Myotech an aggregate of 15,496,547 membership units for an aggregate purchase price of \$3,200,000. Prior to the execution of the Agreement Biophan owned 5,408,194 Class A Membership Units of Myotech. In accordance with the Agreement, upon execution of the Agreement Biophan received 5,000,000 Class A Membership Units and was to receive an addition 4,316,547 Class A Membership Units upon the payment of an aggregate initial purchase price of \$1,200,000. Thereafter, upon the satisfaction of certain conditions, Biophan will purchase an additional 6,180,000 Class A Membership Units of Myotech for a purchase price of \$2,000,000. As a result of these investments, our ownership percentage in Myotech will increase to approximately 75%.

Edgar Filing: BIOPHAN TECHNOLOGIES INC - Form S-1

The following is selected financial data for Myotech, LLC at August 31, 2007 and 2006 and for the six months then ended August 31:

	2007	2006
Total current assets	11,443	\$ 18,719
Intangible assets, net of amortization	22,385,252	23,762,804
Other assets	155,687	47,819
Total assets	\$ 22,552,382	\$ 23,829,342
Current liabilities	\$ 441,632	\$ 489,328
Equity	22,110,750	23,340,014
	\$ 22,552,382	\$ 23,829,342

	Three Months Ended August 31,2007	Three Months Ended August 31,2006	Six Months Ended August 31,2007	Six months Ended August 31,2006
Net loss from operations	\$ (625,770)	\$ (1,015,086)	\$ (1,582,402)	\$ (2,274,929)

LINE OF CREDIT AGREEMENTS:

On May 27, 2005, we entered into a Line of Credit Agreement with Biomed Solutions, LLC, a related party, whereby Biomed agreed to provide a line of credit facility of up to \$2 million. Borrowings under the line, bear interest at 8% per annum, are payable on demand and are convertible at Biomed's election, into the Company's common stock at 90% of the average closing price for the 20 trading days preceding the date of borrowings under the line. In June 2005, the Company borrowed the entire \$2 million under the line in two separate draws of \$1 million each. In accordance with the agreement, Biomed received warrants to purchase 500,000 shares of the Company's common stock at an exercise price of 110% of the average closing price for the 20 trading days preceding the date of execution of the credit agreement. The Company recorded a discount on the borrowings of \$958,160 due to the beneficial conversion feature of the note as well as for the value of the warrants. The discount was amortized as additional interest expense over the term of the note. In August 2005, Biomed elected to convert \$1 million of the note plus accrued interest into 480,899 shares of common stock at which time, the remaining discount related to the \$1 million portion of the loan was fully expensed. On October 7, 2005, we repaid \$500,000 of principal and all accrued interest on the loan. The balance of borrowings on the line was \$500,000 at August 31, 2007.

On January 24, 2006, we entered into an additional Line of Credit Agreement (the "Line of Credit Agreement") with Biomed Solutions, LLC, pursuant to which Biomed committed to make advances to us, in an aggregate amount of up to \$5,000,000. Under the Line of Credit Agreement, advances may be drawn down in such amounts and at such times as we determine upon 15 days prior notice to Biomed, except that we may not draw down more than \$1,500,000 in any 30-day period. Amounts borrowed bear interest at the rate of 8% per annum and were convertible into shares of our Common Stock at the rate of \$1.46 per share. Biomed's obligation to lend to us under the Line of Credit Agreement expires on June 30, 2007, on which date the entire amount borrowed by us (and not converted into shares of our Common Stock) becomes due and payable. In connection with the establishment of the credit facility, we issued to Biomed a warrant to purchase up to 1,198,630 shares of our Common Stock at an exercise price of \$1.89 per share. The Company recorded a discount on the borrowings of \$1,678,425 due to the beneficial conversion feature of the note as well as for the value of the warrant.

On October 11, 2006, in connection with our Securities Purchase Agreement dated October 11, 2006 with Iroquois Master Fund Ltd and other private investors (the "Purchase Agreement"), we amended our January 24, 2006 Line of Credit Agreement (the "Biomed Line of Credit Agreement") with Biomed and the Convertible Promissory Note in the original principal amount of \$5,000,000 issued by us to Biomed on January 24, 2006 pursuant to the Biomed Line of

Credit Agreement (the "\$5,000,000 Biomed Note"). The amendment reduced the price at which the \$5,000,000 Biomed Note is convertible into shares of our Common Stock from \$1.46 per share to a conversion price of \$0.67. In connection with the Purchase Agreement, we also entered into a Subordination and Standstill Agreement (the "Subordination Agreement") with Biomed and the investors who are parties to the Purchase Agreement, pursuant to which Biomed agreed (i) to subordinate its rights to payment under the \$5,000,000 Biomed Note and the Convertible Promissory Note in the original principal amount of \$2,000,000 issued by us to Biomed on May 27, 2005 to the rights of the investors under the Notes and (ii) to convert the entire outstanding amount of principal and interest due under the \$5,000,000 Biomed Note in excess of \$700,000 into shares of our common stock upon the effectiveness of an amendment to our Articles of Incorporation to increase the number of our authorized shares which was effective May 9, 2007. On July 19, 2007, Biomed converted \$2,180,000 of principal and \$195,899 of accrued interest into a total of 3,546,118 shares of our common stock leaving a balance outstanding at August 31, 2007 of \$1,750,000.

The fair value of the notes is not readily determinable as there is a limited market for such related party debt.

F-8

SENIOR SECURED CONVERTIBLE NOTES:

On October 11, 2006, we entered into a Securities Purchase Agreement (the "Purchase Agreement") with 10 private investors led by Iroquois Master Fund Ltd ("Iroquois"). Pursuant to the Purchase Agreement, on October 12, 2006 we issued \$7,250,000 of Senior Secured Convertible Notes (the "Notes") to the investors and received proceeds of \$6,219,880 after paying estimated fees and expenses of \$1,030,120 related to the transaction. The holders of the Notes may elect to convert the Notes at any time into shares of our common stock based upon a price of \$0.67 per share (the "Conversion Price"). Interest on the outstanding principal amount under the Notes is payable quarterly at a rate equal to the six-month London InterBank Overnight Rate plus 500 basis points, with a minimum rate of 10% per annum and a maximum rate of 12% per annum, payable at our option in cash or shares of our common stock registered for resale under the Securities Act of 1933, as amended (the "Securities Act"). If we elect to make an interest payment in common stock, the number of shares issuable by us will be based upon the lower of (i) 90% of the 20-day trailing average volume weighted average price per share as reported on Bloomberg LP (the "VWAPS") or (ii) the Conversion Price. Principal on the Notes amortizes and payments are due in 33 equal monthly installments commencing four months following issuance of the Notes, and may be made at our option in cash or shares of our common stock registered for resale under the Securities Act. If we elect to make a principal payment in common stock, the number of shares issuable by us will be based upon the lower of (i) 87.5% of the 15-day trailing VWAPS prior to the principal payment date or (ii) the Conversion Price. Our obligations under the Notes are secured by a first priority security interest in substantially all of our assets pursuant to a Security Agreement dated as of October 11, 2006 among us, the investors and Iroquois, as agent for the investors (the "Security Agreement").

As further consideration to the investors, we issued to the investors one-year warrants to purchase an aggregate of 10,820,896 shares of our common stock at a price of \$0.67 per share. If the investors elect to exercise these one-year warrants, they will also receive additional five-year warrants to purchase the shares of our common stock equal to the number of shares purchased under the one-year warrants, with 50% of the additional warrants having an exercise price of 115% of the per-share purchase price, and the remaining 50% of the additional five-year warrants having an exercise price of 125% of the per share purchase price. We also issued to the investors five-year warrants to purchase an aggregate of 10,820,896 shares of our common stock. The first five-year warrants allow for the purchase of 5,410,448 shares of our common stock at an exercise price of \$0.81 per share, and the second five-year warrants allow for the purchase of 5,410,448 shares of our common stock at an exercise price of \$0.89 per share. The warrants contain anti-dilution protection that, should we issue equity or equity-linked securities at a price per common share below the exercise price of the five-year warrants, it will automatically adjust the exercise price of the warrants to the price at which we issue such equity or equity-linked securities. The total fair value of the warrants was \$14,554,105. The Company recorded a discount on the Notes of \$7,250,000 for the fair value of the related warrants. The excess of the fair value of the warrants over the carrying value of the notes, which amounted to \$7,304,105, was recognized as additional expense related to warrants in the statement of operations for the year ended February 28, 2007. The discount on the Notes is being amortized over the life of the Notes using the effective interest method. The discount amortization for the three months and six months ended August 31, 2007 amounted to \$905,197 and \$1,910,971 respectively, and is included in interest expense in the accompanying statements of operations.

We further agreed to register for resale under the Securities Act the common stock issuable upon the exercise of the warrants and any shares of common stock we may issue to the holders of the Notes in connection with payments of interest and principal, or which we are obligated to issue upon any conversion of the Notes at the option of the holders. Because we were unable to comply with various provisions of the registration requirements of the Purchase Agreement we incurred liquidated damages amounting to \$652,500 that have been accrued and was charged to operations during the three months ended May 31, 2007.

On February 21, 2007, we entered into a Forbearance Agreement (the "Forbearance Agreement") with the investors pursuant to which the investors agreed that, during the period commencing on February 16, 2007 and ending on the earlier of (i) March 31, 2007 or (ii) the date on which any Termination Event (as defined in the Forbearance

Agreement) first occurs (the "Forbearance Period"), they will forbear from exercising any and all of the rights and remedies which they may have against us or any of our assets under the Notes or the Purchase Agreement or at law or in equity as a result of any default under the Notes or as a result of the occurrence of certain events with respect to the Purchase Agreement. In exchange for entering into the Forbearance Agreement, we issued pro rata to the investors three-year warrants for the purchase of an aggregate of 60,000 shares of our common stock at an exercise price of \$0.51 per share (the "Fee Warrants").

Upon the issuance of the Fee Warrants, the exercise prices of the five-year warrants issued to the investors pursuant to the Purchase Agreement (the "Original Warrants") for the purchase of an aggregate of 10,820,896 shares of our common stock were automatically adjusted from \$0.81 per share and \$0.89 per share, respectively, to \$0.51 per share, and the number of shares of our common stock issuable upon exercise of the Original Warrants was automatically adjusted, proportionately, to an aggregate of 18,034,830 shares. In the Forbearance Agreement, the investors waived, with respect to the issuance of the Fee Warrants, application of similar anti-dilution adjustments contained in the Notes and in a third series of warrants for the purchase, on or before October 12, 2007, of an aggregate of 10,820,896 additional shares of our common stock at an exercise price of \$0.67 per share (the "One Year Warrants"). C.E. Unterberg Towbin, which holds a warrant for the purchase of 865,672 shares of our common stock at an exercise price of \$0.67 per share, issued to it in connection with its services as exclusive placement agent under the Purchase Agreement, separately agreed to waive, with respect to the issuance of the Fee Warrants, application of the anti-dilution provisions set forth in that warrant. Because the anti-dilution adjustment to the Original Warrants is accounted for as a modification of the Original Warrants, we recorded an expense for this modification in the period ended February 28, 2007.

On October 3, 2007, we entered into Amendment No. 1 to the Securities Purchase Agreement, Senior Secured Convertible Notes, Warrants and Security Agreement with the independent private investors. Pursuant to the Amendment, we agreed to amend the Notes to provide that even if the we elect to make a monthly installment payment in cash, the holder will have the right to convert any portion of the Note into common stock of the Company and apply the number of shares the holder would have received had we elected to make payment in common stock. In addition, the Conversion Price was reduced to \$0.15. The Amendment also amended the warrants to reduce the exercise prices of the various warrants to \$0.23. In exchange for the foregoing, the investors released certain intellectual property for the Security Agreement, allowing the Company to transfer and sell such intellectual property. Further, in the Amendment, we agreed to certain spending covenants in connection with the proceeds we will receive from the sale of the intellectual property under the Intellectual Property Assignment Agreement dated as of August 6, 2007 by and between Biophan and Medtronic, Inc.

FAIR VALUE OF WARRANT LIABILITY:

In accordance with the guidance provided by EITF 00-19, Accounting for Derivative Financial Instruments Indexed to and Potentially Settled in, a Company's Own Stock, we recorded a liability of \$10,157,937 for the fair value of the warrants related to the Senior Secured Convertible Notes at February 28, 2007 in order to provide for the possibility that we would not be able to comply with the registration rights of the lenders as contained in the Securities Purchase Agreement because we did not have sufficient available authorized shares to execute a potential conversion of the Notes and related warrants and thus we would be required to settle the contract in cash. In addition, since we did not have sufficient available authorized shares to execute a potential conversion of other outstanding warrants, if requested to do so by the grantees, we could be required to settle any conversion requests in cash. Therefore, we reclassified warrants with an approximate value of \$756,000 from equity to the warrant liability. The fair value of this amount was \$336,069 at February 28, 2007. The Company obtained stockholder approval to increase the authorized shares at a Special Meeting held on May 8, 2007. The total fair value of derivative liability, recorded at \$10,494,006 at February 28, 2007, was adjusted by \$4,339,214 to \$6,154,792 at May 8, 2007 resulting in a net non-cash income adjustment of that amount. The balance of the liability was then reclassified to additional paid-in capital.

STOCKHOLDERS' EQUITY:

The following changes in stockholders equity took place during the six months ended August 31, 2007:

Event	Number of Shares Issued	Common Stock	Additional Paid- in Capital
Balance at February 28, 2007	83,431,699	\$ 417,159	\$ 54,532,204
Fair value of derivative liability			6,154,792
Stock option expense			347,643
Balance at May 31, 2007	83,431,699	417,159	61,034,639
Conversion of Biomed loan principal and accrued interest	3,546,118	17,730	2,358,169
Principal and interest payments to investors	10,893,013	54,465	1,734,896
Stock issued for services	504,859	2,524	76,705
Additional equity contribution from other Myotech members			40,049
Stock option expense			1,596,986
Balance at August 31, 2007	98,375,689	\$ 491,878	\$ 66,841,444

On May 8, 2007, at a Special Meeting of Stockholders, a proposal to increase the authorized shares of common stock, \$.005 par value, from 125 million to 250 million was approved by the stockholders. As a result, additional paid-in capital was increased by \$6,154,792 due to the elimination of the fair value of warrant liability as of the date of the stockholder approval. In June 2007, principal and interest payments to holders of the Senior Secured Convertible Notes commenced.

F-11

SHARE-BASED COMPENSATION PLANS:

The Company has two stock-based compensation plans, entitled Biophan Technologies, Inc. 2001 Stock Option Plan and Biophan Technologies, Inc. 2006 Incentive Stock Plan (the "Plans") which are stockholder approved. The Plans provide for the grant of incentive and non-qualified stock options to selected employees, and the grant of non-qualified options to selected consultants and to directors and advisory board members. In addition, various other types of stock-based awards may be granted. The Plans are administered by the Compensation Committee of the Board and authorizes the grant of options or restricted stock awards for 13,000,000 shares under the 2001 Plan and 7,500,000 shares under the 2006 Plan. The Compensation Committee determines which eligible individuals are to receive options or other awards under the Plans, the terms and conditions of those awards, the applicable vesting schedule, the option price and term for any granted options, and all other terms and conditions governing the option grants and other awards made under the Option Plan. Non-employee directors also receive periodic option grants pursuant to the automatic grant program in effect for them under the 2006 Plan.

Effective March 1, 2006, the Company adopted SFAS No. 123 (revised), "Share-Based Payment" (SFAS 123(R)) utilizing the modified prospective approach. Prior to the adoption of SFAS 123(R), stock option grants to employees and directors were accounted for in accordance with APB Opinion No. 25, "Accounting for Stock Issued to Employees" (the intrinsic value method) and the disclosure-only provisions of SFAS 123, "Accounting for Stock-Based Compensation". Accordingly, employee compensation expense was recognized only to the extent that the fair value of our common stock on the date of grant exceeded the stock option exercise price.

Under the modified prospective approach, SFAS 123(R) applies to new grants and to grants that were outstanding on February 28, 2006 that are subsequently modified, repurchased or cancelled. Under the modified prospective approach, compensation cost recognized beginning in fiscal 2007 includes compensation cost for all share-based payments granted prior to, but not yet vested as of February 28, 2006, based on the grant-date fair value estimated in accordance with the original provisions of SFAS 123, and compensation cost for all share-based payments granted subsequent to February 28, 2006, based on the grant-date fair value estimated in accordance with the provisions of SFAS 123(R). Prior periods were not restated to reflect the impact of adopting the new standard.

We use the Black-Scholes option pricing model to estimate the fair value of stock-based awards with the following assumptions for the indicated periods:

	Three Months Ended August 31, 2007	Three Months Ended August 31, 2006	Six Months Ended August 31, 2007	Six Months Ended August 31, 2006
Expected volatility	78.8	119.7	75.2-81.4	119.7-121.8
Risk-free interest rate	4.8%	5.35%	4.55%-4.8%	4.6%-5.35%
Expected life of options 8 years	8 years	8 years	4-8 years	4-8 years
Expected dividends	-0-	-0-	-0-	-0-

The assumptions above are based on multiple factors, including historical exercise patterns of employees in relatively homogeneous groups with respect to exercise and post-vesting employment termination behaviors, expected future exercising patterns for these same homogeneous groups and the implied volatility of our stock price.

At August 31, 2007, there was \$722,440 of unrecognized compensation cost related to stock-based payments which is expected to be recognized over a weighted-average period of 1.11 years.

The following table represents stock option activity for the six months ended August 31, 2007:

	Number of Shares	Weighted- Average Exercise Price	Weighted- Average Remaining Contract Life(years)
Outstanding options at 2/28/07	9,428,062	\$.96	
Granted	6,277,331	\$.22	
Exercised	-0-		
Forfeited	(631,500)	\$ 1.49	
Expired	-0-		
Outstanding options at 8/31/07	15,073,893	\$.67	7.72
Outstanding exercisable at 8/31/07	13,718,060	\$.59	7.72

In addition to stock option grants of 6,162,331 during the three months ended August 31, 2007, grants of common stock aggregating 504,859 shares were awarded to certain individuals pursuant to the 2006 Incentive Stock Plan.

F-12

At August 31, 2007, shares available for future stock option grants and other stock-based awards to employees and others under our 2001 Stock Option Plan were 1,189,481 and shares available for future stock option grants and other stock-based to employees and others under our 2006 Incentive Stock Plan were 522,833.

At August 31, 2007, the aggregate intrinsic value of shares outstanding was \$20,000, and the aggregate intrinsic value of options exercisable was \$20,000. No options were exercised during the six months ended August 31, 2007.

The following table summarizes our non-vested stock option activity for the six months ended August 31, 2007:

	Number of Shares	Weighted-Average Grant-Date Fair Value
Non-vested stock options at 2/28/07	1,994,583	\$.62
Granted	6,277,331	\$.22
Vested	(6,454,831)	\$.26
Forfeited	(461,250)	\$.50
Non-vested stock options at 8/31/07	1,355,833	\$.66

CONTINGENCIES:

We are not a party to any material legal proceedings and there are no material legal proceedings pending with respect to our property, except as noted below. We are not aware of any legal proceedings contemplated by any governmental authorities involving either us or our property. None of our directors, officers or affiliates is an adverse party in any legal proceedings involving us or our subsidiaries, or has an interest in any proceeding which is adverse to us or our subsidiaries.

The Company is pursuing legal claims against one of its former law firms and certain of its attorneys. Review of the firm's work product and bills revealed questions about the firm's billing practices and other activities. The amount of potential damages has not yet been quantified. Also, the law firm has asserted claims seeking payment of additional legal fees, which claims the Company has denied. The litigation is in an early stage. While, as with any legal proceedings, no assurance can be given as to ultimate outcome, management believes that the outcome of the litigation will not have a material adverse effect upon the Company's financial condition. Accordingly, adjustments, if any that might result from the resolution of this matter have not been reflected in the financial statements.

On April 5, 2007, SBI Brightline LLC and SBI Brightline XI, LLC brought suit against us and Biomed Solutions, LLC in the Superior Court of Orange County, California. The suit alleges, among other things, that in September 2006 we entered into an agreement to terminate the Stock Purchase Agreement dated as of May 27, 2005 and amended on January 8, 2006, between us and SBI Brightline XI, LLC, and seeks unspecified monetary damages and an order by the Court deeming the Stock Purchase Agreement to be terminated. We believe the allegations made by SBI are without basis in fact and in response moved for dismissal of the complaint. The plaintiffs withdrew their complaint following our motion and filed an amended complaint containing nearly identical allegations. We intend to continue to defend the law suit vigorously, including seeking dismissal of the amended complaint. Because of the potential costs of litigation and the anticipated demands that our defense may place on the time and attention of our management our defense of this matter, regardless of the outcome, could have a material adverse effect on our business and operations.

SUBSEQUENT EVENT:

On August 6, 2007, we entered into an Intellectual Property Assignment Agreement with Medtronic, Inc., a Minnesota corporation, pursuant to which we agreed to transfer and sell to Medtronic all of our interest in and to certain intellectual property owned by us for an aggregate purchase price of \$11,000,000, which amount would have been reduced to \$10,500,000 if the closing did not occur within 60 days of the execution of the agreement. On October 5, 2007, we closed the transaction contemplated by the Intellectual Property Assignment Agreement, sold the foregoing intellectual property to Medtronic and received an aggregate of \$11,000,000 as the sale price.

F-13

Edgar Filing: BIOPHAN TECHNOLOGIES INC - Form S-1

REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

To the Board of Directors and Stockholders
Biophan Technologies, Inc.

We have audited the accompanying consolidated balance sheets of Biophan Technologies, Inc. and Subsidiaries (a development stage company) as of February 28, 2007 and 2006 and the related consolidated statements of operations, stockholders' equity (deficiency), and cash flows for each of the three years in the period ended February 28, 2007, and the amounts in the cumulative column in the consolidated statements of operations, stockholders' equity (deficiency), and cash flows for the period from March 1, 2000 to February 28, 2007. These financial statements are the responsibility of the Company's management. Our responsibility is to express an opinion on these financial statements based on our audits.

We conducted our audits in accordance with the standards of the Public Company Accounting Oversight Board (United States). Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement. An audit includes examining, on a test basis, evidence supporting the amounts and disclosures in the financial statements. An audit also includes assessing the accounting principles used and significant estimates made by management, as well as evaluating the overall financial statement presentation. We believe that our audits provide a reasonable basis for our opinion.

In our opinion, the consolidated financial statements referred to above present fairly, in all material respects, the financial position of Biophan Technologies, Inc. and Subsidiaries as of February 28, 2007 and 2006 and the results of its operations and its cash flows for each of the three years in the period ended February 28, 2007 in conformity with United States generally accepted accounting principles. Additionally, the amounts included in the cumulative column in the consolidated statements of operations and cash flows for the period from March 1, 2000 to February 28, 2007 are fairly presented, in all material respects, in conformity with United States generally accepted accounting principles.

The accompanying financial statements have been prepared assuming that the Company will continue as a going concern. As discussed in Note 2 to the financial statements, the Company has suffered recurring losses from operations and has a net capital deficiency that raise substantial doubt about its ability to continue as a going concern. Management's plan in regard to these matters is also described in Note 2. The financial statements do not include any adjustments that might result from the outcome of this uncertainty.

As discussed in Notes 1 and 17 to the consolidated financial statements, effective March 1, 2006, the Company adopted the fair value method of accounting for stock-based compensation as required by Statement of Financial Accounting Standards No. 123(R), Share-Based Payment.

We have also audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States), the effectiveness of the Company's internal control over financial reporting as of February 28, 2007, based on criteria established in Internal Control - Integrated Framework issued by the Committee of Sponsoring Organizations of the Treadway Commission and our report dated May 4, 2007 expressed an unqualified opinion thereon.

/S/ Goldstein Golub Kessler LLP
GOLDSTEIN GOLUB KESSLER LLP
New York, New York

Edgar Filing: BIOPHAN TECHNOLOGIES INC - Form S-1

May 4, 2007, except for Note 11 as to which the
date is October 22, 2007

F-1

Edgar Filing: BIOPHAN TECHNOLOGIES INC - Form S-1

BIOPHAN TECHNOLOGIES, INC. AND SUBSIDIARIES (A DEVELOPMENT STAGE COMPANY)

CONSOLIDATED BALANCE SHEET

	February 28,	
	2007	2006
ASSETS		
Current assets:		
Cash and cash equivalents	\$ 2,418,551	\$ 1,477,716
Accounts receivable	21,448	170,058
Due from related parties	--	4,801
Prepaid expenses	166,171	147,203
Other current assets	25,350	81,048
	2,631,520	1,880,826
Property and equipment, net	418,362	126,341
Other assets:		
Intangible assets, net of amortization:		
Myotech, LLC	23,074,028	24,451,580
Other	1,322,777	1,403,270
Deferred financing costs, net of amortization of \$186,350	1,345,860	--
Investment in New Scale Technologies, Inc.	100,000	100,000
Deposits	3,704	6,049
Deferred tax asset, net of valuation allowance of \$12,784,000 and \$7,560,000, respectively	--	--
	25,846,369	25,960,899
Total Assets	\$ 28,896,251	\$ 27,968,066
LIABILITIES AND STOCKHOLDERS' EQUITY (DEFICIENCY)		
Current liabilities:		
Current portion of capital lease obligation	\$ 7,445	\$ --
Current portion of senior secured convertible notes payable, net of discount of \$2,183,580	672,481	--
Accounts payable and accrued expenses	1,942,033	1,191,812
Note payable	78,007	15,886
Line of credit - related party, net of discount of \$-0- and \$1,323,921, respectively	4,430,000	1,476,079
Due to related parties	80,280	26,548
Deferred revenue	208,333	520,833
	7,418,579	3,231,158
Long-term debt:		
Capital lease obligation	19,604	--
Senior secured convertible notes payable, less discount of \$3,359,354	1,034,585	--
Fair value of warrant liability	10,494,006	--
	18,966,774	3,231,158

Edgar Filing: BIOPHAN TECHNOLOGIES INC - Form S-1

Minority interest	13,139,882	15,189,109
Stockholders' equity (deficiency):		
Common stock, \$.005 par value:		
Authorized, 125,000,000 shares		
Issued, 83,431,699 and		
81,805,243 shares, respectively	417,158	409,026
Additional paid-in capital	54,532,204	49,576,129
	-----	-----
	54,949,362	49,985,155
Less treasury stock, 4,923,080 shares	(8,467,698)	(8,467,698)
	-----	-----
	46,481,664	41,517,457
Deficit accumulated during the development stage	(49,692,069)	(31,969,658)
	-----	-----
Total stockholders' equity (deficiency)	(3,210,405)	9,547,799
	-----	-----
Total liabilities and stockholders'		
equity (deficiency)	\$ 28,896,251	\$ 27,968,066
	=====	=====

The accompanying notes should be read in conjunction with the consolidated financial statements

Edgar Filing: BIOPHAN TECHNOLOGIES INC - Form S-1

BIOPHAN TECHNOLOGIES, INC. AND SUBSIDIARIES (A DEVELOPMENT STAGE COMPANY)

CONSOLIDATED STATEMENT OF OPERATIONS

	Year Ended February 28,			Period from Au
	2007	2006	2005	1, 1968 (date inception) February 28,
Revenues:				
Development payments	\$ --	\$ 225,000	\$ --	\$ 300,000
License fees	562,500	479,166	--	1,041,666
Testing services and consulting fees	427,029	340,695	--	767,722
	-----	-----	-----	-----
	989,529	1,044,861	--	2,109,398
Operating expenses:				
Research and development	7,190,975	6,829,142	2,629,980	20,210,399
General and administrative	6,824,945	8,451,886	3,337,185	24,766,311
Write-down of intellectual property rights	--	--	--	530,000
	-----	-----	-----	-----
	14,015,920	15,281,028	5,967,165	45,506,710
Operating loss	(13,026,391)	(14,236,167)	(5,967,165)	(43,397,322)
	-----	-----	-----	-----
Other income(expense):				
Interest income	82,224	70,701	11,869	211,377
Interest expense	(4,303,543)	(1,140,866)	--	(7,175,333)
Additional expense related to warrants	(7,304,105)	--	--	(7,304,105)
Change in fair value of warrant liability	5,318,064	--	--	5,318,064
Loss on extinguishment of debt - related party	(670,053)	--	--	(670,053)
Other income	161,196	215,789	161,749	853,399
Other expense	(5,442)	--	--	(70,522)
	-----	-----	-----	-----
	(6,721,659)	(854,376)	173,618	(8,837,188)
Loss from continuing operations before minority interest in Myotech, LLC	(19,748,050)	(15,090,543)	(5,793,547)	(52,234,511)
Minority interest in Myotech, LLC	2,025,639	606,159	--	2,631,799
	-----	-----	-----	-----
Loss from continuing operations	(17,722,411)	(14,484,384)	(5,793,547)	(49,602,711)
Loss from discontinued operations	--	--	--	(89,351)
	-----	-----	-----	-----
Net loss	\$ (17,722,411)	\$ (14,484,384)	\$ (5,793,547)	\$ (49,692,062)
	=====	=====	=====	=====
Loss per common share - basic and diluted	\$ (0.23)	\$ (0.19)	\$ (0.08)	
	=====	=====	=====	
Weighted average shares outstanding	77,864,738	75,787,052	69,263,893	

=====

The accompanying notes should be read in conjunction with the consolidated financial statements

F-3

Edgar Filing: BIOPHAN TECHNOLOGIES INC - Form S-1

BIOPHAN TECHNOLOGIES, INC. AND SUBSIDIARIES (A DEVELOPMENT STAGE COMPANY)

CONSOLIDATED STATEMENT OF STOCKHOLDERS' EQUITY

PERIOD FROM AUGUST 1, 1968 (DATE OF INCEPTION) TO FEBRUARY 28, 2007

	Number of Shares Outstanding	Common Stock	Additional Paid-in Capital	Treasury Stock	Stoc Subscrip Receiva
	-----	-----	-----	-----	-----
1969-1993 - 382,130 shares issued for services for \$.05 per share	382,130	\$ 1,911	\$ 17,196		
1970 - 1,405,000 shares issued for mining rights for \$.05 per share	1,405,000	7,025	63,225		
Net loss from inception through February 28, 1998					
Balance at February 28, 1998	1,787,130	8,936	80,421		
1999 - 10,000 shares issued for services for \$.05 per share	10,000	50	450		
1999 - 1,000,000 shares issued for services for \$.005 per share	1,000,000	5,000			
Net loss for the year ended February 28, 1999					
Balance at February 28, 1999	2,797,130	13,986	80,871		
2000 - 1,000,200 shares issued for services for \$.005 per share	1,000,200	5,001			
Net loss for the year ended February 29, 2000					
Balance at February 29, 2000	3,797,330	18,987	80,871		
2000 - 250,000 shares issued for services for \$.005 per share	250,000	1,250			
2000 - Expenses paid by stockholder			2,640		
2000 - 10,759,101 shares issued for acquisition of Antisense Technology, Inc	10,759,101	53,795	121,205		
2000 - 10,759,101 shares issued for cash for \$.005 per share	10,759,101	53,796	121,204		
Net loss for the year ended February 28, 2001					
Balance at February 28, 2001	25,565,532	127,828	325,920		
2001 - 2,399,750 shares issued for cash for \$1.00 per share	2,399,750	11,999	2,387,751		
2001 - 468,823 shares issued for interest	468,823	2,344	466,479		
2001 - Redemption of 200,000 shares	(200,000)	(1,000)			

CONTINUED ON FOLLOWING PAGE

Edgar Filing: BIOPHAN TECHNOLOGIES INC - Form S-1

BIOPHAN TECHNOLOGIES, INC. AND SUBSIDIARIES (A DEVELOPMENT STAGE COMPANY)

CONSOLIDATED STATEMENT OF STOCKHOLDERS' EQUITY

PERIOD FROM AUGUST 1, 1968 (DATE OF INCEPTION) TO FEBRUARY 28, 2007

	Number of Shares Outstanding	Common Stock	Additional Paid-in Capital	Treasury Stock	Stoc Subscrip Receiva
	-----	-----	-----	-----	-----
2001 - 1,315,334 shares issued upon conversion of bridge loans at \$.75 per share	1,315,334	6,576	979,924		
2001 - Offering costs associated with share issuances for cash			(254,467)		
2002 - Grant of stock options for services			702,800		
Net loss for the year ended February 28, 2002					
Balance at February 28, 2002	29,549,439	147,747	4,608,407		
2002 - Shares issued for cash for \$.34 per share	993,886	4,969	337,461		
2002 - Shares issued for cash for \$.15 per share	1,192,874	5,964	167,002		
2002 to 2003 - Shares issued for cash for \$.25 per share	5,541,100	27,706	1,357,569		
2002 to 2003 - Shares issued as commissions on offerings	357,394	1,787	(1,787)		
2002 to 2003 Cash commissions on offerings			(119,488)		
Offering costs			(45,644)		
Grant of stock options for services			485,000		
Intrinsic value of beneficial conversion feature of note payable and MRI liability			800,000		
Net loss for the year ended February 28, 2003					
Balance at February 28, 2003	37,634,693	188,173	7,588,520		
2003 - Shares issued upon conversion of related party loans at \$.14 per share	1,268,621	6,343	177,607		
2003 - Shares issued upon conversion of stockholder loan plus accrued interest at \$.20 per share	775,000	3,875	151,693		
2003 - Shares issued for cash pursuant to equity line of credit at prices from \$.11 to \$.23 per share	3,325,757	16,629	474,561		
2003 - Shares issued for option exercises at \$.14 per share	3,000,000	15,000	412,847		

CONTINUED ON FOLLOWING PAGE

Edgar Filing: BIOPHAN TECHNOLOGIES INC - Form S-1

BIOPHAN TECHNOLOGIES, INC. AND SUBSIDIARIES (A DEVELOPMENT STAGE COMPANY)

CONSOLIDATED STATEMENT OF STOCKHOLDERS' EQUITY

PERIOD FROM AUGUST 1, 1968 (DATE OF INCEPTION) TO FEBRUARY 28, 2007

	Number of Shares Outstanding	Common Stock	Additional Paid-in Capital	Treasury Stock	Sto Subscr Recei
	-----	-----	-----	-----	-----
2004 - Shares issued for warrant exercises at \$.25 and \$.50 per share	995,940	4,980	327,864		
2004 - Shares issued for cash pursuant to stock purchase agreement at prices from \$.15 to \$.40 per share	11,000,000	55,000	2,845,000		
2004 - Shares issued upon conversion of related party loans at \$.10 per share	7,945,000	39,725	754,775		
Offering costs			(209,528)		
Grant of stock options for the year			565,000		
Intrinsic value of beneficial conversion feature of note payable			250,950		
Net loss for the year ended February 29, 2004					
Balance at February 29, 2004	65,945,011	329,725	13,339,289		
2004 - Shares issued for option exercise at \$.32 per share	70,000	350	22,050		
2004 - Shares issued for option exercise at \$.50 per share	24,999	125	12,375		
2004 - Shares issued upon exercise of warrants at \$.25 per share	868,700	4,343	212,832		
2004 - Shares issued upon exercise of warrants at \$.50 per share	926,700	4,634	458,716		
2004 - Shares issued upon exercise of warrants at \$1.00 per share	108,375	542	107,833		
2004 - Shares issued upon cashless exercise of warrants	74,047	370	(370)		
2004 - 2005 - Shares issued for cash pursuant to stock purchase agreement at prices from \$.60 to \$.70 per share	6,000,000	30,000	3,870,000		
2005 - Restricted shares issued in connection with employment agreements at \$1.34 per share	200,000	1,000	267,000		
2005 - Restricted shares issued in connection with acquisition of Biophan Europe at \$1.34 per share	100,000	500	133,500		
Offering costs			(41,998)		

CONTINUED ON FOLLOWING PAGE

Edgar Filing: BIOPHAN TECHNOLOGIES INC - Form S-1

BIOPHAN TECHNOLOGIES, INC. AND SUBSIDIARIES (A DEVELOPMENT STAGE COMPANY)

CONSOLIDATED STATEMENT OF STOCKHOLDERS' EQUITY

PERIOD FROM AUGUST 1, 1968 (DATE OF INCEPTION) TO FEBRUARY 28, 2007

	Number of Shares Outstanding	Common Stock	Additional Paid-in Capital	Treasury Stock	Stoc Subscri Receiv
	-----	-----	-----	-----	-----
Grant of stock options for services			201,000		
Section 16(b) short swing profits			400,725		
Stock subscription receivable					(150,000)
Net loss for the year ended February 28, 2005					
Balance at February 28, 2005	74,317,832	371,589	18,982,952		(150,000)
2005 - Shares issued for option exercise at \$.50 per share	74,998	375	66,206		
2005 - Shares issued for option exercise at \$.67 per share	12,500	63	8,312		
2005 - Shares issued for option exercise at \$1.00 per share	136,667	683	106,901		
2005 - Shares issued upon exercise of warrants at \$.16 per share	54,054	270	8,379		
2005 - Shares issued upon exercise of warrants at \$.39 per share	12,500	62	4,813		
2005 - Shares issued upon exercise of warrants at \$.41 per share	17,520	88	7,095		
2006 - Restricted shares issued in connection with acquisition of Biophan Europe at \$1.34 per share	100,000	500	133,500		
2005 - Shares issued for acquisition of minority interest in Myotech, LLC at \$1.72 per share	4,923,080	24,615	8,443,083		
2005 - Treasury shares	(4,923,080)	--	8,467,698	(8,467,698)	
2006 - Shares issued pursuant to investment agreement with Boston Scientific at \$3.02 per share	1,653,193	8,266	4,991,734		
2006 - 22,000 Restricted shares issued for services at \$1.72 per share	22,000	110	37,730		
2006 - Shares issued upon conversion of related party loans at \$2.12 per share	480,899	2,405	1,017,101		
Beneficial conversion feature of note payable			2,395,485		
Stock options issued for services			4,609,778		
Section 16(b) short swing profits			295,362		
Stock subscription receivable					150,000
Net loss for the year ended February 28, 2006					
Balance at February 28, 2006	76,882,163	409,026	49,576,129	(8,467,698)	

Edgar Filing: BIOPHAN TECHNOLOGIES INC - Form S-1

Shares issued for option exercises in the range of \$.18 to \$.67 per share	38,956	195	12,984	--
Shares issued for cash pursuant to stock purchase agreement with SBI at \$2.00 per share	1,587,500	7,937	3,167,063	--
Extinguishment of debt on related party notes payable	--	--	670,053	--
Allocation of beneficial conversion feature of related party notes payable	--	--	417,070	--
Allocation of proceeds to warrants	--	--	7,250,000	--
Reclassification of warrants	--	--	(8,005,875)	--
Stock options expense	--	--	1,444,780	--
Net loss for the year ended February 28, 2007	--	--	--	--
Balance at February 28, 2007	<u>78,508,619</u>	<u>\$417,158</u>	<u>\$54,532,204</u>	<u>\$(8,467,698)</u>

The accompanying notes should be read in conjunction with the consolidated financial statements

Edgar Filing: BIOPHAN TECHNOLOGIES INC - Form S-1

BIOPHAN TECHNOLOGIES, INC. AND SUBSIDIARIES (A DEVELOPMENT STAGE COMPANY)

CONSOLIDATED STATEMENT OF CASH FLOWS

	Year Ended February 28,		
	2007	2006	2005
Cash flows used for operating activities:			
Net loss	\$ (17,722,411)	\$ (14,484,384)	\$ (5,793,5
Adjustments to reconcile net loss to net cash used in operating activities:			
Amortization of intangible assets	1,458,045	405,441	
Amortization of deferred financing costs	186,350	--	
Depreciation and amortization	95,368	47,241	28,0
Loss on disposal of equipment	9,094	1,505	
Additional expenses related to warrants	7,304,105	--	
Change in fair value of derivative liability	(5,318,064)	--	
Realized and unrealized losses on marketable securities	--	--	
Loss on debt extinguishment of debt-related party	670,053	--	
Accrued interest on note converted to common stock	--	19,506	
Amortization of discount on convertible notes payable	1,707,066	--	
Write-down of intellectual property rights	--	--	
Amortization of discount on payable to related party	1,740,991	1,071,564	
Issuance of common stock for services	--	37,840	268,0
Issuance of common stock for interest	--	--	
Grant of stock options for services	1,444,780	4,609,778	201,0
Expenses paid by stockholder	--	--	
Minority interest	(2,049,227)	(536,616)	
Changes in operating assets and liabilities:			
(Increase) decrease in accounts receivable	148,610	(162,558)	
(Increase) decrease in due from related parties	4,801	156,858	(186,7
(Increase) decrease in prepaid expenses	(18,968)	(55,607)	(22,4
(Increase) decrease in other current assets	55,698	(39,710)	
(Increase) decrease in deposits	2,345	(867)	-
Increase (decrease) in accounts payable and accrued expenses	750,221	(14,742)	405,8
Increase (decrease) in due to related parties	53,732	26,548	
Increase (decrease) in deferred revenues	(312,500)	295,833	225,0
Net cash used in operating activities	(9,789,911)	(8,622,370)	(4,874,8

Edgar Filing: BIOPHAN TECHNOLOGIES INC - Form S-1

BIOPHAN TECHNOLOGIES, INC. AND SUBSIDIARIES
(A DEVELOPMENT STAGE COMPANY)

CONSOLIDATED STATEMENT OF CASH FLOWS (CONTINUED)

	Year Ended February 28,		
	2007	2006	2005
Cash flows used for investing activities:			
Purchases of property and equipment	(369,434)	(70,521)	(39,302)
Sales of marketable securities	--	--	1,150,000
Purchase of investment	--	--	(100,000)
Acquisition costs of intangible assets	--	(466,583)	--
Cash paid for investment in Myotech, net of cash received of \$19,408	--	(280,594)	--
Cash paid for acquisition of Biophan Europe, net of cash received of \$107,956	--	--	(258,874)
Purchases of marketable securities	--	--	--
Net cash provided by (used in) investing activities	(369,434)	(817,698)	751,824
Cash flows provided by financing activities:			
Proceeds of bridge loans	--	--	--
Loan from stockholder	--	--	--
Line of credit borrowing from related party	3,130,000	4,300,000	--
Line of credit payments	(1,500,000)	(500,000)	--
Proceeds of convertible notes payable	7,250,000	--	--
Notes payable	62,121	(184,114)	--
Proceeds from sales of capital stock	3,175,000	6,050,000	2,850,000
Exercise of options	13,179	182,541	34,900
Exercise of warrants	--	20,707	788,900
Swing profits	--	295,362	400,725
Deferred financing costs	(1,030,120)	--	--
Deferred equity placement costs	--	--	(22,107)
Net cash provided by financing activities	11,100,180	10,164,496	4,052,418
Net increase (decrease) in cash and equivalents	940,835	724,428	(70,612)
Cash and equivalents, beginning	1,477,716	753,288	823,900
Cash and equivalents, ending	\$ 2,418,551	\$ 1,477,716	\$ 753,288
Supplemental schedule of cash paid for:			
Interest	\$ 30,000	\$ 9,800	\$ --

CONTINUED ON FOLLOWING PAGE

Edgar Filing: BIOPHAN TECHNOLOGIES INC - Form S-1

BIOPHAN TECHNOLOGIES, INC. AND SUBSIDIARIES
(A DEVELOPMENT STAGE COMPANY)

CONSOLIDATED STATEMENT OF CASH FLOWS (CONTINUED)

	Year Ended February 28,		
	2007	2006	2005
Supplemental schedule of non-cash investing and financing activities:			
Allocation of proceeds from line of credit - related party to beneficial conversion feature and warrants	\$ 417,070	\$ 2,395,485	\$
Allocation of proceeds from notes payable and warrants	\$7,250,000	\$ --	\$
Change in fair value of warrants reclassified from equity to warrants liability	\$ 755,876	\$ --	\$
Capital lease obligation	\$ 27,049	\$ --	\$
Issuance of common stock upon conversion of LOC loans	\$ --	\$ 1,000,000	\$
Issuance of common stock for the acquisition of initial 35% interest in Myotech, LLC	\$ --	\$ 8,467,698	\$
Issuance of common stock in satisfaction of accounts payable	\$ --	\$ 134,000	\$
Common stock issued for subscription receivable	\$ --	\$ (1,050,000)	\$1,050,
Liabilities assumed in conjunction with acquisition of 51% interest in Biophan Europe and certain intellectual property rights:			
Fair value of assets acquired			\$1,105,
Cash paid			(366,
Promissory note issued			(200,
Restricted stock issued			(134,
Payables incurred			(226,
Liabilities assumed	\$ --	\$ --	\$ 178,
Issuance of common stock upon conversion of bridge loans	\$ --	\$ --	\$
Acquisition of intellectual property	\$ --	\$ --	\$
Intellectual property acquired through issuance of capital stock and assumption of related party payable	\$ --	\$ --	\$

Edgar Filing: BIOPHAN TECHNOLOGIES INC - Form S-1

The accompanying notes should be read in conjunction with the consolidated financial statements

F-10

Edgar Filing: BIOPHAN TECHNOLOGIES INC - Form S-1

BIOPHAN TECHNOLOGIES, INC. AND SUBSIDIARIES
(A DEVELOPMENT STAGE COMPANY)

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

1. PRINCIPAL BUSINESS ACTIVITY AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES:

BASIS OF CONSOLIDATION:

The consolidated financial statements include the accounts of Biophan Technologies, Inc. ("Biophan"), its wholly owned subsidiaries, LTR Antisense Technology, Inc. ("Antisense") and Nanolution, LLC, formerly MRIC Drug Delivery Systems, LLC, ("Nanolution"), its majority owned subsidiaries Biophan Europe GmbH ("Biophan Europe"), formerly aMRIs GmbH, and TE Bio LLC ("TE Bio"), and Myotech, LLC ("Myotech"), a variable interest entity, collectively referred to as the "Company". All significant inter-company accounts and transactions have been eliminated in consolidation.

COMPANY HISTORY:

The Company was incorporated under the laws of the State of Idaho on August 1, 1968 and on January 12, 2000, changed its domicile to Nevada by merging into a Nevada corporation, and on July 19, 2001, changed its name to Biophan Technologies, Inc. From the inception of the current line of business on December 1, 2000, the Company has not generated any material revenues and operating profits. Therefore, the Company is in the development stage and will remain so until the realization of significant revenues and operating profits. The Company's ability to continue in business is dependent upon maintaining sufficient financing or attaining future profitable operations.

PRINCIPAL BUSINESS ACTIVITIES:

The primary mission is to develop and commercially exploit technologies for improving the performance, and as a result, the competitiveness of biomedical devices manufactured by third party companies. The Company possesses technologies for enabling biomedical devices, both implantable and those used in diagnostic and interventional procedures, to be safe (do not harm the patient or physician) and image compatible (allow effective imaging of the device and its surrounding tissue) with MRI (magnetic resonance imaging). The Company is also developing and marketing an image compatible ceramic motor; a system for generating power for implantable devices from body heat, and a series of implantable devices including MRI-visible vascular implants such as a vena cava filter, a heart valve and an occluder for the treatment of atrial septal defects, a hole in the wall separating the left and right chambers of the heart. The Company's first licensee for several of these technologies is Boston Scientific (NYSE: BSX). The Company is also an owner of a substantial minority interest, with rights to take a majority interest, in Myotech, (accounted for as a variable interest entity) developer of the MYO-VAD, a cardiac assist device that does not contact circulating blood and utilizes technology that has the potential to become a standard of care in the device market for treating multiple types of acute and chronic heart failure including congestive heart failure and sudden cardiac arrest.

CASH AND CASH EQUIVALENTS

For purposes of the statement of cash flows, the Company considers all highly liquid instruments with an original maturity of three months or less to be cash equivalents. The Company places its temporary cash investments with high credit quality financial institutions. At times such investments may be in excess of the Federal Deposit Insurance Corporation (FDIC) insurance limit.

Edgar Filing: BIOPHAN TECHNOLOGIES INC - Form S-1

CONCENTRATION OF CREDIT RISK

Financial instruments that potentially subject the Company to concentrations of credit risk consist principally of cash deposits. Accounts are insured by the Federal Deposit Insurance Corporation (FDIC) up to \$100,000. At times throughout the year, the Company has balances on account in excess of insured limits.

F-11

Edgar Filing: BIOPHAN TECHNOLOGIES INC - Form S-1

BIOPHAN TECHNOLOGIES, INC. AND SUBSIDIARIES (A DEVELOPMENT STAGE COMPANY)

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

ACCOUNTS RECEIVABLE

Accounts receivable are reported at their outstanding unpaid principal balances. The Company writes off accounts receivable when they are deemed uncollectible. The Company has historically experienced insignificant amounts of bad debts.

PROPERTY AND EQUIPMENT

Property and equipment are recorded at cost. Expenditures for major additions and improvements are capitalized, and minor replacements, maintenance, and repairs are charged to expense as incurred. When property and equipment are retired or otherwise disposed of, the cost and accumulated depreciation are removed from the accounts and any resulting gain or loss is included in the results of operations for the respective period. Depreciation is provided over the estimated useful lives of the related assets using the straight-line method. Leasehold improvements are amortized over the lesser of the assets' useful lives or the remaining term of the lease.

The estimated useful lives for significant property and equipment categories are as follows:

Computers	5 year
Furniture and equipment	5 to 7 years
Internet website	7 years
Leasehold improvements	15 years

INTANGIBLE ASSETS

The Company evaluates the recoverability of identifiable intangible assets whenever events or changes in circumstances indicate that an intangible asset's carrying amount may not be recoverable. Such circumstances could include, but are not limited to: (1) a significant decrease in the market value of an asset, (2) a significant adverse change in the extent or manner in which an asset is used, or (3) an accumulation of costs significantly in excess of the amount originally expected for the acquisition of an asset. The Company measures the carrying amount of the asset against the estimated undiscounted future cash flows associated with it. Should the sum of the expected future net cash flows be less than the carrying value of the asset being evaluated, an impairment loss would be recognized. The impairment loss would be calculated as the amount by which the carrying value of the asset exceeds its fair value. The fair value is measured based on quoted market prices, if available. If quoted market prices are not available, the estimate of fair value is based on various valuation techniques, including the discounted value of estimated future cash flows. The evaluation of asset impairment requires the Company to make assumptions about future cash flows over the life of the asset being evaluated. These assumptions require significant judgment and actual results may differ from assumed and estimated amounts. Also, at each balance sheet date, the Company evaluates the period of amortization of intangible assets.

DEFERRED TAXES

Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases. Deferred tax assets and liabilities are measured using enacted rates expected to apply when the differences are expected to be realized. A valuation

Edgar Filing: BIOPHAN TECHNOLOGIES INC - Form S-1

allowance is recognized if it is anticipated that some or all of the deferred tax asset may not be realized.

LOSS PER SHARE

Basic loss per common share is computed by dividing net loss by the weighted-average number of shares of common stock outstanding during the period. Diluted loss per common share gives effect to dilutive options, warrants and other potential common stock outstanding during the period. Potential common stock has not been included in the computation of diluted loss per share, as the effect would be antidilutive.

F-12

Edgar Filing: BIOPHAN TECHNOLOGIES INC - Form S-1

BIOPHAN TECHNOLOGIES, INC. AND SUBSIDIARIES
(A DEVELOPMENT STAGE COMPANY)

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

STOCK OPTION PLANS

On March 1, 2006 the Company adopted the fair value based method of accounting prescribed in FASB Statement of Financial Accounting Standards No. 123R (Share-Based Payment) for its employee stock option plans.

REVENUE RECOGNITION:

The Company earns and recognizes revenue under development agreements when the phase of the agreement to which amounts relate is completed and the Company has no further performance obligation. Completion is determined by the attainment of specified milestones, such as a written progress report. Advance fees received on such agreements are deferred until recognized.

The Company recognizes initial license fees over the term of the related agreement. Revenue related to a performance milestone is recognized upon the achievement of the milestone, as defined in the respective agreements.

The Company recognizes revenues from testing services and consulting fees as services are performed.

ESTIMATES

Preparing the Company's financial statements in conformity with accounting principles generally accepted in the United States of America ("GAAP") requires management to make estimates and assumptions that affect reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.

RECLASSIFICATION

For comparative purposes, certain amounts in the accompanying statement of operations for fiscal 2005 have been reclassified to conform to the presentation used for fiscal 2007 and 2006. These reclassifications had no effect on previously reported results of operations or accumulated deficit.

RECENT ACCOUNTING PRONOUNCEMENTS

In June 2006, the Financial Accounting Standards Board ("FASB") issued FASB Interpretation No. 48, "Accounting for Uncertainty in Income Taxes - an interpretation of FASB Statement No. 109" ("FIN 46"). FIN 46 clarifies the accounting for uncertainty in income taxes recognized in a company's financial statements in accordance with SFAS No. 109, "Accounting for Income Taxes." FIN 48 prescribes a recognition threshold and measurement attribute for the financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return. FIN 46 is effective for fiscal years beginning after December 15, 2006. The Company is currently evaluating the effect, if any, that FIN 46 will have on its consolidated financial position or results of operations.

In September 2006, the FASB issued SFAS No. 157, "Fair Value Measurements" ("SFAS No. 157"). SFAS No. 157 defines fair value, establishes a framework for measuring fair value in generally accepted accounting principles, and expands disclosures about fair value measurements. SFAS No. 157 applies under other

Edgar Filing: BIOPHAN TECHNOLOGIES INC - Form S-1

accounting standards that require or permit fair value measurements. Accordingly, SFAS No. 157 does not require any new fair value measurement. SFAS No. 157 emphasizes that fair value is a market-based measurement that should be determined based on the assumptions that market participants would use in pricing an asset or liability. Companies will be required to disclose the extent to which fair value is used to measure assets and liabilities, the inputs used to develop the measurements and the effect of certain of the measurements on earnings (or changes in net assets) for the period. SFAS No. 157 is effective for financial statements issued for fiscal years beginning after November 15, 2007, and interim periods within those fiscal years. The Company is currently evaluating the effect, if any, that SFAS No. 157 will have on its consolidated financial position or results of operations.

In February 2007, the FASB issued SFAS No. 159, "The Fair Value Option for Financial Assets and Financial Liabilities". SFAS No. 159 permits entities to choose to measure many financial instruments and certain other items at fair value. Most of the provisions of SFAS No. 159 apply only to entities that elect the fair value option. We do not believe the adoption of this standard will have a material impact on our Consolidated Financial Statements. This standard will become effective for us in the first fiscal quarter of 2008.

In September 2006, the SEC issued Staff Accounting Bulletin No. 108 "Considering the Effects of Prior Year Misstatements when Quantifying Misstatements in Current Year Financial Statements" ("SAB No. 108"). SAB No. 108 provides guidance on the consideration of the effects of prior year misstatements in quantifying current year misstatements for the purpose of determining whether the current year's financial statements are materially misstated. SAB No. 108 is effective as of the end of the Company's 2006 fiscal year, allowing a one-time transitional cumulative effect adjustment to beginning retained earnings as of January 1, 2006, for errors that were not previously deemed material, but are material under the guidance in SAB No. 108. The Company does not believe that SAB No. 108 had a material effect on its consolidated financial position or results of operations for the year ended February 28, 2007.

In December 2006, the FASB issued Staff Position No. EITF 00-19-2. This FSP addresses an issuer's accounting for registration payment arrangements and specifies that the contingent obligation to make future payments or otherwise transfer consideration under a registration payment arrangement should be separately recognized and measured in accordance with FASB No. 5. The guidance in this FSP amends FASB Statements 133 and 150 and FASB Interpretation No. 45 to include scope exceptions for registration payment arrangements. This FSP further clarifies that a financial instrument subject to a registration payment arrangement should be accounted for without regard to the contingent obligation to transfer consideration pursuant to the registration payment arrangement. This guidance is effective for financial statements issued for fiscal years beginning after December 15, 2006. The Company will adopt this FSP in the first quarter of fiscal 2008 in connection with the issuance of the Senior Secured Convertible Notes and related warrants. See Note 11, "Senior Secured Convertible Notes."

Management does not believe that any other recently issued, but not yet effective, accounting standards if currently adopted would have a material effect on the accompanying financial statements.

2. GOING CONCERN:

As presented in the accompanying financial statements, the Company has been in the development stage since inception, incurring recurring losses from operations, and as of February 28, 2007, the Company's current liabilities exceeded its current assets by \$4,787,059 and the Company has a stockholders' deficiency of \$3,210,045. These factors raise potential doubt about the Company's ability to continue as a going concern. Management is taking several actions to ensure that the Company will continue as a going concern.

Edgar Filing: BIOPHAN TECHNOLOGIES INC - Form S-1

The Company is in regular contact with its current investors and prospective new investors, and believes that it will be able to raise additional capital on the warrants that are currently being registered with the Securities and Exchange Commission and that it will be able to service its debt using the warrant shares that are being registered for this purpose.

Further, in order to address the current situation, management has instituted a cost reduction program that included a reduction in monthly costs from approximately \$1,100,000 at this time last year to under \$500,000 per month currently. In addition, the Company has reduced its investments in several product lines and pursued alternative funding vehicles. The Company has reorganized its efforts on the Myotech cardiac assist device development while keeping core functions operational and maintaining intellectual property and designs.

Management believes these factors and actions will contribute toward obtaining sufficient financing for the near term and ultimate profitability. The accompanying financial statements do not include any adjustments that might be necessary if the Company is unable to continue as a going concern.

3. BUSINESS COMBINATIONS

Effective June 3, 2004, the Company executed final agreements for the acquisition of a 51% ownership interest in TE Bio, LLC ("TE Bio"), a newly formed limited liability company that acquired an exclusive license to certain technology from Biomed Solutions LLC ("Biomed"), a related party. TE Bio is also owned 46.5% by Biomed, a related company, and 2.5% by Stuart G. MacDonald, Vice-President of Research and Development for the Company. The primary reason for the acquisition was the development of an implantable biothermal battery using body heat gradients to power medical devices. The Payment Agreement (the "Agreement") provides for the investment in TE Bio of \$300,000 per year for three years from the Company's working capital. In addition, the Company will provide certain administrative, marketing, and research and development services to TE Bio. The results of operations of TE Bio beginning June 3, 2004 are included in the accompanying consolidated statement of operations. TE Bio had no significant assets, liabilities or operations at time of acquisition.

On February 24, 2005, the Company entered into an agreement for the purchase of a 51% ownership interest in aMRIs GmbH, a German company formed November 2004. Concurrently, aMRIs acquired a 58.4% interest in MR:comp GmbH. The name of aMRIs was subsequently changed to Biophan Europe GmbH. For accounting purposes, the acquisition is treated as a purchase as of February 28, 2005. Operating results of the subsidiary for the period from February 25 through February 28, 2005 were not material and are not included.

Edgar Filing: BIOPHAN TECHNOLOGIES INC - Form S-1

BIOPHAN TECHNOLOGIES, INC. AND SUBSIDIARIES (A DEVELOPMENT STAGE COMPANY)

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

The principal reasons for the acquisition, in addition to obtaining a European market presence, were to add complementary intellectual property to the Company's existing technologies, further expertise to its management team, and additional research and development capabilities. Accordingly, in connection with the purchase, the Company executed an exclusive license agreement for certain patents related to the Company's own proprietary technologies in the area of MRI safety and compatibility, employment agreements with key executives of aMRIs and agreed to contribute to aMRIs \$2,000,000 over four years for funding specific salaries and research and development expenses.

Total consideration for the 51% interest in aMRIs and for intellectual property rights was \$1,105,714, consisting of the following:

Cash paid	\$ 132,500
Promissory note issued	200,000
Amount payable in cash	92,500
Amount payable in restricted stock	134,000
Restricted stock issued (100,000 shares)	134,000
Direct acquisition costs	234,330
Liabilities assumed	178,384

Total purchase price	\$1,105,714
	=====

The allocation of the purchase price is as follows:

Intellectual property rights (estimated useful life of 17 years)	\$ 927,738
Current assets	176,954
Equipment	1,022

Total	\$1,105,714

The following summarized pro forma consolidated statement of operations (unaudited) for the year ended February 28, 2005, assumes the acquisition of aMRIs as if it had occurred on March 1, 2004:

Operating expenses:	
Research and development	\$ 2,737,038
General and administrative	3,505,300

	6,242,338

Operating loss	(6,242,338)
Other income	246,745

Edgar Filing: BIOPHAN TECHNOLOGIES INC - Form S-1

Net loss	\$ (5,995,593)
	=====
Loss per common share-basic and diluted	\$ (0.09)
	=====
Weighted average shares outstanding	69,263,893
	=====

Effective November 30, 2005, we entered into a Securities Purchase Agreement for the acquisition of an initial 35% interest in Myotech, LLC ("Myotech"), a New York limited liability company, whereby we exchanged 4,923,080 shares of our common stock, par value \$.005, for 3,768,488 Class A (voting) units of Myotech.

Based upon the terms of the Securities Purchase Agreement, we were obligated to purchase for cash consideration of \$2.225 million an additional 811,037 Class A units. We may elect to acquire up to an additional 3,563,097 Class A units for further cash consideration of up to \$9.775 million, over a 24-month period, which may result in the Company owning a majority interest in Myotech. During the three month period ended February 28, 2006, Biophan provided \$1,185,000 of additional funding for 431,946 newly issued Class A units of Myotech. During the year ended February 28, 2007, Biophan has provided \$1,040,000 of additional funding satisfying the cash consideration of \$2.225 million cited above, for 379,091 newly issued Class A units of Myotech. In addition, Biophan has also provided an additional investment of \$1,994,349 to Myotech against milestone 2 in the year ended February 28, 2007 for 726,963 newly issued Class A units, which increased our ownership to 43.7%. Additional investments of \$105,175 against milestone 2 have been made since February 28, 2007 for 38,337 additional newly issued Class A units, which raised our ownership percentage to 43.8% to date.

Edgar Filing: BIOPHAN TECHNOLOGIES INC - Form S-1

We have determined that Myotech is a Variable Interest Entity within the meaning of FIN 46(R) and that we are the primary beneficiary (as defined in FIN 46(R)). Consequently, the financial statements of Myotech have been consolidated with our consolidated financial statements for all periods ending on or after November 30, 2005, the date of our initial investment in Myotech.

The following is selected financial data for Myotech, LLC at February 28, 2007 and 2006, respectively:

	For the Year Ended February 28, 2007	For the Three Months Ended February 28, 2006
	-----	-----
Total current assets	\$ 338,548	\$ 59,608
Intangible assets, net of amortization	23,074,028	24,451,580
Other assets	196,915	37,156
	-----	-----
Total assets	\$ 23,609,491	\$ 24,548,344
	=====	=====
Current liabilities	\$ 352,072	\$ 169,948
Equity	23,257,419	24,378,396
	-----	-----
	\$ 23,609,491	\$ 24,548,344
	=====	=====
Net loss from operations	\$ (4,163,326)	\$ (992,026)
	=====	=====

Edgar Filing: BIOPHAN TECHNOLOGIES INC - Form S-1

BIOPHAN TECHNOLOGIES, INC. AND SUBSIDIARIES (A DEVELOPMENT STAGE COMPANY)

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

4. PREPAID EXPENSES:

Prepaid expenses consist of the following:

	February 28,	
	2007	2006
Prepaid insurance	\$ 36,812	\$ 33,403
Prepaid license fees - related company	10,000	15,000
Prepaid legal fees	30,000	30,000
Prepaid rent	22,492	--
Prepaid royalties - related company	35,000	35,000
Prepaid conference fees	--	29,400
Other	31,867	4,400
	\$166,171	\$147,203
	=====	=====

5. PROPERTY AND EQUIPMENT:

Property and equipment, at cost, consists of the following:

	February 28,	
	2007	2006
Furniture and Equipment	\$ 349,298	\$ 123,664
Computers	143,543	85,843
Internet Website	54,159	54,159
Leasehold Improvements	75,700	--
	622,700	263,666
Less accumulated depreciation	(204,338)	(137,325)
	\$ 418,362	\$ 126,341
	=====	=====

Property and equipment includes amounts acquired under capital leases of \$27,049 and \$0 at February 28, 2007 and 2006, respectively, with accumulated depreciation of approximately \$5,400 and \$0, respectively.

Depreciation and amortization expense for the years ended February 28, 2007, 2006, and 2005 amounted to \$95,368, \$47,241 and \$28,020, respectively. Depreciation expense for the period from August 1, 1968 (date of inception) to February 28, 2007 was \$234,802.

6. INTANGIBLE ASSETS:

Certain intellectual property rights were acquired on December 1, 2000 in

Edgar Filing: BIOPHAN TECHNOLOGIES INC - Form S-1

connection with the merger that established the Company in its present form. Additional intangible assets were acquired on February 24, 2005 in connection with the acquisition of Biophan-Europe and on November 30, 2005 in connection with the investment in Myotech, LLC. Such rights encompass the utilization of new proprietary technology to prevent implantable cardiac pacemakers and other critical and life-sustaining medical devices from being affected by MRI and other equipment using magnetic fields, radio waves and similar forms of electromagnetic interference and the development of a cardiac assist device. These assets are amortized over the estimated 17 to 18 year economic lives of the underlying patents and core technology. Estimated amortization expense for the next five years is as follows:

Fiscal year ending February,	Amount
-----	-----
2008	\$1,458,045
2009	1,458,045
2010	1,458,045
2011	1,458,045
2012	1,458,045

Amortization expense for the year ended February 28, 2007 and 2006 was \$1,458,045 and \$405,441, respectively. Amortization expense for the period from August 1, 1968 (date of inception) to February 28, 2007 was \$1,863,486.

Edgar Filing: BIOPHAN TECHNOLOGIES INC - Form S-1

BIOPHAN TECHNOLOGIES, INC. AND SUBSIDIARIES
(A DEVELOPMENT STAGE COMPANY)

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

7. INVESTMENT:

The investment in New Scale Technologies, Inc. represents a 10% investment in its common stock, a non-public company, stated at cost.

8. LINE OF CREDIT AGREEMENTS:

On May 27, 2005, we entered into a Line of Credit Agreement with Biomed Solutions, LLC, a related party, whereby Biomed agreed to provide a line of credit facility of up to \$2 million. Borrowings under the line, bear interest at 8% per annum, are payable on demand and are convertible at Biomed's election, into the Company's common stock at 90% of the average closing price for the 20 trading days preceding the date of borrowings under the line. In June 2005, the Company borrowed the entire \$2 million under the line in two separate draws of \$1 million each. In accordance with the agreement, Biomed received warrants to purchase 500,000 shares of the Company's common stock at an exercise price of 110% of the average closing price for the 20 trading days preceding the date of execution of the credit agreement. The Company recorded a discount on the borrowings of \$958,160 due to the beneficial conversion feature of the note as well as for the value of the warrants. The discount was amortized as additional interest expense over the term of the note. In August 2005, Biomed elected to convert \$1 million of the note plus accrued interest into 480,899 shares of common stock at which time, the remaining discount related to the \$1 million portion of the loan was fully expensed. On October 7, 2005, we repaid \$500,000 of principal and all accrued interest on the loan. The balance of borrowings on the line was \$500,000 at February 28, 2007.

On January 24, 2006, we entered into an additional Line of Credit Agreement (the "Line of Credit Agreement") with Biomed Solutions, LLC, pursuant to which Biomed committed to make advances to us, in an aggregate amount of up to \$5,000,000. Under the Line of Credit Agreement, advances may be drawn down in such amounts and at such times as we determine upon 15 days prior notice to Biomed, except that we may not draw down more than \$1,500,000 in any 30-day period. Amounts borrowed bear interest at the rate of 8% per annum and were convertible into shares of our Common Stock at the rate of \$1.46 per share. Biomed's obligation to lend to us under the Line of Credit Agreement expires on June 30, 2007, on which date the entire amount borrowed by us (and not converted into shares of our Common Stock) becomes due and payable. In connection with the establishment of the credit facility, we issued to Biomed a warrant to purchase up to 1,198,630 shares of our Common Stock at an exercise price of \$1.89 per share. The Company recorded a discount on the borrowings of \$1,678,425 due to the beneficial conversion feature of the note as well as for the value of the warrant.

On October 11, 2006, in connection with our Securities Purchase Agreement dated October 11, 2006 with Iroquois Master Fund Ltd and other private investors (the "Purchase Agreement"), we amended our January 24, 2006 Line of Credit Agreement (the "Biomed Line of Credit Agreement") with Biomed and the Convertible Promissory Note in the original principal amount of \$5,000,000 issued by us to Biomed on January 24, 2006 pursuant to the Biomed Line of Credit Agreement (the "\$5,000,000 Biomed Note"). The amendment reduced the price at which the \$5,000,000 Biomed Note is convertible into shares of our Common Stock from \$1.46 per share to a conversion price of \$0.67. In connection with the Purchase Agreement, we also entered into a Subordination and Standstill Agreement (the "Subordination Agreement") with Biomed and the investors who are parties to the Purchase Agreement, pursuant to which Biomed agreed (i) to subordinate its

Edgar Filing: BIOPHAN TECHNOLOGIES INC - Form S-1

rights to payment under the \$5,000,000 Biomed Note and the Convertible Promissory Note in the original principal amount of \$2,000,000 issued by us to Biomed on May 27, 2005 to the rights of the investors under the Notes and (ii) to convert the entire outstanding amount of principal and interest due under the \$5,000,000 Biomed Note in excess of \$700,000 into shares of our common stock upon the effectiveness of an amendment to our Articles of Incorporation to increase the number of our authorized shares which we have agreed, in the Purchase Agreement, to propose to our stockholders. For accounting purposes, these amendments have been treated, in substance, as an extinguishment of the old debt. Accordingly, the remaining unamortized discount on the old debt of \$1,098,442 was written off, a loss on extinguishment of \$670,053 on the old debt was recognized, and a discount was recorded and fully amortized on the new debt of \$175,970 during the year ended February 28, 2007. The balance of the borrowings of the line was \$3,930,000 at February 28, 2007. The fair value of the note is not readily determinable as there is a limited market for such related party debt.

F-17

Edgar Filing: BIOPHAN TECHNOLOGIES INC - Form S-1

BIOPHAN TECHNOLOGIES, INC. AND SUBSIDIARIES (A DEVELOPMENT STAGE COMPANY)

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

9. ACCOUNTS PAYABLE AND ACCRUED EXPENSES:

Accounts payable and accrued expenses consist of the following:

	February 28,	
	2007	2006
Accounts payable	\$1,010,060	\$ 793,873
Bonuses - Biophan-Europe	75,000	150,000
Accrued payroll and related expenses	152,395	76,977
Accounting fees	75,000	--
Consulting fees	30,000	--
Interest payable	504,078	34,112
License fees	--	70,000
Other	95,500	66,850
	-----	-----
	\$1,942,033	\$1,191,812
	=====	=====

10. CAPITAL LEASE OBLIGATION:

The Company leases equipment under a capital lease that expires in 2010. The lease requires monthly payments of \$934 including interest at 14.75% per annum.

Future minimum lease payments required under the capital lease are as follows:

Year Ending	Amount
February 28,	-----
2008	\$ 11,212
2009	11,212
2010	11,212

	\$ 33,636
	=====
Less amount representing interest	(6,587)

	27,049
Less current maturities	(7,445)

Long-term debt, less maturities	\$ 19,604
	=====

11. SENIOR SECURED CONVERTIBLE NOTES:

On October 11, 2006, we entered into a Securities Purchase Agreement (the "Purchase Agreement") with 10 private investors led by Iroquois Master Fund Ltd

Edgar Filing: BIOPHAN TECHNOLOGIES INC - Form S-1

("Iroquois"). Pursuant to the Purchase Agreement, on October 12, 2006 we issued \$7,250,000 of Senior Secured Convertible Notes (the "Notes") to the investors and received proceeds of \$6,219,880 after paying estimated fees and expenses of \$1,030,120 related to the transaction. The holders of the Notes may elect to convert the Notes at any time into shares of our common stock based upon a price of \$0.67 per share (the "Conversion Price"). Interest on the outstanding principal amount under the Notes is payable quarterly at a rate equal to the six-month London InterBank Overnight Rate plus 500 basis points, with a minimum rate of 10% per annum and a maximum rate of 12% per annum, payable at our option in cash or shares of our common stock registered for resale under the Securities Act of 1933, as amended (the "Securities Act"). If we elect to make an interest payment in common stock, the number of shares issuable by us will be based upon the lower of (i) 90% of the 20-day trailing average volume weighted average price per share as reported on Bloomberg LP (the "VWAPS") or (ii) the Conversion Price. Principal on the Notes amortizes and payments are due in 33 equal monthly installments commencing four months following issuance of the Notes, and may be made at our option in cash or shares of our common stock registered for resale under the Securities Act. If we elect to make a principal payment in common stock, the number of shares issuable by us will be based upon the lower of (i) 87.5% of the 15-day trailing VWAPS prior to the principal payment date or (ii) the Conversion Price. Our obligations under the Notes are secured by a first priority security interest in substantially all of our assets pursuant to a Security Agreement dated as of October 11, 2006 among us, the investors and Iroquois, as agent for the investors (the "Security Agreement").

Edgar Filing: BIOPHAN TECHNOLOGIES INC - Form S-1

BIOPHAN TECHNOLOGIES, INC. AND SUBSIDIARIES
(A DEVELOPMENT STAGE COMPANY)

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

As further consideration to the investors, we issued to the investors one-year warrants to purchase an aggregate of 10,820,896 shares of our common stock at a price of \$0.67 per share. If the investors elect to exercise these one-year warrants, they will also receive additional five-year warrants to purchase the shares of our common stock equal to the number of shares purchased under the one-year warrants, with 50% of the additional warrants having an exercise price of \$.85 per share, and the remaining 50% of the additional five-year warrants having an exercise price of \$.92 per share. We also issued to the investors five-year warrants to purchase an aggregate of 10,820,896 shares of our common stock. The first five-year warrants allow for the purchase of 5,410,448 shares of our common stock at an exercise price of \$0.81 per share, and the second five-year warrants allow for the purchase of 5,410,448 shares of our common stock at an exercise price of \$0.89 per share. The warrants contain anti-dilution protection that, should we issue equity or equity-linked securities at a price per common share below the exercise price of the five-year warrants, it will automatically adjust the exercise price of the warrants to the price at which we issue such equity or equity-linked securities. The total fair value of the warrants was \$14,554,105. The Company recorded a discount on the Notes of \$7,250,000 for the fair value of the related warrants. This discount on the Notes is being amortized over the life of the Notes using the effective interest method. The discount amortization through February 28, 2007 amounted to \$1,707,066 and has been included in interest expense. In addition, the excess of the fair value of the warrants over the carrying value of the notes, which amounted to \$7,304,105, was recognized as additional expense related to warrants in the accompanying 2007 statement of operations.

We further agreed to register for resale under the Securities Act the common stock issuable upon the exercise of the warrants and any shares of common stock we may issue to the holders of the Notes in connection with payments of interest and principal, or which we are obligated to issue upon any conversion of the Notes at the option of the holders.

On February 21, 2007, we entered into a Forbearance Agreement (the "Forbearance Agreement") with the investors pursuant to which the investors agreed that, during the period commencing on February 16, 2007 and ending on the earlier of (i) March 31, 2007 or (ii) the date on which any Termination Event (as defined in the Forbearance Agreement) first occurs (the "Forbearance Period"), they will forbear from exercising any and all of the rights and remedies which they may have against us or any of our assets under the Notes or the Purchase Agreement or at law or in equity as a result of any default under the Notes or as a result of the occurrence of certain events with respect to the Purchase Agreement. In exchange for entering into the Forbearance Agreement, we issued pro rata to the investors three-year warrants for the purchase of an aggregate of 60,000 shares of our common stock at an exercise price of \$0.51 per share (the "Fee Warrants").

Upon the issuance of the Fee Warrants, the exercise prices of the five-year warrants issued to the investors pursuant to the Purchase Agreement (the "Original Warrants") for the purchase of an aggregate of 10,820,896 shares of our common stock were automatically adjusted from \$0.81 per share and \$0.89 per share, respectively, to \$0.51 per share, and the number of shares of our common stock issuable upon exercise of the Original Warrants was automatically adjusted, proportionately, to an aggregate of 18,034,830 shares. In the Forbearance Agreement, the investors waived, with respect to the issuance of the Fee Warrants, application of similar anti-dilution adjustments contained in the

Edgar Filing: BIOPHAN TECHNOLOGIES INC - Form S-1

Notes and in a third series of warrants for the purchase, on or before October 12, 2007, of an aggregate of 10,820,896 additional shares of our common stock at an exercise price of \$0.67 per share (the "One Year Warrants"). C.E. Unterberg Towbin, which holds a warrant for the purchase of 865,672 shares of our common stock at an exercise price of \$0.67 per share, issued to it in connection with its services as exclusive placement agent under the Purchase Agreement, separately agreed to waive, with respect to the issuance of the Fee Warrants, application of the anti-dilution provisions set forth in that warrant. Because the anti-dilution adjustment to the Original Warrants is accounted for as a modification of the Original Warrants, we recorded an expense for this modification in the period ended February 28, 2007 of which is included in the caption "Change in fair value of warrant liability" in the statement of operations for the year ended February 28, 2007.

12. FAIR VALUE OF WARRANT LIABILITY

In accordance with the guidance provided by EITF 00-19, Accounting for Derivative Financial Instruments Indexed to and Potentially Settled in, a Company's Own Stock, we have recorded a liability of \$10,157,937 for the fair value of the warrants related to the Senior Secured Convertible Notes at February 28, 2007 in order to provide for the possibility that we may be unable to comply with the registration rights of the lenders as contained in the Securities Purchase Agreement and we currently do not have sufficient available authorized shares to execute a potential conversion of the Notes and related warrants and thus we would be required to settle the contract in cash. In addition, since we currently do not have sufficient available authorized shares to execute a potential conversion of other outstanding warrants if requested to do so by the grantees, we could be required to settle any conversion requests in cash. Therefore, we reclassified warrants with an approximate value of \$756,000 from equity to the warrant liability. The fair value of this amount was \$336,069 at February 28, 2007. The Company expects to seek stockholder approval to increase the authorized shares at a Special Meeting to be scheduled on May 8, 2007. The total fair value of derivative liability, originally recorded at \$15,309,980 on October 12, 2006, was adjusted by \$4,815,974 to \$10,494,006 at February 28, 2007 resulting in a net non-cash income adjustment of \$1,986,041 during the year ended February 28, 2007.

Edgar Filing: BIOPHAN TECHNOLOGIES INC - Form S-1

BIOPHAN TECHNOLOGIES, INC. AND SUBSIDIARIES (A DEVELOPMENT STAGE COMPANY)

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

The warrants subject to the Stand-Still Agreement were not reclassified because they are not exercisable until the increase in the number of authorized shares and the investors have agreed not to require a cash settlement in the event the number of authorized shares is not increased.

As noted above, the fair value of the derivative liability pertaining to the warrants related to the Senior Secured Convertible Notes is volatile. Several factors and underlying assumptions are included in the Black-Scholes model to derive the fair value of the warrants. The factors and the assumptions are as follows:

1. Number of warrants: varies from time to time dependent upon current period grants, conversions, forfeitures, and expirations,
2. Term to expiration: expiration dates vary by grant and currently range from 1-5 years,
3. Market price at the valuation date: \$0.70/share at October 12, 2006; \$0.41/share at February 28, 2007,
4. Exercise price of the warrants: varies by grant,
5. Dividend yield - assumed to be zero,
6. Interest rate - we use the US Federal Reserve - "Treasury constant maturities rates" at the measurement date matched to the maturities of the warrants. The rates change over time and the maturities of the warrants change over time.
7. Company stock price volatility on a look-back basis as a proxy for expected future volatility in stock price. We use the look-back approach because the stock has a relatively short trading history as a publicly traded security.

While most of these factors changed during the period of October 12, 2006 to February 28, 2007, the most significant factor impacting the change in fair value were the change in stock price and the repricing of the original warrants to \$0.51 per share as further described in Note 11.

13. STOCKHOLDERS' EQUITY:

On February 5, 2004 the Company entered into a stock purchase agreement with SBI Brightline Consulting, LLC ("SBI") that obligated SBI to purchase, upon the Company's election, up to 17,750,000 shares of common stock for an aggregate purchase price of \$25 million. Only 6,000,000 shares covered by this stock purchase agreement were registered for resale. SBI was not obligated to purchase the remaining shares covered by the stock purchase agreement unless and until the Company had registered the resale of such shares by SBI. During the year ended February 28, 2005, the Company elected to sell the 6,000,000 shares to SBI for an aggregate of \$3,900,000. On May 27, 2005, this stock purchase agreement was cancelled and a new agreement was executed with SBI. The agreement provides a \$30 million fixed price financing for up to 10,000,000 shares at prices ranging from \$2 to \$4 a share. The sales of stock must be taken in tranches of 1 million shares each and the financing agreement requires the shares to be registered for resale by SBI. There are no resets, warrants, finder's fees or commissions associated with this financing transaction. Registration of the shares for resale by SBI was effective on May 18, 2006. The Company elected to put the first tranche of 1 million shares at \$2 per share on May 23, 2006 and

Edgar Filing: BIOPHAN TECHNOLOGIES INC - Form S-1

received the entire proceeds. The Company elected to put the second tranche of 1 million shares at \$2 per share on July 21, 2006. Under this second tranche, only \$1,175,000 has been received to date and only 587,500 additional shares have been issued to SBI. On October 11, 2006, the Company elected to put the entire remaining tranches, at a weighted average price of \$2.60 per share, to SBI. To date, SBI has failed to meet its obligation to purchase these shares and the Company has not issued the shares.

We believe that SBI's failure to purchase all of the shares which we elected to sell to them on July 21, 2006 or any of the shares which we elected to sell to them on October 11, 2006 constitutes a breach of SBI's contractual obligations under the SBI Agreement. Under the SBI Agreement, SBI is irrevocably bound to purchase the shares in the amounts and at the times determined by us. We have been engaged in discussions with SBI in an effort to address SBI's default. In our Purchase Agreement with Iroquois Master Fund Ltd and other investors (See Note 11) we agreed (i) to enforce all of our rights and remedies under the SBI Agreement in connection with the breach by SBI, and (ii) not to agree to any settlement, amendment, waiver or consent under the SBI Agreement without the prior written consent of Iroquois.

SBI has alleged that in September 2006 the Company and SBI entered into an oral settlement agreement pursuant to which the Stock Purchase Agreement was terminated and SBI's obligation to purchase the shares was extinguished. The Company believes that SBI's claim is without basis in fact.

On February 24, 2005, in connection with the acquisition of Biophan Europe (see Note 3), 100,000 shares of restricted stock, valued at \$134,000, were issued, fully charged and accrued to intellectual property rights; and in connection with Employment Agreements of the same date, 200,000 shares of restricted stock valued at \$268,000 were issued to two key executives of the German subsidiary company aMRIs GmbH and fully charged to operating expenses in the year ended February 28, 2005.

Edgar Filing: BIOPHAN TECHNOLOGIES INC - Form S-1

BIOPHAN TECHNOLOGIES, INC. AND SUBSIDIARIES (A DEVELOPMENT STAGE COMPANY)

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

On August 2, 2005, the Company entered into an investment agreement with Boston Scientific Scimed. At that time, 1,653,193 shares of common stock were issued for \$5,000,000.

On November 30, 2005, the Company issued 4,923,080 shares of common stock, valued at \$8,467,698 for the acquisition of a 35% minority ownership in Myotech, LLC. Under EITF 98-2, Accounting by a Subsidiary or Joint Venture for an Investment in the Stock of its Parent Company, these shares are accounted for as treasury stock.

On December 6, 2005, in connection with the acquisition of Biophan Europe (see Note 3), 100,000 shares of restricted stock, valued at \$134,000, were issued in satisfaction of accounts payable in the accompanying consolidated balance sheet at February 28, 2006.

Also, on December 6, 2005, the Company issued 22,000 restricted shares of common stock valued at \$37,840 for certain services.

During the years ended February 28, 2007, 2006 and 2005, the Company issued no shares, 84,074 and 1,903,775 shares of stock upon the exercise of warrants for total proceeds of \$0, \$20,707 and \$788,900, respectively. As of February 28, 2007 and 2006, warrants to purchase 33,229,318 and 3,247,920 shares of our common stock were outstanding, respectively. The exercise prices for these warrants range from \$.15 per share to \$2.49 per share, and the weighted-average exercise price for all of the outstanding warrants is \$.64 per share. In addition, during the years ended February 28, 2007, 2006 and 2005, 38,956, 224,165 and 94,999 shares of stock were issued upon the exercise of options for total proceeds of \$13,179, \$182,541 and \$34,900, respectively.

Additional paid-in capital was further increased by \$1,444,780, \$4,609,778 and \$201,000 of expense related to stock options issued for services during the years ended February 28, 2007, 2006 and 2005, respectively. Also, \$-0-, \$295,362 and \$400,725 of profits were received during the years ended February 28, 2007, 2006 and 2005, respectively, from a related company owed pursuant to the "short swing profit" rules of the Securities Exchange Act of 1934.

14. RESEARCH AND DEVELOPMENT COSTS:

Expenditures for research activities relating to intellectual property development and improvement are charged to expense as incurred. Such expenditures amounted to \$7,190,975, \$6,829,142, and \$2,629,980 for the years ended February 28, 2007, 2006, and 2005, respectively.

15. COMMITMENTS:

Lease Obligation

The Company was obligated under operating leases for office space originally expiring January 30, 2008, which the Company had the right to terminate upon ninety days prior written notice to the landlord. The notice of termination was given to the landlord and the Company continued on a month-to-month basis until it vacated the premises on February 9, 2007. The Company has entered into new operating leases for office space commencing March 2007 and expiring April 30, 2022, subject to our right to terminate at any time after December 31, 2008 upon 90 days' notice.

Edgar Filing: BIOPHAN TECHNOLOGIES INC - Form S-1

The following is a schedule of future minimum rental payments, included annual increases, required under the operating lease agreements:

Year Ending February 28, -----	Amount -----
2008	\$ 102,891
2009	139,558
2010	146,536
2011	153,636
2012	157,990
Thereafter	1,600,939

	\$2,301,550
	=====

Rent expense, net of subrentals, charged to operations under these operating lease aggregated \$113,161, \$70,775 and \$58,546 for the years ended February 28, 2007, 2006, and 2005, respectively. Rent expense, net of subrentals, charged to operations for the period from August 1, 1968 (Date of Inception) to February 28, 2006 was \$368,626.

Cooperative Research and Development Agreement (CRADA):

In March 2006, the Company entered into a Cooperative Research and Development Agreement (CRADA) with the Food and Drug Administration to evaluate the safety of medical implants in the presence of electromagnetic fields from magnetic resonance imaging for a term of 2.5 years. Pursuant to the Agreement, the Company is committed to a total of \$187,500 of which \$75,000 has been paid at February 28, 2007.

Edgar Filing: BIOPHAN TECHNOLOGIES INC - Form S-1

BIOPHAN TECHNOLOGIES, INC. AND SUBSIDIARIES (A DEVELOPMENT STAGE COMPANY)

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

License Agreements

The Company is obligated under seven license or royalty agreements for patents that expire at various dates through 2025. These agreements may be terminated by the Company with 60 days written notice. Aggregate minimum future payments over the remaining life of the patents under these agreements total \$5,447,500. License/royalty expense charged to operations was \$152,410, \$594,890 and \$89,880 for the years ended February 28, 2007, 2006 and 2005, respectively.

Employment Agreements

Biophan has employment agreements with its executive officers that renew annually unless terminated by either party. Such agreements, which have been revised from time to time, provide for minimum salary levels, adjusted annually for cost-of-living changes, as well as for incentive bonuses that are payable if specified management goals are attained.

Also, Biophan has an employment contract with an officer that expires November 9, 2007, and Biophan Europe has an employment agreement with a key employee that expires on February 24, 2009. These agreements provide for base salaries, bonuses based on attaining certain milestones, a restricted stock grant and stock options. The aggregate commitment for future base salaries at February 28, 2007, excluding bonuses and other awards approximates \$313,750.

16. RELATED PARTY TRANSACTIONS:

The Company has affiliations with three entities, Biomed, Technology Innovations, and Myotech (through November 30, 2005) that are related by virtue of common senior management personnel and stock ownership. During the years ended February 28, 2007, 2006, and 2005, the Company charged Biomed and Myotech (through November 30, 2005) for services of certain Company personnel. The total of these charges was \$197,362, \$156,647 and \$161,014, respectively. The Company also charges Biomed, TI and Myotech (through November 30, 2005) for expenses allocable to and paid on their behalf. During the years ended February 28, 2007, 2006, and 2005, expenses paid by the Company on their behalf was approximately \$175,220, \$647,000, and \$240,000, respectively. At February 28, 2007, the combined balances due from these related parties was \$16,301. The amounts do not bear interest and the Company received payment within forty-five days.

During the years ended February 28, 2007, 2006 and 2005, the Company was billed \$35,290, \$93,000 and \$9,000, respectively, for legal services provided by Bramson & Pressman of which Robert S. Bramson, a former director of the Company, is a partner. Mr. Bramson resigned July 18, 2006.

Steven Katz & Associates, Inc. of which Steven Katz, a former director of the Company is an owner, billed the Company \$183,500 and \$110,500 during the years ended February 28, 2007 and 2006, respectively, for consulting services. The firm did not bill us for services during the year ended February 28, 2005. Mr. Katz resigned March 9, 2007.

17. SHARE-BASED COMPENSATION PLAN:

The Company has two stock-based compensation plans, entitled Biophan Technologies, Inc. 2001 Stock Option Plan and Biophan Technologies, Inc. 2006 Incentive Stock Plan (the "Plans") which are stockholder approved. The Plans provide for the grant of incentive and non-qualified stock options to selected

Edgar Filing: BIOPHAN TECHNOLOGIES INC - Form S-1

employees, and the grant of non-qualified options to selected consultants and to directors and advisory board members. In addition, various other types of stock-based awards may be granted. The Plans are administered by the Compensation Committee of the Board and authorizes the grant of options or restricted stock awards for 13,000,000 shares under the 2001 Plan and 7,500,000 shares under the 2006 Plan. The Compensation Committee determines which eligible individuals are to receive options or other awards under the Plans, the terms and conditions of those awards, the applicable vesting schedule, the option price and term for any granted options, and all other terms and conditions governing the option grants and other awards made under the Option Plan. Non-employee directors also receive periodic option grants pursuant to the automatic grant program in effect for them under the 2006 Plan.

F-22

Edgar Filing: BIOPHAN TECHNOLOGIES INC - Form S-1

BIOPHAN TECHNOLOGIES, INC. AND SUBSIDIARIES (A DEVELOPMENT STAGE COMPANY)

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

Effective March 1, 2006, the Company adopted SFAS No. 123 (revised), "Share-Based Payment" (SFAS 123(R)) utilizing the modified prospective approach. Prior to the adoption of SFAS 123(R), stock option grants to employees and directors were accounted for in accordance with APB Opinion No. 25, "Accounting for Stock Issued to Employees" (the intrinsic value method) and the disclosure-only provisions of SFAS 123, "Accounting for Stock-Based Compensation". Accordingly, employee compensation expense was recognized only to the extent that the fair value of our common stock on the date of grant exceeded the stock option exercise price.

Under the modified prospective approach, SFAS 123(R) applies to new grants and to grants that were outstanding on February 28, 2006 that are subsequently modified, repurchased or cancelled. Under the modified prospective approach, compensation cost recognized in fiscal 2007 includes compensation cost for all share-based payments granted prior to, but not yet vested as of February 28, 2006, based on the grant-date fair value estimated in accordance with the original provisions of SFAS 123, and compensation cost for all share-based payments granted subsequent to February 28, 2006, based on the grant-date fair value estimated in accordance with the provisions of SFAS 123(R). Prior periods were not restated to reflect the impact of adopting the new standard.

As a result of adopting SFAS 123(R) on March 1, 2006, our net loss and basic and diluted loss per share for the year ended February 28, 2007 were \$1,206,640 (\$.015 per share) higher than if we had continued to account for stock-based compensation under APB Opinion No. 25 for our stock option grants.

The following table illustrates the effect on operating results and per share information had the Company accounted for stock-based compensation in accordance with SFAS 123(R) for the years ended February 28:

	2006	2005
	-----	-----
Net loss - as reported	\$ (14,484,384)	\$ (5,793,547)
Add: Stock-based employee compensation expense included in reported net loss, net of related tax effects	4,384,530	201,000
Deduct: Total stock-based employee compensation expense determined under fair value based method for all awards, net of related tax effects	(6,520,862)	(342,000)
	-----	-----
Net loss - pro forma	\$ (16,620,716)	\$ (5,934,547)
	=====	=====
Basic and diluted loss per share - as reported	\$ (0.19)	\$ (0.08)
	=====	=====
Basic and diluted loss per share - pro forma	\$ (0.22)	\$ (0.08)
	=====	=====

We use the Black-Scholes option pricing model to estimate the fair value of stock-based awards with the following weighted-average assumptions for the years ended February 28:

Edgar Filing: BIOPHAN TECHNOLOGIES INC - Form S-1

	2007	2006	2005
Expected volatility	71%-122%	60%-103%	88%-150%
Risk-free interest rate	4.54%-5.35%	4.50%-4.60%	4.04%-4.50%
Expected life of options (years)	3.75-8 years	5-10 years	5-10 years
Expected dividends	-0-	-0-	-0-

F-23

Edgar Filing: BIOPHAN TECHNOLOGIES INC - Form S-1

BIOPHAN TECHNOLOGIES, INC. AND SUBSIDIARIES (A DEVELOPMENT STAGE COMPANY)

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

The assumptions above are based on multiple factors, including historical exercise patterns of employees in relatively homogeneous groups with respect to exercise and post-vesting employment termination behaviors, expected future exercising patterns for these same homogeneous groups and the implied volatility of our stock price.

At February 28, 2007, there was \$1,249,419 of unrecognized compensation cost related to stock-based payments which is expected to be recognized over a weighted-average period of 1.23 years.

The following table represents stock option activity for the years ended February 28, 2005 through 2007:

	Number of Shares	Weighted- Average Exercise Price	Weighted- Average Remaining Contract Life (years)
	-----	-----	-----
Outstanding options at 2/28/04	3,869,993	\$.39	
Granted	4,149,859	\$.96	
Exercised	(94,999)	\$.37	

Outstanding options at 2/28/05	7,924,853	\$.69	
Granted	1,968,331	\$1.88	
Forfeited	(74,999)	\$.83	
Exercised	(224,165)	\$.81	

Outstanding options at 2/28/06	9,594,020	\$.95	
Granted	354,997	\$.96	
Exercised	(38,956)	\$.34	
Forfeited	(367,000)	\$.47	
Expired	(114,999)	\$.50	

Outstanding options at 2/28/07	9,428,062	\$.96	6.74
	=====	=====	=====
Outstanding exercisable at 2/28/07	7,433,479	\$.86	6.39
	=====	=====	=====

At February 28, 2007, shares available for future stock option grants to employees and others under our 2001 Stock Option Plan were 597,981 and shares available for future stock option grants to employees and others under our 2006 Incentive Stock Plan were 7,265,003.

At February 28, 2007, the aggregate intrinsic value of shares outstanding was \$302,550, and the aggregate intrinsic value of options exercisable was \$302,550. Total intrinsic value of options exercised was \$ 17,223 for the year ended February 28, 2007.

The following table summarizes our non-vested stock option activity for the year ended February 28, 2007:

Edgar Filing: BIOPHAN TECHNOLOGIES INC - Form S-1

	Number of Shares	Weighted-Average Grant-Date Fair Value
	-----	-----
Non-vested stock options at 2/28/06	3,048,750	\$1.31
Granted	160,000	\$.86
Vested	(1,032,167)	\$1.09
Forfeited/Expired	(182,000)	\$.93

Non-vested stock options at 2/28/07	1,994,583	\$.62
	=====	

18. 401(K) SAVINGS PLAN

The Company maintains a tax-qualified retirement plan that provides all eligible employees with an opportunity to save for retirement on a tax-advantaged basis. Under the 401(k) Plan, participants may elect to defer a portion of their compensation on a pre-tax basis and have it contributed to the Plan subject to applicable annual Internal Revenue Code limits. Pre-tax contributions are allocated to each participant's individual account and are then invested in selected investment alternatives according to the participants' directions. Employee elective deferrals are 100% vested at all times. The 401(k) Plan allows for matching contributions to be made by the Company. As a tax-qualified retirement plan, contributions to the 401(k) Plan and earnings on those contributions are not taxable to the employees until distributed from the 401(k) Plan and all contributions are deductible by the Company when made.

Edgar Filing: BIOPHAN TECHNOLOGIES INC - Form S-1

BIOPHAN TECHNOLOGIES, INC. AND SUBSIDIARIES (A DEVELOPMENT STAGE COMPANY)

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

For eligible employees, our Investing Plans likewise use base and lump-sum merit pay as components of "eligible compensation" under the applicable plans (incentive plan awards are not part of "eligible compensation"). In addition, our "qualified" plans are subject to applicable IRS limits.

Company matching contributions to the Plan totaled \$51,892, \$53,242 and \$6,240 for the years ended February 28, 2007, 2006, and 2005, respectively. No discretionary contributions were made in 2007, 2006 or 2005.

19. INCOME TAXES:

As of February 28, 2007, the Company had net operating loss carryforwards of approximately \$22,124,000 for federal income tax purposes, which expire through 2027.

The reconciliation of income tax computed at the U.S. federal statutory tax rates to income tax expense is as follows:

	For the Years Ended		

	February 28,		

	2007	2006	2005
	----	----	----
Tax benefit at U.S. statutory rates	(34%)	(34%)	(34%)
Increase in valuation allowance	34%	34%	34%
	---	---	---
	0%	0%	0%
	===	===	===

	February 28,	

	2007	2006
	-----	-----
Deferred tax asset is comprised of the following:		
Net operating loss carryforwards	\$ 10,224,000	\$ 7,400,000
Write-down of intellectual property rights	160,000	160,000
Stock option expense	2,400,000	--
	-----	-----
Total deferred tax asset	12,784,000	7,560,000
Valuation allowance	\$ (12,784,000)	\$ (7,560,000)
	=====	=====

20. CONTINGENCIES:

We are not a party to any material legal proceedings and there are no material legal proceedings pending with respect to our property, except as noted below. We are not aware of any legal proceedings contemplated by any governmental authorities involving either us or our property. None of our directors, officers or affiliates is an adverse party in any legal proceedings involving us or our

Edgar Filing: BIOPHAN TECHNOLOGIES INC - Form S-1

subsidiaries, or has an interest in any proceeding which is adverse to us or our subsidiaries.

The Company is pursuing legal claims against one of its former law firms and certain of its attorneys. Review of the firm's work product and bills recently revealed questions about the firm's billing practices and other activities. The amount of potential damages has not yet been quantified. Also, the law firm has asserted claims seeking payment of additional legal fees, which claims the Company has denied. The litigation is in an early stage. While, as with any legal proceedings, no assurance can be given as to ultimate outcome, management believes that the outcome of the litigation will not have a material adverse effect upon the Company's financial condition. Accordingly, adjustments, if any that might result from the resolution of this matter have not been reflected in the financial statements.

On April 5, 2007, SBI Brightline LLC and SBI Brightline XI, LLC brought suit against us and Biomed Solutions, LLC in the Superior Court of Orange County, California. The suit alleges, among other things, that in September 2006 we entered into an oral agreement to terminate the Stock Purchase Agreement dated as of May 27, 2005 and amended on January 8, 2006, between us and SBI Brightline XI, LLC, and seeks unspecified monetary damages and an order by the Court deeming the Stock Purchase Agreement to be terminated. We believe the allegations made by SBI are without basis in fact and we intend to defend the lawsuit vigorously. Because of the potential costs of litigation and the anticipated demands that our defense may place on the time and attention of our management our defense of this matter, regardless of the outcome, could have a material adverse effect on our business and operations.

Edgar Filing: BIOPHAN TECHNOLOGIES INC - Form S-1

BIOPHAN TECHNOLOGIES, INC. AND SUBSIDIARIES (A DEVELOPMENT STAGE COMPANY)

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

21. QUARTERLY STATEMENTS OF OPERATIONS (UNAUDITED)

	Year Ended February 28, 2007*			
	May 31	August 31	November 30	February 28
Quarter ended:				
Revenues	\$ 344,922	\$ 310,099	\$ 226,094	\$ 108,414
Research and development expenses	2,588,408	1,941,513	1,737,351	923,703
General and administrative expenses	2,086,191	1,573,434	1,264,228	1,901,092
Other income (expense)	(249,592)	(329,508)	(3,061,966)	(3,080,593)
Minority interest in Myotech, LLC	695,825	520,095	470,674	339,045
Net loss	\$ (3,883,444)	\$ (3,014,261)	\$ (5,366,777)	\$ (5,457,929)
Loss per common share - basic and diluted	\$ (.05)	\$ (.04)	\$ (.07)	\$ (.07)
Weighted average shares outstanding	76,893,764	77,893,673	77,654,013	77,864,738

	Year Ended February 28, 2006*			
	May 31	August 31	November 30	February 28
Quarter ended:				
Revenues	\$ --	\$ 62,500	\$ 466,935	\$ 515,426
Research and development expenses	1,599,742	2,291,762	1,212,239	1,725,399
General and administrative expenses	1,895,984	3,123,641	1,548,299	1,883,962
Other income (expense)	85,887	(670,575)	(81,098)	(188,590)
Minority interest in Myotech, LLC	--	--	--	606,159
Net loss	\$ (3,409,839)	\$ (6,023,478)	\$ (2,374,701)	\$ (2,676,366)
Loss per common share - basic and diluted	\$ (.05)	\$ (.08)	\$ (.03)	\$ (.03)
Weighted average shares outstanding	74,417,378	75,129,518	76,760,163	76,874,030

22. VALUATION AND QUALIFYING ACCOUNTS

Description	Years ended February 28, 2007, 2006 and 2005			
	Balance at beginning of year	Additions charged to expense (*)	Deductions	B en

Edgar Filing: BIOPHAN TECHNOLOGIES INC - Form S-1

Year ended February 28, 2007:				
Valuation allowance- deferred tax asset	\$7,560,000	\$5,224,000	\$-0-	\$1
Year ended February 28, 2006:				
Valuation allowance- deferred tax asset	\$4,787,000	\$2,773,000	\$-0-	\$
Year ended February 28, 2005:				
Valuation allowance-deferred tax asset	\$2,926,000	\$1,861,000	\$-0-	\$

(*) Offset to tax benefit of net operating losses.

F-26

Pro Forma Information

On August 6, 2007, the Company entered into an Intellectual Property Assignment Agreement with Medtronic, Inc., a Minnesota corporation, pursuant to which the Company agreed to transfer and sell to Medtronic all of its interest in and to certain intellectual property owned by the Company for an aggregate purchase price of \$11,000,000, which amount would have reduced to \$10,500,000 if the closing did not occur within 60 days of the execution of the agreement. The intellectual property which the Company agreed to transfer and sell consists of the Company's patents related to MRI safety of implantable medical devices, including pacemakers. On October 5, 2007, the Company closed the transaction contemplated by the Intellectual Property Assignment Agreement, sold the foregoing intellectual property to Medtronic and received an aggregate of \$11,000,000 as the sale price.

The following information depicts the effects of the sale of the intellectual property rights as described above as if the transaction were consummated on March 1, 2007, the beginning of the six-month period ended August 31, 2007, the latest date for which financial statements have been filed with the Securities and Exchange Commission:

Condensed Consolidated Pro Forma Balance Sheet

	Historical August 31, 2007	Pro Forma Adjustments	Pro Forma August 31, 2007
Assets			
Current assets:			
Cash and cash equivalents	\$ 268,716(1)	\$ 10,500,000	\$ 10,768,716
Accounts receivable	40,325		40,325
Prepaid expenses	197,344		197,344
Other current assets	46,384		46,384
Total current assets	552,769	10,500,000	11,052,769
Property and equipment, net	369,322		369,322
Other assets:			
Intangible assets, net of amortization			
Myotech, LLC	22,385,252		22,385,252
Other	1,275,531(2)	(63,000)	1,212,531
Deferred financing costs, net amortization	1,097,394		1,097,394
Investment in New Scale Technologies, Inc.	100,000		100,000
Deposits	206		206
Deferred tax asset, net of valuation allowance	(3)		0
	24,858,383	(63,000)	24,795,383
	\$ 25,780,474	\$ 10,437,000	\$ 36,217,474
Liabilities and Stockholders' Equity			
Current Liabilities:			
Current portion of capital lease obligation	\$ 14,680		\$ 14,680
Current portion of senior secured convertible notes, net of discount	1,090,294		1,090,294
Accounts payable and accrued expenses	1,965,020		1,965,020
Liquidated damages payable	652,500		652,500
Note payable	57,969		57,969
Line of credit - related party	2,250,000		2,250,000
Due to related parties	62,894		62,894
Deferred revenues	583,333(1)	(500,000)	83,333
Total current liabilities	6,676,690	(500,000)	6,176,690
Long -term debt:			
Capital lease obligation	15,534		15,534
Senior secured convertible notes payable, less discount	1,278,621		1,278,621
Total liabilities	7,970,845		7,470,845
Minority interest	12,367,582		12,367,582
Stockholders' equity:			
Common stock	491,878		491,878
Additional paid-in capital	66,841,444		66,841,444
	67,333,322		67,333,322

Edgar Filing: BIOPHAN TECHNOLOGIES INC - Form S-1

Less treasury stock	(8,467,698)		(8,467,698)
	58,865,624		58,865,624
Deficit accumulated during the development stage	(53,423,577)(1)(2)	10,937,000	(42,486,577)
Total stockholders' equity	5,442,047	10,937,000	16,379,047
	\$ 25,780,474	\$ 10,437,000	\$ 36,217,474

F-1

Condensed Consolidated Pro Forma Statement of Operations

	Historical Six Months August 31, 2007	Pro Forma Adjustments	Pro Forma Six Months August 31, 2007
Revenues:			
Sale of intellectual property rights	\$ (1)	11,000,000	\$ 11,000,000
License fees	125,000		125,000
Grant revenues	75,000		75,000
Consulting fees	132,351		132,351
	332,351	11,000,000	11,332,351
Operating expenses:			
Research and development	2,817,784(2)	(7,000)	2,810,784
General and administrative	3,290,423		3,290,423
Write-off of intellectual property rights	-(2)	70,000	70,000
	6,108,207	63,000	6,171,207
Operating income (loss):	(5,775,856)	10,937,000	5,161,144
Other income (expense):			
Interest income	20,431		20,431
Interest expense	(1,714,326)		(1,714,326)
Change in fair value of warrant liability	3,434,017		3,434,017
Debt forgiveness	197,614		197,614
Liquidated damages	(652,500)		(652,500)
Other income	33,939		33,939
	1,319,175	0	1,319,175
Loss from continuing operations before minority interest in Myotech, LLC	(4,456,681)	10,937,000	6,480,319
Minority interest in Myotech, LLC	725,173		725,173
Income (loss) before income taxes	(3,731,508)	10,937,000	7,205,492
Income tax provision	-(3)	-	-
Net income (loss)	\$ (3,731,508)	\$ 10,937,000	\$ 7,205,492
Net income (loss) per common share:			
Basic	\$ (0.046)		\$ 0.089
Diluted	\$ (0.046)		\$ 0.089
Weighted average shares outstanding:			
Basic	81,167,908		81,167,908
Diluted	81,167,908		81,392,352

Pro Forma Adjustments:

- (1) Receipt of cash consideration
- (2) Write off unamortized cost of intellectual property rights sold

(3) Income tax provision reflects the reversal of the deferred tax valuation allowance of approximately \$2.7 million offset entirely by the recognition of a deferred tax expense of approximately \$2.7 million attributed to the utilization of net operating loss carryforwards, to reduce taxable income to zero.

F-2

PART II

INFORMATION NOT REQUIRED IN PROSPECTUS

ITEM 13. OTHER EXPENSES OF ISSUANCE AND DISTRIBUTION.

The following table sets forth the estimated costs and expenses to be incurred in connection with the issuance and distribution of the securities registered under this Registration Statement. All amounts are estimates except the Securities and Exchange Commission registration fee. The following expenses will be borne solely by the registrant.

SEC registration fee	\$ 169.61
Printing and engraving expenses	\$ 500.00
Legal fees and expenses	\$ 20,000.00
Accounting fees and expenses	\$ 7,000.00
Miscellaneous expenses	\$ 1,000.00
Total	\$ 28,669.61

The Registrant has agreed to bear expenses incurred by the selling stockholders that relate to the registration of the shares of common stock being offered and sold by the selling stockholders.

ITEM 14. INDEMNIFICATION OF DIRECTORS AND OFFICERS.

Under Nevada Revised Statutes Section 78.138, a director or officer is generally not individually liable to the corporation or its shareholders for any damages as a result of any act or failure to act in his capacity as a director or officer, unless it is proven that

- o his act or failure to act constituted a breach of his fiduciary duties as a director or officer; and
- o his breach of those duties involved intentional misconduct, fraud or a knowing violation of law.

This provision is intended to afford directors and officers protection against and to limit their potential liability for monetary damages resulting from suits alleging a breach of the duty of care by a director or officer. As a consequence of this provision, stockholders of Biophan will be unable to recover monetary damages against directors or officers for action taken by them that may constitute negligence or gross negligence in the performance of their duties unless such conduct falls within one of the foregoing exceptions. The provision, however, does not alter the applicable standards governing a director's or officer's fiduciary duty and does not eliminate or limit the right of Biophan or any stockholder to obtain an injunction or any other type of non-monetary relief in the event of a breach of fiduciary duty.

As permitted by Nevada law, Biophan's By-Laws include a provision which provides for indemnification of a director or officer by Biophan against expenses, judgments, fines and amounts paid in settlement of claims against the director or officer arising from the fact that he was a director or officer, provided that the director or officer acted in good faith and in a manner he believed to be in or not opposed to the best interests of Biophan. Biophan has purchased insurance under a policy that insures both Biophan and its officers and directors against exposure and liability normally insured

against under such policies, including exposure on the indemnities described above.

Insofar as indemnification for liabilities arising under the Securities Act may be permitted to directors, officers and controlling persons pursuant to the foregoing provisions, or otherwise, we have been advised that in the opinion of the Securities and Exchange Commission such indemnification is against public policy as expressed in the Securities Act and is, therefore, unenforceable.

II-1

ITEM 15. RECENT SALES OF UNREGISTERED SECURITIES.

The following sets forth information regarding unregistered securities sold by the registrant since October 2003.

(a) On February 21, 2007, we issued to ten holders of our Senior Secured Convertible Notes, all of whom are qualified institutional buyers (as such term is defined in Rule 144A under the Securities Act) or accredited investors (as such term is defined in Rule 501 (a) under the Securities Act) three-year warrants for the purchase of an aggregate of 60,000 shares of our common stock at an exercise price of \$0.51 per share. The warrants were issued in consideration for the Note holders' execution of a Forbearance Agreement relating to certain payment due, or to come due, under the Notes. The issuance of the warrants was made without registration under the Securities Act pursuant to the exemption provided in Section 4(2) thereof in as much as it did not involve any public offering.

(b) On October 18, 2006, we issued and sold 587,500 shares of our common stock, at a price of \$2.00 per share, to SBI Brightline XI, LLC ("SBI"). The sale was made pursuant to the Stock Purchase Agreement dated as of May 27, 2005 between us and SBI (as amended by Amendment No. 1 thereto dated January 9, 2006, the "Stock Purchase Agreement"). The shares sold on October 18 constitute a portion of the second of ten tranches of shares which we may require SBI to purchase under the Stock Purchase Agreement. The issuance and sale of the shares was made without registration under the Securities Act of 1933 pursuant to the exemption provided in Section 4(2) thereof. We have been advised by SBI that it intends to sell all such shares pursuant to our Registration Statement on Form S-3 (No. 333-130920) which was declared effective by the Securities and Exchange Commission on May 18, 2006.

(c) On October 11, 2006, we entered into a Securities Purchase Agreement (the "Purchase Agreement"). Pursuant to the Purchase Agreement, on October 12, 2006, we issued to ten qualified institutional buyers (as such term is defined in Rule 144A under the Securities Act) and/or accredited investors (as such term is defined in Rule 501(a) under the Securities Act) the following securities (the "Securities"):

(i) an aggregate of \$7,250,000 principal amount of our Senior Secured Convertible Notes due October 11, 2009 (the "Notes");

(ii) five-year warrants for the purchase of an aggregate of 5,410,498 shares of our common stock at an exercise price of \$0.81 per share (the "\$0.81 Warrants");

(iii) five-year warrants for the purchase of an aggregate of 5,410,498 shares of our common stock at an exercise price of \$0.89 per share; (the "\$0.89 Warrants");and

(iv) one-year warrants for the purchase of an aggregate of 10,820,896 shares of our common stock at an exercise price of \$0.67 per share.

The Notes are convertible, at any time at the election of the holders, into shares of our common stock at a conversion price of \$0.67 per share. If the entire principal amount of the Notes were converted, we would issue to the holders an aggregate of 10,820,896 shares of our common stock. The Securities were issued in a private placement not involving any public offering and exempt from registration under the Securities Act pursuant to the exemptions provided by Section 4(2) of such Act and by Regulation D and Regulation S promulgated under such Act. The Securities were sold for cash at an aggregate offering price of \$7,250,000. C.E. Unterberg, Towbin acted as the exclusive placement agent in the offering. We paid the placement agent a cash fee of \$580,000 and issued to it a five-year warrant to purchase an aggregate of 865,672 shares of our common stock at a price of \$0.67 per share. Pursuant to anti-dilution provisions contained in the \$0.81 Warrants and the \$0.89 Warrants, the exercise prices of those warrants were subsequently adjusted to \$0.51 and the number of the shares of our common stock issuable upon exercise thereof was adjusted, proportionately, to 8,543,079 and 9,441,751, respectively.

On October 3, 2007, the Company entered into Amendment No. 1 to the Purchase Agreement (the “Amendment”). Pursuant to the Amendment, the Company agreed to amend the Notes to provide that even if the Company elects to make a monthly payment in cash, the holder will have the right to convert any portion of the Note into common stock of the Company and apply the number of shares the holder would have received had the Company elected to make payment in common stock. In addition, the Conversion Price was reduced to \$0.15. The Amendment also amended the warrants to reduce the exercise prices of the various warrants to \$0.23. In exchange for the foregoing the investors released certain intellectual property, allowing the Company to transfer and sell such intellectual property.

II-2

Pursuant to the Amendment the Company also agreed to certain spending covenants in connection with the proceeds it will receive from the sale of the intellectual property under the Intellectual Property Assignment Agreement dated as of August 6, 2007 by and between Biophan and Medtronic, Inc. The Amendment also granted certain additional rights to the investors related to Biophan's majority owned subsidiary Myotech including the right to consent to the appointment of Biophan's representatives to the Board of Directors.

(d) On May 23, 2006, we issued and sold 1,000,000 shares of our common stock, at a price of \$2.00 per share, to SBI Brightline XI, LLC ("SBI"). The sale was made pursuant to the Stock Purchase Agreement dated as of May 27, 2005 between us and SBI (as amended by Amendment No. 1 thereto dated January 9, 2006, the "Stock Purchase Agreement"). The shares sold on May 23 constitute the first of ten tranches of shares which we may require SBI to purchase under the Stock Purchase Agreement. The issuance and sale of the shares was made without registration under the Securities Act of 1933 pursuant to the exemption provided in Section 4(2) thereof. We were advised by SBI that it has sold all such shares pursuant to our Registration Statement on Form S-3 (No. 333-130920) which was declared effective by the Securities and Exchange Commission on May 18, 2006.

(e) On January 24, 2006, we entered into a Line of Credit Agreement (the "Line of Credit Agreement") with Biomed Solutions, LLC, a New York limited liability company ("Biomed"), pursuant to which Biomed has committed to make advances to us, in an aggregate amount of up to \$5,000,000. Under the Line of Credit Agreement, advances may be drawn down in such amounts and at such times as we determine upon 15 days' prior notice to Biomed, except that we may not draw down more than \$1,500,000 in any 30-day period. We are obligated to utilize the entire credit facility. Amounts borrowed will bear interest at the rate of 8% per annum and are convertible into shares of our common stock at the rate of \$0.67 per share. Any amounts drawn down and repaid may be reborrowed at any time (subject to a requirement of 15 days' notice and the limitation that not more than \$1,500,000 may be drawn down during any 30-day period). Biomed's obligation to lend to us under the Line of Credit Agreement expires on June 30, 2007, on which date the entire amount borrowed by us (and not converted into shares of our common stock) becomes due and payable. Our obligations with respect to borrowings under the credit facility are governed by a Convertible Promissory Note issued by us to Biomed on January 24, 2006. In connection with the establishment of the credit facility under the Line of Credit Agreement, on January 24, 2006, we issued to Biomed a Stock Purchase Warrant (the "Warrant") entitling Biomed to purchase up to 1,198,630 shares of our common stock at an exercise price of \$1.89 per share. Biomed's purchase rights under the Warrant expire on January 23, 2011. The Note and the Warrant were, and any shares issuable upon conversion of the Note or exercise of the Warrant will be, issued in a private placement exempt from the registration requirements of the Securities Act of 1933 pursuant to the exemption set forth in Section 4(2) of such Act and Regulation D promulgated thereunder.

(f) On November 30, 2005, we entered into a Securities Purchase Agreement for the acquisition of an initial 35% interest in Myotech, LLC ("Myotech"), a New York limited liability company, whereby we exchanged 4,923,020 shares of our common stock, par value \$.005, for 3,687,719 Class A (voting) units of Myotech. The shares issuable to Myotech under the Securities Purchase Agreement are subject to a Rights Agreement between us and Myotech entered into on November 30, 2005. Under the Rights Agreement, we agreed among other things, to register the Biophan shares issued to Myotech. The shares were offered and issued pursuant to an exemption from the registration requirements of the Securities Act of 1933 under Section 4(2) of such Act.

(g) On June 30, 2005, we entered into a license agreement and an investment agreement with Boston Scientific Scimed, Inc., an affiliate of Boston Scientific Corporation ("BSS") in connection with the licensing of our technology to BSS. The investment agreement called for the purchase by BSS of shares of our common stock for a total purchase price of \$5 million, the shares to be priced at 110% of the average of the closing prices of our common stock on the OTC Bulletin Board for the 30 calendar-day period prior to the closing. Upon the satisfaction of certain conditions to the agreement, on August 2, 2005, BSS paid us the \$5 million purchase price and we issued to BSS 1,653,193 shares of our common stock at a price per share of \$3.024 (representing a 10% premium over the average closing price of \$2.75 on the OTC Bulletin Board over the period July 3, 2005 through August 1, 2005). The shares were offered and

sold pursuant to an exemption from the registration requirements of the Securities Act of 1933 under Section 4(2) of such Act and Rule 506 promulgated thereunder.

II-3

(h) On February 24, 2005, pursuant to the terms of a License Agreement ("License"), dated February 24, 2005, between Biophan and aMRIs Patent GmbH ("Licensor"), Biophan agreed to issue 200,000 shares of its unregistered common stock to aMRIs Patent GmbH, the Licensor. The shares issued were exempt from registration pursuant to the exemption set forth in Section 4(2) and Regulation S. Biophan did not receive any cash consideration for the shares of common stock and no underwriters were involved in the placement of the common stock.

(i) On January 21, 2004 and February 10, 2004, respectively, we issued 932,000 and 500,000 shares of common stock for the conversion of \$93,200 and \$50,000 of line of credit obligation payable to Biomed Solutions, LLC. Biomed had previously sold those portions of its receivable to a single purchaser, Bellador Advisory Services (Labuan) Ltd., a Kuala Lumpur, Malaysia company. The shares were issued to Bellador and its assigns pursuant to the exemption provided by Section 3(a)(9) of the Securities Act of 1933, involving an exchange of securities with an existing securityholder where no commission is payable. The debt was assigned by Biomed to Bellador pursuant to the provisions of Regulation S of the Securities Act. All recipients of the shares were nonaffiliated, non U.S. persons deemed to be accredited investors and/or persons with knowledge of business. There was no general solicitation or general advertising related to the transaction, and the recipients were required to represent that they were non U.S. persons and that they were not acquiring the shares for the account or benefit of any U.S. Person. The offer to purchase the shares was not made to a person in the United States and, at the time of the transaction, the purchasers were outside the United States.

(j) On February 10, 2004, we issued 3,000,000 shares of common stock upon the conversion of \$300,000 of the obligations under our obligation payable to Biomed Solutions, LLC under a transfer agreement. Biomed had previously sold that portion of its rights to SBI Brightline Consulting, LLC. The shares were issued to SBI pursuant to the exemption provided by Section 3(a)(9) of the Securities Act of 1933, involving an exchange of securities with an existing securityholder where no commission is payable. The debt was assigned by Biomed to SBI in a transaction that was exempt from registration under Section 4(2) of the Securities Act because it did not involve any public offering.

(k) On February 10, 2004, we issued 3,513,000 shares of common stock upon the conversion of our outstanding debt obligations payable to Biomed (\$200,000 under a transfer agreement and \$151,300 under a line of credit). The shares were issued to Biomed pursuant to the exemption provided by Section 3(a)(9) of the Securities Act of 1933, involving an exchange of securities with an existing securityholder where no commission is payable.

(l) On February 5, 2004 we entered into a stock purchase agreement with SBI Brightline Consulting, LLC pursuant to which SBI agreed to purchase up to 17,750,000 shares of our common stock at fixed prices ranging from \$.60 to \$2.00 per share. This transaction was treated as completed at the time of the signing of the stock purchase agreement and was exempt from registration under Section 4(2) of the Securities Act because it did not involve any public offering.

(m) Between January 15, 2004 and February 29, 2004, we issued 995,940 shares of our common stock upon the exercise of outstanding warrants for aggregate gross proceeds of \$332,844. The shares were issued pursuant to the exemption provided by Section 3(a)(9) of the Securities Act of 1933, involving an exchange of securities with an existing securityholder where no commission is payable.

(n) On October 1, 2003 we entered into a stock purchase agreement with SBI Brightline Consulting, LLC pursuant to which SBI agreed to purchase up to 11,000,000 shares of our common stock at fixed prices ranging from \$.15 to \$.40 per share. This transaction was treated as completed at the time of the signing of the stock purchase agreement and was exempt from registration under Section 4(2) of the Securities Act because it did not involve any public offering. We sold the shares pursuant to the stock purchase agreement between December 3, 2003 and January 12, 2004 for aggregate proceeds of \$2.9 million. We were advised by SBI that it sold all of such shares pursuant to our Registration Statement on Form SB-2 (No. 333-109592) which was declared effective by the Securities and Exchange Commission on November 17, 2003.

II-4

ITEM 16. EXHIBITS.

Please refer to the exhibit index following the signature page of this registration statement.

ITEM 17. UNDERTAKINGS.

The undersigned Company hereby undertakes to:

(1) To file, during any period in which offers or sales are being made, a post-effective amendment to this registration statement:

(i) To include any prospectus required by Section 10(a)(3) of the Securities Act of 1933;

(ii) To reflect in the prospectus any facts or events arising after the effective date of the registration statement (or the most recent post-effective amendment thereof) which, individually or in the aggregate, represent a fundamental change in the information set forth in the registration statement. Notwithstanding the foregoing, any increase or decrease in volume of securities offered (if the total dollar value of securities offered would not exceed that which was registered) and any deviation from the low or high end of the estimated maximum offering range may be reflected in the form of prospectus filed with the Securities and Exchange Commission pursuant to Rule 424(b) if, in the aggregate, the changes in volume and price represent no more than a 20 percent change in the maximum aggregate offering price set forth in the "Calculation of Registration Fee" table in the effective registration statement, and

(iii) To include any material information with respect to the plan of distribution not previously disclosed in the registration statement or any material change to such information in the registration statement.

(2) That, for the purpose of determining any liability under the Securities Act of 1933, each such post-effective amendment shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.

(3) To remove from registration by means of a post-effective amendment any of the securities being registered which remain unsold at the termination of the offering.

Insofar as indemnification for liabilities arising under the Securities Act of 1933 may be permitted to directors, officers and controlling persons of the registrant pursuant to the foregoing provisions, or otherwise, the registrant has been advised that in the opinion of the Securities and Exchange Commission such indemnification is against public policy as expressed in the Securities Act and is, therefore, unenforceable. In the event that a claim for indemnification against such liabilities (other than the payment by the registrant of expenses incurred or paid by a director, officer or controlling person of the registrant in the successful defense of any action, suit or proceeding) is asserted by such director, officer or controlling person in connection with the securities being registered, the registrant will, unless in the opinion of its counsel the matter has been settled by controlling precedent, submit to a court of appropriate jurisdiction the question whether such indemnification by it is against public policy as expressed in the Securities Act and will be governed by the final adjudication of such issue.

The undersigned registrant hereby undertakes:

That, for the purpose of determining liability under the Securities Act of 1933 to any purchaser, each prospectus filed pursuant to Rule 424(b) as part of a registration statement relating to an offering, other than registration statements relying on Rule 430B or other than prospectuses filed in reliance on Rule 430A, shall be deemed to be part of and included in the registration statement as of the date it is first used after effectiveness. Provided, however, that no statement made in a registration statement or prospectus that is part of the registration statement or made in a

document incorporated or deemed incorporated by reference into the registration statement or prospectus that is part of the registration statement will, as to a purchaser with a time of contract of sale prior to such first use, supersede or modify any statement that was made in the registration statement or prospectus that was part of the registration statement or made in any such document immediately prior to such date of first use.

II-5

That, for the purpose of determining liability of the registrant under the Securities Act of 1933 to any purchaser in the initial distribution of the securities:

The undersigned registrant undertakes that in a primary offering of securities of the undersigned registrant pursuant to this registration statement, regardless of the underwriting method used to sell the securities to the purchaser, if the securities are offered or sold to such purchaser by means of any of the following communications, the undersigned registrant will be a seller to the purchaser and will be considered to offer or sell such securities to such purchaser:

- (i) Any preliminary prospectus or prospectus of the undersigned registrant relating to the offering required to be filed pursuant to Rule 424;
- (ii) Any free writing prospectus relating to the offering prepared by or on behalf of the undersigned registrant or used or referred to by the undersigned registrant;
- (iii) The portion of any other free writing prospectus relating to the offering containing material information about the undersigned registrant or its securities provided by or on behalf of the undersigned registrant; and
- (iv) Any other communication that is an offer in the offering made by the undersigned registrant to the purchaser.

II-6

SIGNATURES

Pursuant to the requirements of the Securities Act of 1933, as amended, the registrant has duly caused this Registration Statement on Form S-1 to be signed on its behalf by the undersigned, thereunto duly authorized, in the Town of Pittsford, New York, on October 25, 2007.

BIOPHAN TECHNOLOGIES, INC.

By: /s/ John F. Lanzafame
John F. Lanzafame
Chief Executive Officer (Principal Executive Officer)

By: /s/ Robert J. Wood
Robert J. Wood
Chief Financial Officer
(Principal Accounting Officer and Principal Financial Officer)

II-7

POWER OF ATTORNEY

KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below constitutes and appoints John F. Lanzafame and Robert J. Wood, and each of them, as his true and lawful attorneys-in-fact and agents, with full power of substitution and resubstitution, for the undersigned and in his or her name, place and stead, in any and all capacities, to sign any or all amendments (including post-effective amendments) to the Registration Statement and to file the same, with all exhibits thereto, and all documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorneys-in-fact and agents, full power and authority to do and perform each and every act and thing requisite and necessary to be done in connection therewith, as fully to all intents and purposes as he or she might or could do in person, hereby ratifying and confirming all that said attorneys-in-fact and agents, or any of them or their or his substitute or substitutes, may lawfully do or cause to be done by virtue hereof.

Pursuant to the requirements of the Securities Act of 1933, as amended, this Registration Statement has been signed by the following persons in the capacities and on the dates indicated:

Signature	Title	Date
/s/ John F. Lanzafame John F. Lanzafame	Chief Executive Officer (Principal Executive Officer)	October 25, 2007
/s/ Robert J. Wood Robert J. Wood	Chief Financial Officer (Principal Accounting Officer and Principal Financial Officer)	October 25, 2007
/s/ Guenter H. Jaensch Guenter H. Jaensch	Director and Chairman of the Board	October 25, 2007
/s/ Theodore A. Greenberg Theodore A. Greenberg	Director	October 25, 2007
/s/ Bonita L. Labosky Bonita L. Labosky	Director	October 25, 2007
/s/ Stan Yakatan Stan Yakatan	Director	October 25, 2007

Exhibit Number	Description of Exhibit	Location
3.1	Articles of Incorporation	(1)
3.2	Amendment to Articles of Incorporation	(2)
3.3	Certificate of Amendment to Articles of Incorporation	(3)
3.4	Certificate of Amendment to Articles of Incorporation	*
3.5	Bylaws	(4)
4.1	Stock Purchase Agreement dated May 27, 2005 between Biophan and SBI Brightline XI, LLC	(5)
4.2	Amendment No. 1, dated January 8, 2006, to Stock Purchase Agreement by and between Biophan and SBI Brightline XI, LLC	(6)
4.3	Line of Credit Agreement dated as of May 27, 2005 between Biophan and Biomed Solutions, LLC	(7)
4.4	First Amendment to Line of Credit Agreement between Biophan and Biomed Solutions, LLC	(8)
4.5	Convertible Promissory Note of Biophan in the face amount of \$2,000,000 payable to the order of Biomed Solutions, LLC dated May 27, 2005	(9)
4.6	First Amendment to Convertible Promissory Note	(10)
4.7	Stock Purchase Warrant issued to Biomed Solutions, LLC dated May 27, 2005	(11)
4.8	Rights Agreement among Myotech, LLC, the Members of Myotech, LLC and Biophan	(12)
4.9	Line of Credit Agreement dated as of January 24, 2006 between Biophan and Biomed Solutions, LLC	(13)
4.10	Amendment No. 1, dated October 11, 2006, to Line of Credit Agreement by and between Biophan Technologies, Inc. and Biomed Solutions, LLC	(14)
4.11	Convertible Promissory Note of Biophan in the face amount of \$5,000,000 payable to the order of Biomed Solutions, LLC dated January 24, 2006	(15)
4.12	Amended and Restated Convertible Promissory Note of Biophan Technologies, Inc., in the principal amount of \$5,000,000, dated October 11, 2006, payable to the order of Biomed Solutions, LLC	(16)
4.13	Stock Purchase Warrant for the Purchase of up to 1,198,630 Shares of Common Stock issued to Biomed Solutions, LLC	(17)
4.14		(18)

Edgar Filing: BIOPHAN TECHNOLOGIES INC - Form S-1

Subordination and Standstill Agreement dated October 11, 2006, by and among Biophan Technologies, Inc., Biomed Solutions, LLC, and those Purchasers named therein

- 4.15 Form of Senior Secured Convertible Notes due October 11, 2009 issued pursuant to the Securities Purchase Agreement, dated October 11, 2006, by and among Biophan Technologies, Inc. and those Purchasers named therein (19)
- 4.16 Form of Senior Secured Convertible Notes due October 11, 2009 issued pursuant to the Securities Purchase Agreement, dated October 11, 2006, by and among Biophan Technologies, Inc. and those Purchasers named therein (20)
- 4.17 Form of One-Year Warrants issued pursuant to the Securities Purchase Agreement, dated October 11, 2006, by and among Biophan Technologies, Inc. and those Purchasers named therein (21)
-

Exhibit Number	Description of Exhibit	Location
4.18	Form of Three-Year Warrants issued pursuant to the Forbearance Agreement dated as of February 16, 2007 by and among Biophan Technologies, Inc. and the Note Holders named therein.	(22)
4.19***	Amended and Restated 2001 Stock Option Plan	(23)
4.20***	2006 Incentive Stock Plan	(24)
4.21	Amendment No. 1 to Securities Purchase Agreement, Senior Secured Convertible Notes, Warrants and Security Agreement, by and among Biophan Technologies, Inc. and those Purchasers named therein.	(55)
4.22	Consent and Authorization Agreement, dated October 3, 2007.	(55)
5.1	Opinion of Sichenzia Ross Friedman Ference LLP	*
10.1	Agreement dated as of February 24, 2005 among Biophan, aMRIs GmbH, Dr. Michael Friebe, Tomovation GmbH, Prof. Dr. Andreas Melzer, Dipl.-Ing. Gregor Schaefers, and Dipl. Betriebsw. Andreas Pieper	(25)
10.2	Note and Pledge Agreement dated November 24, 2005 between Biophan, Tomovation GmbH and Prof. Dr. Andreas Melzer	(26)
10.3	Termination of Stock Purchase Agreement between Biophan and SBI Brightline Consulting, LLC	(27)
10.4	Investment Agreement dated June 30, 2005 between Biophan and Boston Scientific Scimed, Inc.	(28)
10.5	Securities Purchase Agreement, dated October 11, 2006, by and among Biophan Technologies, Inc. and those Purchasers named therein.	(29)
10.6	Security Agreement, dated as of October 11, 2006, by and among Biophan Technologies, Inc., the Purchasers named therein and Iroquois Master Fund Ltd., as agent for the Purchasers	(30)
10.7	Forbearance Agreement dated as of February 16, 2007 by and among Biophan Technologies, Inc. and the Note Holders named therein.	(31)
10.8	License Agreement between Biophan, Xingwu Wang and Nanoset, LLC dated January 15, 2004	(32)
10.9	Development Agreement between Biophan and Greatbatch Enterprises, Inc. dated February 28, 2001	(33)
10.10	License Agreement between Biophan and Johns Hopkins University	(34)
10.11	AMP-Biophan License Agreement dated February 24, 2005 between Biophan and aMRIs Patent GmbH (Confidential treatment has been granted with respect to certain	(35)

Edgar Filing: BIOPHAN TECHNOLOGIES INC - Form S-1

positions of this Agreement. This Agreement has been filed separately with the SEC)

10.12	License Agreement dated June 30, 2005 between Biophan and Boston Scientific Scimed, Inc.	(36)
10.13	Capital Pledge Agreement dated February 24, 2005 among Biophan, TomoVation GmbH, and Prof. Dr. Andreas Melzer	(37)
10.14	Securities Purchase Agreement between Biophan and Myotech, LLC, dated November 30, 2005	(38)
10.15	Letter Agreement, Amendment and Waiver of Certain Conditions to Closing, between Biophan and Myotech, LLC, dated December 21, 2005	(39)

Exhibit Number	Description of Exhibit	Location
10.16	Amendment No. 2 to Securities Purchase Agreement dated as of November 28, 2006 between Myotech LLC and Biophan	(40)
10.17	Letter Agreement dated August 19, 2002 between Biomed Solutions, LLC and Biophan	(41)
10.18	Payment Agreement dated June 3, 2004 between Biophan and TE Bio LLC	(42)
10.19	Joint Research Agreement between Nanolution, LLC and NaturalNano Inc. dated as of May 25, 2005, together with Non-Disclosure Agreement	(58)
10.20	Lease Agreement between Biophan and High Technology of Rochester, Inc.	(43)
10.21	Lease between Schoen Place LLC and Biophan Technologies, Inc.	(44)
10.22	Amendment No. 1 to Lease between Schoen Place LLC and Biophan Technologies, Inc.	(45)
10.23	Severance and Covenants Agreement between Biophan and Michael L. Weiner dated October 3, 2007	(46)
10.24	** Executive Employment Agreement between Biophan and Jeffrey L. Helfer dated June 6, 2002	(47)
10.25	** Executive Employment Agreement between Biophan and Stuart G. MacDonald dated June 6, 2002	(48)
10.26	** Executive Employment Agreement between Biophan and John F. Lanzafame effective as of September 9, 2004	(49)
10.27	** Amendment to Executive Employment Agreement, between Biophan and John F. Lanzafame, dated September 10, 2007	(50)
10.28	** Executive Employment Agreement dated as of January 1, 2006 between Biophan and Jeffrey L. Helfer	(51)
10.29	** Employment Agreement dated February 24, 2005 among aMRIs GmbH, Dr. Michael Friebe and Biophan	(52)
10.30	Intellectual Property Assignment Agreement, dated August 6, 2007, by and between Biophan Technologies, Inc. and with Medtronic, Inc.	(53)
10.30	Amendment to Executive Employment Agreement by and between Biophan Technologies, Inc. and John F. Lanzafame, dated September 10, 2007.	(54)
10.31	Securities Purchase Agreement, dated October 2, 2007, by and between Biophan Technologies, Inc. and Myotech, LLC	(56)
10.32	Severance and Covenants Agreement dated October 3, 2007	(57)
21.1	Subsidiaries	(59)

23.1 Consent of Sichenzia Ross Friedman Ference LLP (See Exhibit 5.1)

23.2 Consent of Goldstein Golub Kessler LLP

*

* Filed herewith

** May be deemed a compensatory plan or arrangement.

(1) Incorporated by reference to Exhibit 3.1 to Form 10-KSB for the year ended February 29, 2000 (the "2000 10-KSB").

- (2) Incorporated by reference to Exhibit 3.1(i) to Form 8-K filed on December 15, 2000.
- (3) Incorporated by reference to Exhibit 3.1(i) to Form 8-K filed on August 27, 2001.
- (4) Incorporated by reference to Exhibit 3.4 to Form S-1/A filed on May 24, 2007.
- (5) Incorporated by reference to Exhibit 3.2 to Form 10-SB filed on May 13, 1999.
- (6) Incorporated by reference to Exhibit 4.21 to Form 10-KSB/A for the year ended February 28, 2005 (the "2005 10-KSB").
- (7) Incorporated by reference to Exhibit 4.1 to Form 8-K filed January 9, 2006.
- (8) Incorporated by reference to Exhibit 10.50 to the 2005 10-KSB.
- (9) Incorporated by reference to Exhibit 4.2 to Form 10-Q for the period ended November 30, 2005 (the "Q3'05 10-Q").
- (10) Incorporated by reference to Exhibit 4.22 to the 2005 10-KSB.
- (11) Incorporated by reference to Exhibit 4.3 to the Q3'05 10-Q.
- (12) Incorporated by reference to Exhibit 4.23 to the 2005 10-KSB.
- (13) Incorporated by reference to Exhibit 4.1 to the Q3'05 10-Q.
- (14) Incorporated by reference to Exhibit 4.1 to Form 8-K filed January 25, 2006 (the "January 25, 2006 8-K").
- (15) Incorporated by reference to Exhibit 10.2 to Form 8-K filed October 13, 2006 (the "October 13, 2006 8-K").
- (16) Incorporated by reference to Exhibit 4.2 to the January 25, 2006 8-K.
- (17) Incorporated by reference to Exhibit 10.3 to the October 13, 2006 8-K.
- (18) Incorporated by reference to Exhibit 4.3 to the January 25, 2006 8-K.
- (19) Incorporated by reference to Exhibit 10.4 to the October 13, 2006 8-K.
- (20) Incorporated by reference to Exhibit 4.2 to the October 13, 2006 8-K.
- (21) Incorporated by reference to Exhibit 4.3 to the October 13, 2006 8-K.
- (22) Incorporated by reference to Exhibit 4.4 to the October 13, 2006 8-K.
- (23) Incorporated by reference to Exhibit 4.1 to Form 8-K filed February 27, 2007 (the "february 27,2007 8-K")
- (24) Incorporated by reference to Appendix A to Proxy Statement filed on Schedule 14A on June 28, 2005.
- (25) Incorporated by reference to Appendix A to Proxy Statement filed on Schedule 14A on June 21, 2006.

(26) Incorporated by reference to Exhibit 2.4 to the 2005 10-KSB.

(27) Incorporated by reference to Exhibit 4.10 to the 2005 10-KSB.

(28) Incorporated by reference to Exhibit 4.20 to the 2005 10-KSB.

- (29) Incorporated by reference to Exhibit 4.5 to Form 10-Q for the period ended August 31, 2005.
- (30) Incorporated by reference to Exhibit 4.1 to the October 13, 2006 8-K.
- (31) Incorporated by reference to Exhibit 10.1 to the October 13, 2006 8-K.
- (32) Incorporated by reference to Exhibit 10.1 to the February 27, 2007 8-K.
- (33) Incorporated by reference to Exhibit 10.50 to Registration Statement on Form SB-2 (File No. 333-109592) filed on October 9, 2003.
- (34) Incorporated by reference to Exhibit 10.28 to Amendment No. 2 to Registration Statement on Form SB-2/A (File No. 333-102526) filed on May 1, 2003.
- (35) Incorporated by reference to Exhibit 10.23 to Amendment No. 1 to Registration Statement on Form SB-2/A (File No. 333-102526) filed on March 14, 2003.
- (36) Incorporated by reference to Exhibit 10.46 to the amended 2005 10-KSB.
- (37) Incorporated by reference to Exhibit 10.2 to Amended Form 10-Q for the period ended August 31, 2005, filed January 9, 2006.
- (38) Incorporated by reference to Exhibit 10.48 to the 2005 10-KSB.
- (39) Incorporated by reference to Exhibit 10.1 to the Q3'05 10-Q.
- (40) Incorporated by reference to Exhibit 10.2 to the Q3'05 10-Q.
- (41) Incorporated by reference to Exhibit 10.1 to Form 8-K filed on December 8, 2006.
- (42) Incorporated by reference to Exhibit 10.54 to Amendment No. 2 to Registration Statement on Form SB-2 (File No. 333-112678) filed on April 9, 2004.
- (43) Incorporated by reference to Exhibit 99.1 to Form 8-K filed on June 3, 2004.
- (44) Incorporated by reference to Exhibit 10.19 to Amendment No. 1 to Registration Statement on Form SB-2/A (File No. 333-102526) filed on March 14, 2003.
- (45) Incorporated by reference to Exhibit 10.1 to Form 8-K filed on November 9, 2006.
- (46) Incorporated by reference to Exhibit 10.1 to the Form 8-K filed October 8, 2007.
- (47) Incorporated by reference to Exhibit 10.7 to Form 10-QSB for the period ended May 31, 2002 (the "Q1'02 10-QSB").
- (48) Incorporated by reference to Exhibit 10.8 to the Q1'02 10-QSB.
- (48) Incorporated by reference to Exhibit 10.9 to the Q1'02 10-QSB.
- (49) Incorporated by reference to Exhibit 10.49 to the 2005 10-KSB.

(50) Incorporated by reference to Exhibit 10.2 to Form 8-K filed September 13, 2007.

(51) Incorporated by reference to Exhibit 10.2 to Form 8-K filed January 26, 2006.

(52) Incorporated by reference to Exhibit 10.47 to the 2005 10-KSB.

(53) Incorporated by reference to Exhibit 10.1 to Form 8-K filed August 9, 2007.

(54) Incorporated by reference to Exhibit 10.2 to Form 8-K filed September 13, 2007.

(55) Incorporated by reference to Exhibit 4.5 and 4.6 to Form 8-K filed October 5, 2007.

(56) Incorporated by reference to Exhibit 10.1 to Form 8-K filed October 5, 2007.

(57) Incorporated by reference to Exhibit 10.1 to Form 8-K filed October 9, 2007.

(58) Incorporated by reference to Exhibit 10.16 to Form S-1 filed November 13, 2006.

(59) Incorporated by reference to Exhibit 21.1 to Form 10-K for the year ended February 28, 2007 filed on May 8, 2007.
